[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLGyUgxVFg-HwyqJH7m0pK_NPY4bAZsLEf4pMuYM2s0g":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":72,"rows":79},"Astellas Pharma Inc",[4],523,false,7,146,182147,26,11,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Healthy",34,{"name":18,"count":19},"Healthy Subjects",29,{"name":21,"count":22},"Kidney Transplantation",28,{"name":24,"count":25},"Overactive Bladder",21,{"name":27,"count":28},"Type 2 Diabetes Mellitus",20,{"name":30,"count":31},"Healthy Volunteers",17,{"name":33,"count":31},"Urinary Bladder, Overactive",{"name":35,"count":31},"Liver Transplantation",[37,42,47,52,57,62,67],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03182244","A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","2023-12-25","Gilteritinib",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03971253","Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis","2026-05-31","Peficitinib",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06364696","A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors","2027-04-30","ASP4396",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06970665","A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration","2027-06-30","avacincaptad pegol",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07094204","A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","2028-11-30","ASP5834",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05382559","A Study of ASP3082 in Adults With Advanced Solid Tumors","2028-12-31","Setidegrasib",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT07318714","A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke","2030-02-28","ASP2246",[73,74,75,76,77,78],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[80,104,157,180,198,216,234,252,273,344,392,414,439,457,477,495,513,531,549,567,585,603,621,639,657,675,797,999,1178,1346,1443,1546,1630,1677,1749,1800,1845,1886,1938,1991,2034,2082,2121,2147,2173,2199,2225,2272,2308,2334,2360,2382,2413,2447,2465,2483,2501,2519,2545,2566,2591,2616,2634,2657,2675,2698,2716,2734,2752,2770,2795,2813,2837,2855,2878,2900,2918,2936,2954,2972,2990,3014,3037,3055,3073,3095,3113,3318,3451,3564,3650,3740,3807,3903,3969,4030,4092,4146,4176,4215,4241,4267,4303,4347,4388,4414,4442,4464,4494,4530,4566,4588,4619,4653,4682,4704,4729,4751,4773,4791,4809,4831,4855,4877,4902,4926,4944,4968,4986,5004,5022,5047,5065,5089,5107,5131,5153,5171,5192,5210,5233,5251,5269,5292,5310,5328,5350,5368,5386,5404,5422,5445,5468,5491,5513,5531,5549,5567,5585,5608,5687,5739,5797,5850,5880,5929,5975,6019,6061,6087,6125,6147,6183,6219,6247,6271,6312,6344,6377,6406,6437,6455,6477,6495,6520,6538,6556,6574,6592,6610,6631,6653,6679,6697,6727,6753,6771,6795,6818,6841,6863,6881,6899,6922,6940,6958,6980,6998,7022,7045,7066,7089,7107,7125,7149,7242,7296,7326,7350,7384,7413,7439,7469,7491,7513,7545,7577,7600,7618,7636,7657,7678,7704,7722,7743,7761,7779,7797,7815,7833,7854,7876,7894,7915,7933,7951,7975,7993,8011,8032,8055,8073,8091,8113,8131,8154,8177,8195,8213,8235,8253,8271,8294,8315,8338,8356,8374,8392,8413,8431,8453,8471,8489,8507,8530,8553,8575,8598,8927,9084,9198,9264,9346,9412,9452,9508,9536,9570,9601,9624,9649,9673,9696,9721,9746,9764,9788,9810,9831,9854],{"intervention":56,"totalTrials":81,"cells":82},1,{"EARLY_PHASE1":83,"PHASE1":86,"PHASE2":88,"PHASE3":90,"PHASE4":92,"NA":102},{"trials":84,"activeCount":85},[],0,{"trials":87,"activeCount":85},[],{"trials":89,"activeCount":85},[],{"trials":91,"activeCount":85},[],{"trials":93,"activeCount":81,"soonestReadout":55},[94],{"nctId":53,"briefTitle":54,"status":95,"phases":96,"primaryCompletion":55,"completion":55,"start":97,"enrollment":28,"conditions":98,"interventions":101},"RECRUITING",[77],"2025-07-08",[99,100],"Geographic Atrophy","Age-Related Macular Degeneration",[56],{"trials":103,"activeCount":85},[],{"intervention":41,"totalTrials":105,"cells":106},3,{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":122,"PHASE3":138,"PHASE4":153,"NA":155},{"trials":108,"activeCount":85},[],{"trials":110,"activeCount":85},[111],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":121},"NCT02181660","Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia","COMPLETED",[74],"2016-06-27","2014-06-16",24,[120],"Acute Myeloid Leukemia (AML)",[41],{"trials":123,"activeCount":85},[124],{"nctId":125,"briefTitle":126,"status":114,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":135},"NCT02310321","A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.",[74,75],"2021-08-25","2024-07-09","2015-02-26",97,[133,134],"Acute Myeloid Leukemia","FLT3-mutated Acute Myeloid Leukemia",[41,136,137],"Idarubicin","Cytarabine",{"trials":139,"activeCount":81,"soonestReadout":40},[140],{"nctId":38,"briefTitle":39,"status":141,"phases":142,"primaryCompletion":40,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"ACTIVE_NOT_RECRUITING",[76],"2027-03-31","2017-10-25",276,[147],"AML With FLT3 Mutation",[41,137,149,150,151,152],"Mitoxantrone","Etoposide","G-CSF","Fludarabine",{"trials":154,"activeCount":85},[],{"trials":156,"activeCount":85},[],{"intervention":137,"totalTrials":158,"cells":159},2,{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":170,"PHASE4":176,"NA":178},{"trials":161,"activeCount":85},[],{"trials":163,"activeCount":85},[],{"trials":165,"activeCount":85},[166],{"nctId":125,"briefTitle":126,"status":114,"phases":167,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":168,"interventions":169},[74,75],[133,134],[41,136,137],{"trials":171,"activeCount":81,"soonestReadout":40},[172],{"nctId":38,"briefTitle":39,"status":141,"phases":173,"primaryCompletion":40,"completion":143,"start":144,"enrollment":145,"conditions":174,"interventions":175},[76],[147],[41,137,149,150,151,152],{"trials":177,"activeCount":85},[],{"trials":179,"activeCount":85},[],{"intervention":149,"totalTrials":81,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":194,"NA":196},{"trials":183,"activeCount":85},[],{"trials":185,"activeCount":85},[],{"trials":187,"activeCount":85},[],{"trials":189,"activeCount":81,"soonestReadout":40},[190],{"nctId":38,"briefTitle":39,"status":141,"phases":191,"primaryCompletion":40,"completion":143,"start":144,"enrollment":145,"conditions":192,"interventions":193},[76],[147],[41,137,149,150,151,152],{"trials":195,"activeCount":85},[],{"trials":197,"activeCount":85},[],{"intervention":150,"totalTrials":81,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":212,"NA":214},{"trials":201,"activeCount":85},[],{"trials":203,"activeCount":85},[],{"trials":205,"activeCount":85},[],{"trials":207,"activeCount":81,"soonestReadout":40},[208],{"nctId":38,"briefTitle":39,"status":141,"phases":209,"primaryCompletion":40,"completion":143,"start":144,"enrollment":145,"conditions":210,"interventions":211},[76],[147],[41,137,149,150,151,152],{"trials":213,"activeCount":85},[],{"trials":215,"activeCount":85},[],{"intervention":151,"totalTrials":81,"cells":217},{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":230,"NA":232},{"trials":219,"activeCount":85},[],{"trials":221,"activeCount":85},[],{"trials":223,"activeCount":85},[],{"trials":225,"activeCount":81,"soonestReadout":40},[226],{"nctId":38,"briefTitle":39,"status":141,"phases":227,"primaryCompletion":40,"completion":143,"start":144,"enrollment":145,"conditions":228,"interventions":229},[76],[147],[41,137,149,150,151,152],{"trials":231,"activeCount":85},[],{"trials":233,"activeCount":85},[],{"intervention":152,"totalTrials":81,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":248,"NA":250},{"trials":237,"activeCount":85},[],{"trials":239,"activeCount":85},[],{"trials":241,"activeCount":85},[],{"trials":243,"activeCount":81,"soonestReadout":40},[244],{"nctId":38,"briefTitle":39,"status":141,"phases":245,"primaryCompletion":40,"completion":143,"start":144,"enrollment":145,"conditions":246,"interventions":247},[76],[147],[41,137,149,150,151,152],{"trials":249,"activeCount":85},[],{"trials":251,"activeCount":85},[],{"intervention":71,"totalTrials":81,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":267,"PHASE4":269,"NA":271},{"trials":255,"activeCount":85},[],{"trials":257,"activeCount":85},[],{"trials":259,"activeCount":81,"soonestReadout":70},[260],{"nctId":68,"briefTitle":69,"status":95,"phases":261,"primaryCompletion":70,"completion":70,"start":262,"enrollment":263,"conditions":264,"interventions":266},[74,75],"2026-04-03",84,[265],"Chronic Ischemic Stroke",[71],{"trials":268,"activeCount":85},[],{"trials":270,"activeCount":85},[],{"trials":272,"activeCount":85},[],{"intervention":274,"totalTrials":275,"cells":276},"Docetaxel",4,{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":300,"PHASE3":338,"PHASE4":340,"NA":342},{"trials":278,"activeCount":85},[],{"trials":280,"activeCount":81,"soonestReadout":65},[281],{"nctId":63,"briefTitle":64,"status":95,"phases":282,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":285,"interventions":287},[74],"2022-06-08",681,[286],"Solid Tumor",[66,288,289,290,291,292,293,294,274,295,296,297,298,299],"Cetuximab","Leucovorin","Oxaliplatin","Fluorouracil","Irinotecan","Nanoparticle albumin-bound-paclitaxel","Gemcitabine","Pembrolizumab","Cisplatin","Carboplatin","Pemetrexed","Liposomal Irinotecan",{"trials":301,"activeCount":85},[302,314,327],{"nctId":303,"briefTitle":304,"status":114,"phases":305,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":312},"NCT01038804","A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer",[75],"2012-06","2013-06","2009-12",101,[311],"Breast Cancer",[313,274],"YM155",{"nctId":315,"briefTitle":316,"status":114,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":324},"NCT00514267","An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors",[74,75],"2010-03","2007-05",32,[322,323],"Prostate Cancer","Tumors",[325,274,326],"YM 155","Prednisone",{"nctId":328,"briefTitle":329,"status":114,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":337},"NCT01009775","A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma",[75],"2011-03","2012-08","2009-11",64,[336],"Melanoma",[313,274],{"trials":339,"activeCount":85},[],{"trials":341,"activeCount":85},[],{"trials":343,"activeCount":85},[],{"intervention":294,"totalTrials":105,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":371,"PHASE3":386,"PHASE4":388,"NA":390},{"trials":347,"activeCount":85},[],{"trials":349,"activeCount":81,"soonestReadout":65},[350,367],{"nctId":351,"briefTitle":352,"status":353,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":275,"conditions":357,"interventions":362},"NCT01016054","A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer","TERMINATED",[74],"2010-04","2009-10",[358,359,360,361],"Carcinoma","Ovarian Cancer","Ovarian Diseases","Ovarian Neoplasms",[363,364,365,366],"AGS-8M4","Pegylated liposomal doxorubicin","gemcitabine","carboplatin",{"nctId":63,"briefTitle":64,"status":95,"phases":368,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":369,"interventions":370},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":372,"activeCount":85},[373],{"nctId":374,"briefTitle":375,"status":114,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":384},"NCT00902291","A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer",[75],"2012-04","2009-04",205,[381,382,383],"Carcinoma, Pancreatic Ductal","Pancreatic Cancer","Pancreatic Disease",[385,294],"AGS-1C4D4",{"trials":387,"activeCount":85},[],{"trials":389,"activeCount":85},[],{"trials":391,"activeCount":85},[],{"intervention":366,"totalTrials":158,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":395,"activeCount":85},[],{"trials":397,"activeCount":81,"soonestReadout":65},[398,402],{"nctId":351,"briefTitle":352,"status":353,"phases":399,"primaryCompletion":355,"completion":355,"start":356,"enrollment":275,"conditions":400,"interventions":401},[74],[358,359,360,361],[363,364,365,366],{"nctId":63,"briefTitle":64,"status":95,"phases":403,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":404,"interventions":405},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":407,"activeCount":85},[],{"trials":409,"activeCount":85},[],{"trials":411,"activeCount":85},[],{"trials":413,"activeCount":85},[],{"intervention":61,"totalTrials":81,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":417,"activeCount":85},[],{"trials":419,"activeCount":81,"soonestReadout":60},[420],{"nctId":58,"briefTitle":59,"status":95,"phases":421,"primaryCompletion":60,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":429},[74],"2029-04-30","2025-07-25",364,[286,426,427,428],"Non-Small-Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma","Colorectal Cancer",[61,430],"panitumumab",{"trials":432,"activeCount":85},[],{"trials":434,"activeCount":85},[],{"trials":436,"activeCount":85},[],{"trials":438,"activeCount":85},[],{"intervention":430,"totalTrials":81,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":442,"activeCount":85},[],{"trials":444,"activeCount":81,"soonestReadout":60},[445],{"nctId":58,"briefTitle":59,"status":95,"phases":446,"primaryCompletion":60,"completion":422,"start":423,"enrollment":424,"conditions":447,"interventions":448},[74],[286,426,427,428],[61,430],{"trials":450,"activeCount":85},[],{"trials":452,"activeCount":85},[],{"trials":454,"activeCount":85},[],{"trials":456,"activeCount":85},[],{"intervention":51,"totalTrials":81,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":469,"PHASE3":471,"PHASE4":473,"NA":475},{"trials":460,"activeCount":85},[],{"trials":462,"activeCount":81,"soonestReadout":50},[463],{"nctId":48,"briefTitle":49,"status":141,"phases":464,"primaryCompletion":50,"completion":50,"start":465,"enrollment":466,"conditions":467,"interventions":468},[74],"2024-04-16",175,[286],[51],{"trials":470,"activeCount":85},[],{"trials":472,"activeCount":85},[],{"trials":474,"activeCount":85},[],{"trials":476,"activeCount":85},[],{"intervention":66,"totalTrials":81,"cells":478},{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":493},{"trials":480,"activeCount":85},[],{"trials":482,"activeCount":81,"soonestReadout":65},[483],{"nctId":63,"briefTitle":64,"status":95,"phases":484,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":485,"interventions":486},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":488,"activeCount":85},[],{"trials":490,"activeCount":85},[],{"trials":492,"activeCount":85},[],{"trials":494,"activeCount":85},[],{"intervention":288,"totalTrials":81,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":498,"activeCount":85},[],{"trials":500,"activeCount":81,"soonestReadout":65},[501],{"nctId":63,"briefTitle":64,"status":95,"phases":502,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":503,"interventions":504},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":506,"activeCount":85},[],{"trials":508,"activeCount":85},[],{"trials":510,"activeCount":85},[],{"trials":512,"activeCount":85},[],{"intervention":289,"totalTrials":81,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":523,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":516,"activeCount":85},[],{"trials":518,"activeCount":81,"soonestReadout":65},[519],{"nctId":63,"briefTitle":64,"status":95,"phases":520,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":521,"interventions":522},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":524,"activeCount":85},[],{"trials":526,"activeCount":85},[],{"trials":528,"activeCount":85},[],{"trials":530,"activeCount":85},[],{"intervention":290,"totalTrials":81,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":534,"activeCount":85},[],{"trials":536,"activeCount":81,"soonestReadout":65},[537],{"nctId":63,"briefTitle":64,"status":95,"phases":538,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":539,"interventions":540},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":542,"activeCount":85},[],{"trials":544,"activeCount":85},[],{"trials":546,"activeCount":85},[],{"trials":548,"activeCount":85},[],{"intervention":291,"totalTrials":81,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":552,"activeCount":85},[],{"trials":554,"activeCount":81,"soonestReadout":65},[555],{"nctId":63,"briefTitle":64,"status":95,"phases":556,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":557,"interventions":558},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":560,"activeCount":85},[],{"trials":562,"activeCount":85},[],{"trials":564,"activeCount":85},[],{"trials":566,"activeCount":85},[],{"intervention":292,"totalTrials":81,"cells":568},{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":570,"activeCount":85},[],{"trials":572,"activeCount":81,"soonestReadout":65},[573],{"nctId":63,"briefTitle":64,"status":95,"phases":574,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":575,"interventions":576},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":578,"activeCount":85},[],{"trials":580,"activeCount":85},[],{"trials":582,"activeCount":85},[],{"trials":584,"activeCount":85},[],{"intervention":293,"totalTrials":81,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":595,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":588,"activeCount":85},[],{"trials":590,"activeCount":81,"soonestReadout":65},[591],{"nctId":63,"briefTitle":64,"status":95,"phases":592,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":593,"interventions":594},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":596,"activeCount":85},[],{"trials":598,"activeCount":85},[],{"trials":600,"activeCount":85},[],{"trials":602,"activeCount":85},[],{"intervention":295,"totalTrials":81,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":613,"PHASE3":615,"PHASE4":617,"NA":619},{"trials":606,"activeCount":85},[],{"trials":608,"activeCount":81,"soonestReadout":65},[609],{"nctId":63,"briefTitle":64,"status":95,"phases":610,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":611,"interventions":612},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":614,"activeCount":85},[],{"trials":616,"activeCount":85},[],{"trials":618,"activeCount":85},[],{"trials":620,"activeCount":85},[],{"intervention":296,"totalTrials":81,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":631,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":624,"activeCount":85},[],{"trials":626,"activeCount":81,"soonestReadout":65},[627],{"nctId":63,"briefTitle":64,"status":95,"phases":628,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":629,"interventions":630},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":632,"activeCount":85},[],{"trials":634,"activeCount":85},[],{"trials":636,"activeCount":85},[],{"trials":638,"activeCount":85},[],{"intervention":298,"totalTrials":81,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":642,"activeCount":85},[],{"trials":644,"activeCount":81,"soonestReadout":65},[645],{"nctId":63,"briefTitle":64,"status":95,"phases":646,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":647,"interventions":648},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":650,"activeCount":85},[],{"trials":652,"activeCount":85},[],{"trials":654,"activeCount":85},[],{"trials":656,"activeCount":85},[],{"intervention":299,"totalTrials":81,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":660,"activeCount":85},[],{"trials":662,"activeCount":81,"soonestReadout":65},[663],{"nctId":63,"briefTitle":64,"status":95,"phases":664,"primaryCompletion":65,"completion":65,"start":283,"enrollment":284,"conditions":665,"interventions":666},[74],[286],[66,288,289,290,291,292,293,294,274,295,296,297,298,299],{"trials":668,"activeCount":85},[],{"trials":670,"activeCount":85},[],{"trials":672,"activeCount":85},[],{"trials":674,"activeCount":85},[],{"intervention":676,"totalTrials":12,"cells":677},"peficitinib",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":722,"PHASE3":753,"PHASE4":786,"NA":788},{"trials":679,"activeCount":85},[],{"trials":681,"activeCount":85},[682,691,702,713],{"nctId":683,"briefTitle":684,"status":114,"phases":685,"primaryCompletion":686,"completion":686,"start":687,"enrollment":118,"conditions":688,"interventions":689},"NCT02760342","A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin",[74],"2016-06-26","2016-05-15",[18],[676,690],"Metformin",{"nctId":692,"briefTitle":693,"status":114,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT01754805","A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis",[74],"2010-03-25","2010-01-22",15,[699],"Rheumatoid Arthritis",[676,701],"methotrexate",{"nctId":703,"briefTitle":704,"status":114,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":712},"NCT01225224","Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers",[74],"2010-03-10","2009-11-18",72,[710,711],"Pharmacokinetics of ASP015K","Healthy Volunteer",[676],{"nctId":714,"briefTitle":715,"status":114,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":721},"NCT02531191","Bioequivalence Evaluation of a New and Current Tablet of ASP015K",[74],"2015-07-15","2015-06-21",40,[30],[676],{"trials":723,"activeCount":85},[724,734,743],{"nctId":725,"briefTitle":726,"status":114,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":733},"NCT01649999","A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects",[75],"2013-07-20","2012-03-01",281,[732],"Arthritis, Rheumatoid",[676],{"nctId":735,"briefTitle":736,"status":114,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":742},"NCT01554696","A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate",[75],"2014-02-11","2012-07-06",379,[732],[676,701],{"nctId":744,"briefTitle":745,"status":114,"phases":746,"primaryCompletion":747,"completion":747,"start":748,"enrollment":749,"conditions":750,"interventions":752},"NCT01096862","A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis",[75],"2011-07-27","2010-03-23",124,[751],"Psoriasis",[676],{"trials":754,"activeCount":85},[755,766,777],{"nctId":756,"briefTitle":757,"status":114,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":764},"NCT02308163","A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs",[76],"2017-01-23","2017-11-22","2014-08-08",509,[699],[46,765],"Etanercept",{"nctId":767,"briefTitle":768,"status":114,"phases":769,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":775},"NCT02305849","A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment",[76],"2017-06-20","2017-11-28","2014-07-25",519,[699],[46,776],"Methotrexate",{"nctId":778,"briefTitle":779,"status":114,"phases":780,"primaryCompletion":781,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":785},"NCT01638013","A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K",[76],"2019-09-30","2012-06-13",843,[732],[46],{"trials":787,"activeCount":85},[],{"trials":789,"activeCount":81,"soonestReadout":45},[790],{"nctId":43,"briefTitle":44,"status":95,"phases":791,"primaryCompletion":45,"completion":45,"start":792,"enrollment":793,"conditions":794,"interventions":796},[],"2019-09-02",3000,[795],"Rheumatoid Arthritis (RA)",[46],{"intervention":798,"totalTrials":31,"cells":799},"Mycophenolate Mofetil",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":814,"PHASE3":854,"PHASE4":933,"NA":997},{"trials":801,"activeCount":85},[],{"trials":803,"activeCount":85},[804],{"nctId":805,"briefTitle":806,"status":114,"phases":807,"primaryCompletion":808,"completion":808,"start":809,"enrollment":118,"conditions":810,"interventions":812},"NCT01364987","Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers",[74],"2009-06","2009-05",[18,811,710],"Drug Interactions",[813,798],"ASP015K",{"trials":815,"activeCount":85},[816,830,842],{"nctId":817,"briefTitle":818,"status":114,"phases":819,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":824},"NCT00543569","A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients",[75],"2011-02","2008-02",323,[21],[825,826,827,828,829],"Alefacept","tacrolimus","basiliximab","mycophenolate mofetil","Corticosteroids",{"nctId":831,"briefTitle":832,"status":114,"phases":833,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":838},"NCT00693524","Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX",[75],"2004-03","2002-11",94,[35],[826,839,840,841],"Anti-IL2R AB","Mycophenolate mofetil","prednisone",{"nctId":843,"briefTitle":844,"status":114,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":851},"NCT00617604","A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients",[75],"2009-09","2007-12",218,[850],"De Novo Kidney Transplantation",[825,852,798,853],"Tacrolimus","Steroids",{"trials":855,"activeCount":85},[856,867,878,891,903,914,924],{"nctId":857,"briefTitle":858,"status":114,"phases":859,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":863,"interventions":865},"NCT00321113","Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys",[76],"2008-03","2004-09",142,[864],"KIDNEY TRANSPLANTATION",[826,828,866],"steroids",{"nctId":868,"briefTitle":869,"status":114,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":875},"NCT01011205","Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation",[76],"2013-01-04","2009-09-30",893,[35],[876,798,877,829],"Advagraf","Basiliximab",{"nctId":879,"briefTitle":880,"status":114,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":888},"NCT00157014","Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens",[76],"2008-07-18","2004-05-10",111,[886,887],"Heart Diseases","Heart Transplantation",[852,889,840,890,326],"Cyclosporine","Methylprednisolone",{"nctId":892,"briefTitle":893,"status":114,"phases":894,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":900},"NCT00064701","Comparative Study of Modified Release (MR) Tacrolimus\u002FMycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients",[76],"2005-03","2009-03","2003-06",668,[21],[901,852,902,828],"Tacrolimus Modified Release","cyclosporine microemulsion",{"nctId":904,"briefTitle":905,"status":114,"phases":906,"primaryCompletion":896,"completion":896,"start":907,"enrollment":908,"conditions":909,"interventions":910},"NCT00481819","A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation",[76],"2007-07",240,[21],[911,912,798,890,913],"FK506MR","Prograf","Prednisolone",{"nctId":915,"briefTitle":916,"status":114,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":922},"NCT00693381","Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus\u002FMMF\u002FSteroid Triple Regimen After Kidney Transplantation",[76],"2004-08","2003-02",152,[21],[852,798,923],"methylprednisolone and prednisone",{"nctId":925,"briefTitle":926,"status":114,"phases":927,"primaryCompletion":821,"completion":821,"start":928,"enrollment":929,"conditions":930,"interventions":931},"NCT00296348","Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation",[76],"2005-11",198,[21],[826,828,932,866],"daclizumab",{"trials":934,"activeCount":85},[935,945,957,967,978,987],{"nctId":936,"briefTitle":937,"status":114,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":943},"NCT01304836","A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids",[77],"2013-05-22","2011-01-22",1166,[21],[876,798,944,829],"Simulect",{"nctId":946,"briefTitle":947,"status":114,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":953},"NCT00717470","A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection",[77],"2010-03-02","2008-05-14",1252,[21],[954,955,798,944,956],"Prograf®","Advagraf®","methylprednisolone \u002F prednisone",{"nctId":958,"briefTitle":959,"status":114,"phases":960,"primaryCompletion":896,"completion":896,"start":961,"enrollment":962,"conditions":963,"interventions":964},"NCT00113269","Safety\u002FEfficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients",[77],"2005-05",501,[21],[827,965,826,966,828,866],"rabbit anti-thymocyte globulin","alemtuzumab",{"nctId":968,"briefTitle":969,"status":114,"phases":970,"primaryCompletion":971,"completion":971,"start":319,"enrollment":972,"conditions":973,"interventions":976},"NCT00717379","Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation",[77],"2008-10",50,[21,974,975],"Kidney Failure, Chronic","Renal Insufficiency, Chronic",[852,798,977,326],"Methylprednisolone or equivalent",{"nctId":979,"briefTitle":980,"status":353,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":986},"NCT00133172","Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection",[77],"2007-03","2005-07",85,[21],[852,828,326],{"nctId":988,"briefTitle":989,"status":114,"phases":990,"primaryCompletion":991,"completion":991,"start":992,"enrollment":993,"conditions":994,"interventions":995},"NCT01363752","A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.",[77],"2013-09-18","2011-03-08",853,[21],[876,798,996,829],"Sirolimus",{"trials":998,"activeCount":85},[],{"intervention":1000,"totalTrials":31,"cells":1001},"solifenacin succinate",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1036,"PHASE3":1060,"PHASE4":1114,"NA":1176},{"trials":1003,"activeCount":85},[],{"trials":1005,"activeCount":85},[1006,1018,1028],{"nctId":1007,"briefTitle":1008,"status":114,"phases":1009,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":118,"conditions":1012,"interventions":1014},"NCT01406158","A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation",[74],"2011-07","2011-05",[1013,30],"Pharmacokinetics of Solifenacin Succinate",[1015,1016,1017],"Solifenacin Succinate Formulation A","Solifenacin Succinate Formulation B","Solifenacin Succinate",{"nctId":1019,"briefTitle":1020,"status":114,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":896,"enrollment":1023,"conditions":1024,"interventions":1026},"NCT01297192","A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously",[74],"2009-07",41,[30,1025],"Pharmacokinetics of Mirabegron",[1000,1027],"mirabegron",{"nctId":1029,"briefTitle":1030,"status":114,"phases":1031,"primaryCompletion":333,"completion":333,"start":846,"enrollment":118,"conditions":1032,"interventions":1034},"NCT01015040","Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers",[74],[1033,1013,30],"Bioavailability of Solifenacin Succinate",[1035,1000],"solifenacin succinate suspension",{"trials":1037,"activeCount":85},[1038,1050],{"nctId":1039,"briefTitle":1040,"status":114,"phases":1041,"primaryCompletion":1042,"completion":1042,"start":1043,"enrollment":1044,"conditions":1045,"interventions":1048},"NCT00507455","Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction",[75],"2008-08","2007-06",222,[1046,1047],"Lower Urinary Tract Symptoms","Bladder Outlet Obstruction",[1000,1049],"tamsulosin hydrochloride",{"nctId":1051,"briefTitle":1052,"status":114,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1059},"NCT00510406","A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS\u002FBPH",[75],"2007-09","2007-01",919,[1046,1058],"Prostatic Hyperplasia",[1049,1000],{"trials":1061,"activeCount":85},[1062,1071,1081,1091,1100,1106],{"nctId":1063,"briefTitle":1064,"status":114,"phases":1065,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1070},"NCT00454740","Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder",[76],"2005-08","2004-06",441,[33],[1000],{"nctId":1072,"briefTitle":1073,"status":114,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT00801944","Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms",[76],"2005-10","2004-04",973,[33],[1080],"Solifenacin succinate",{"nctId":1082,"briefTitle":1083,"status":114,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1089},"NCT00802373","Solifenacin Succinate Versus Tolterodine 4mg Once Daily",[76],"2004-10","2003-07",1355,[33],[1080,1090],"Tolterodine",{"nctId":1092,"briefTitle":1093,"status":114,"phases":1094,"primaryCompletion":860,"completion":860,"start":1095,"enrollment":1096,"conditions":1097,"interventions":1098},"NCT00368706","A Double-Blind, Paralleled Study Comparing Efficacy\u002FSafety of Solifenacin to Tolterodine in Overactive Bladder Patients",[76],"2006-09",246,[33],[1000,1099],"tolterodine",{"nctId":1101,"briefTitle":1102,"status":114,"phases":1103,"conditions":1104,"interventions":1105},"NCT00189800","A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder",[76],[24],[1080],{"nctId":1107,"briefTitle":1108,"status":114,"phases":1109,"primaryCompletion":1110,"completion":1110,"start":1067,"enrollment":1111,"conditions":1112,"interventions":1113},"NCT00463541","Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms",[76],"2005-04",2225,[33],[1000],{"trials":1115,"activeCount":85},[1116,1125,1135,1144,1157,1165],{"nctId":1117,"briefTitle":1118,"status":114,"phases":1119,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1122,"conditions":1123,"interventions":1124},"NCT00573508","Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life",[77],"2008-07","2007-08",768,[33],[1017],{"nctId":1126,"briefTitle":1127,"status":114,"phases":1128,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1134},"NCT01371994","A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy",[77],"2013-10-21","2011-08-02",640,[1133],"Urinary Incontinence",[1000],{"nctId":1136,"briefTitle":1137,"status":114,"phases":1138,"primaryCompletion":1055,"completion":1055,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1142},"NCT00333112","A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.",[77],"2006-05",398,[1133],[1000,1143],"tamsulosin",{"nctId":1145,"briefTitle":1146,"status":114,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1155},"NCT00629642","Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis",[77],"2011-01-28","2008-03-14",249,[1152,1153,1154],"Multiple Sclerosis","Neurogenic Bladder","Spinal Cord Diseases",[1017,1017,1156],"Oxybutynin Hydrochloride",{"nctId":1158,"briefTitle":1159,"status":114,"phases":1160,"primaryCompletion":319,"completion":319,"start":1139,"enrollment":1161,"conditions":1162,"interventions":1164},"NCT00337558","A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)",[77],643,[24,1133,1163],"Urge Incontinence",[1080],{"nctId":1166,"briefTitle":1167,"status":114,"phases":1168,"primaryCompletion":1169,"completion":1169,"start":971,"enrollment":1170,"conditions":1171,"interventions":1174},"NCT00771394","Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia",[77],"2010-01",638,[1172,1173,24],"Benign Prostatic Hyperplasia","Benign Prostatic Hypertrophy",[1175,1080],"Tamsulosin hydrochloride",{"trials":1177,"activeCount":85},[],{"intervention":1179,"totalTrials":1180,"cells":1181},"Micafungin",16,{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1223,"PHASE3":1255,"PHASE4":1331,"NA":1344},{"trials":1183,"activeCount":85},[],{"trials":1185,"activeCount":85},[1186,1198,1206,1215],{"nctId":1187,"briefTitle":1188,"status":114,"phases":1189,"primaryCompletion":356,"completion":356,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1197},"NCT00607763","Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug",[74],"2007-10",9,[1193,1194,1195,1196],"Invasive Candidiasis","Esophageal Candidiasis","Oropharyngeal Candidiasis","Candidemia",[1179],{"nctId":1199,"briefTitle":1200,"status":114,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":263,"conditions":1204,"interventions":1205},"NCT00608335","Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug",[74],"2011-09-08","2007-10-14",[1195,1196,1193,1194],[1179],{"nctId":1207,"briefTitle":1208,"status":114,"phases":1209,"primaryCompletion":896,"completion":896,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1214},"NCT00606268","A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant",[74],"2007-11",42,[1213],"Fungal Infections",[1179],{"nctId":1216,"briefTitle":1217,"status":114,"phases":1218,"primaryCompletion":1190,"completion":1190,"start":1121,"enrollment":1219,"conditions":1220,"interventions":1222},"NCT00818584","An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates",[74],13,[1221],"Candida",[1179],{"trials":1224,"activeCount":85},[1225,1236,1246],{"nctId":1226,"briefTitle":1227,"status":114,"phases":1228,"primaryCompletion":1229,"completion":1229,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1234},"NCT01122368","A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects",[75],"2011-12-15","2010-07-13",252,[1233],"Mycoses",[1235],"micafungin",{"nctId":1237,"briefTitle":1238,"status":353,"phases":1239,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":31,"conditions":1242,"interventions":1244},"NCT00376337","Micafungin Salvage Mono-therapy in Invasive Aspergillosis",[75],"2008-09","2006-06",[1243],"Invasive Aspergillosis",[1179,1245],"Systemic antifungal therapy",{"nctId":1247,"briefTitle":1248,"status":353,"phases":1249,"primaryCompletion":919,"completion":919,"start":1250,"enrollment":158,"conditions":1251,"interventions":1253},"NCT00047827","Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis",[75],"2002-12",[1252],"Aspergillosis",[1179,1254],"Liposomal Amphotericin B",{"trials":1256,"activeCount":85},[1257,1267,1275,1284,1294,1304,1313,1321],{"nctId":1258,"briefTitle":1259,"status":114,"phases":1260,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":1263,"conditions":1264,"interventions":1266},"NCT00106288","Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia",[76],"2005-12","2003-01",637,[1265],"Candidiasis",[1179,1254],{"nctId":1268,"briefTitle":1269,"status":353,"phases":1270,"primaryCompletion":897,"completion":897,"start":1262,"enrollment":1271,"conditions":1272,"interventions":1274},"NCT00048750","Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU",[76],104,[1273],"Invasive Fungal Infections",[1179],{"nctId":1276,"briefTitle":1277,"status":114,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":861,"enrollment":1280,"conditions":1281,"interventions":1282},"NCT00105144","Study of Micafungin in Patients With Invasive Candidiasis or Candidemia",[76],"2006-04",611,[1265,1196],[1179,1283],"Caspofungin",{"nctId":1285,"briefTitle":1286,"status":114,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1067,"enrollment":1289,"conditions":1290,"interventions":1292},"NCT00665639","Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis",[76],"2004-12",454,[1291],"Candidiasis, Oral",[1235,1293],"caspofungin",{"nctId":1295,"briefTitle":1296,"status":114,"phases":1297,"primaryCompletion":333,"completion":333,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1302},"NCT00794703","A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections",[76],"2008-11",288,[1301,1213],"Fungemia",[1235,1303],"itraconazole",{"nctId":1305,"briefTitle":1306,"status":114,"phases":1307,"primaryCompletion":1308,"completion":1308,"start":1309,"enrollment":6,"conditions":1310,"interventions":1311},"NCT00666185","Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis",[76],"2004-02","2003-08",[1291],[1179,1312],"Fluconazole",{"nctId":1314,"briefTitle":1315,"status":114,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":918,"enrollment":118,"conditions":1318,"interventions":1319},"NCT00189709","Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia",[76],"2006-07",[1193,1196],[1179,1320],"fluconazole",{"nctId":1322,"briefTitle":1323,"status":114,"phases":1324,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1329},"NCT01058174","Liver Transplant European Study Into the Prevention of Fungal Infection",[76],"2012-05-03","2009-12-15",350,[35,1233],[1235,1320,1330,1293],"liposomal amphotericin B",{"trials":1332,"activeCount":85},[1333],{"nctId":1334,"briefTitle":1335,"status":1336,"phases":1337,"start":1338,"enrollment":85,"conditions":1339,"interventions":1342},"NCT00423163","A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis","WITHDRAWN",[77],"2007-02",[1340,1341],"Aspergillosis\u002FBlood","Aspergillosis\u002FInvasive",[1235,1343],"voriconazole",{"trials":1345,"activeCount":85},[],{"intervention":1347,"totalTrials":12,"cells":1348},"alefacept",{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1361,"PHASE3":1388,"PHASE4":1414,"NA":1441},{"trials":1350,"activeCount":85},[],{"trials":1352,"activeCount":85},[1353],{"nctId":1354,"briefTitle":1355,"status":114,"phases":1356,"primaryCompletion":1120,"completion":1120,"start":860,"enrollment":1357,"conditions":1358,"interventions":1360},"NCT00653822","A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers",[74],75,[1359],"Pharmacokinetics of Alefacept",[1347],{"trials":1362,"activeCount":85},[1363,1367,1375,1379],{"nctId":817,"briefTitle":818,"status":114,"phases":1364,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":1365,"interventions":1366},[75],[21],[825,826,827,828,829],{"nctId":1368,"briefTitle":1369,"status":114,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":378,"enrollment":1372,"conditions":1373,"interventions":1374},"NCT00808223","Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis",[75],"2012-02",30,[751],[1347],{"nctId":843,"briefTitle":844,"status":114,"phases":1376,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":1377,"interventions":1378},[75],[850],[825,852,798,853],{"nctId":1380,"briefTitle":1381,"status":114,"phases":1382,"primaryCompletion":895,"completion":895,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1387},"NCT00659412","A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis",[75],"2003-09",185,[1386],"Psoriatic Arthritis",[825,776],{"trials":1389,"activeCount":85},[1390,1398,1406],{"nctId":1391,"briefTitle":1392,"status":114,"phases":1393,"primaryCompletion":1076,"completion":1076,"start":1086,"enrollment":1394,"conditions":1395,"interventions":1397},"NCT00674063","A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis",[76],78,[1396],"Chronic Plaque Psoriasis",[1347],{"nctId":1399,"briefTitle":1400,"status":114,"phases":1401,"primaryCompletion":961,"completion":961,"start":1402,"enrollment":1403,"conditions":1404,"interventions":1405},"NCT00673556","A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate",[76],"2003-10",195,[1396],[1347],{"nctId":1407,"briefTitle":1408,"status":114,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":466,"conditions":1412,"interventions":1413},"NCT00692172","Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis",[76],"2004-11","2001-12",[751],[825],{"trials":1415,"activeCount":85},[1416,1424,1432],{"nctId":1417,"briefTitle":1418,"status":114,"phases":1419,"primaryCompletion":308,"completion":308,"start":1190,"enrollment":1420,"conditions":1421,"interventions":1423},"NCT00658606","Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects",[77],98,[1422],"Plaque Psoriasis",[1347],{"nctId":1425,"briefTitle":1426,"status":114,"phases":1427,"primaryCompletion":1120,"completion":1120,"start":907,"enrollment":1428,"conditions":1429,"interventions":1430},"NCT00493324","Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis",[77],43,[1396],[1347,1431],"polyvalent pneumococcal vaccine",{"nctId":1433,"briefTitle":1434,"status":114,"phases":1435,"primaryCompletion":895,"completion":895,"start":1436,"enrollment":1437,"conditions":1438,"interventions":1440},"NCT00168753","Community Based Trial for AMEVIVE®",[77],"2004-07",114,[1439],"Moderate to Severe Chronic Plaque Psoriasis",[825],{"trials":1442,"activeCount":85},[],{"intervention":912,"totalTrials":12,"cells":1444},{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1460,"PHASE4":1524,"NA":1544},{"trials":1446,"activeCount":85},[],{"trials":1448,"activeCount":85},[],{"trials":1450,"activeCount":85},[1451],{"nctId":1452,"briefTitle":1453,"status":114,"phases":1454,"primaryCompletion":1455,"completion":1455,"start":1010,"enrollment":31,"conditions":1456,"interventions":1459},"NCT01332201","Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®",[75],"2013-11",[887,1457,1458],"Lung Transplantation","Pancreas (Including SPK) Transplantation",[876,912],{"trials":1461,"activeCount":85},[1462,1470,1481,1490,1494,1502,1509,1517],{"nctId":1463,"briefTitle":1464,"status":114,"phases":1465,"primaryCompletion":318,"completion":318,"start":378,"enrollment":1466,"conditions":1467,"interventions":1468},"NCT00909571","Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus",[76],10,[35],[1469,912],"FK506E",{"nctId":1471,"briefTitle":1472,"status":114,"phases":1473,"primaryCompletion":846,"completion":846,"start":847,"enrollment":1474,"conditions":1475,"interventions":1478},"NCT00720408","A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.",[76],48,[35,1476,1477],"Transplantation Immunology","Host vs Graft Reaction",[1479,912,1480],"Prograf-XL","MMF",{"nctId":1482,"briefTitle":1483,"status":114,"phases":1484,"primaryCompletion":860,"completion":860,"start":1485,"enrollment":1486,"conditions":1487,"interventions":1488},"NCT00720265","A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients",[76],"2006-02",135,[21],[912,1489],"MR4",{"nctId":904,"briefTitle":905,"status":114,"phases":1491,"primaryCompletion":896,"completion":896,"start":907,"enrollment":908,"conditions":1492,"interventions":1493},[76],[21],[911,912,798,890,913],{"nctId":1495,"briefTitle":1496,"status":114,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":1485,"enrollment":1499,"conditions":1500,"interventions":1501},"NCT00719745","A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients",[76],"2008-06",74,[35],[912,1489],{"nctId":1503,"briefTitle":1504,"status":114,"phases":1505,"primaryCompletion":355,"completion":355,"start":847,"enrollment":1506,"conditions":1507,"interventions":1508},"NCT00717678","A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients",[76],73,[21,1476,1477],[1479,912,1480],{"nctId":1510,"briefTitle":1511,"status":114,"phases":1512,"primaryCompletion":896,"completion":896,"start":1513,"enrollment":1514,"conditions":1515,"interventions":1516},"NCT00619398","A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients",[76],"2008-01",172,[35],[912,911],{"nctId":1518,"briefTitle":1519,"status":114,"phases":1520,"primaryCompletion":896,"completion":896,"start":982,"enrollment":1211,"conditions":1521,"interventions":1522},"NCT00459719","A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation",[76],[35],[1523,912],"Tacrolimus modified-release",{"trials":1525,"activeCount":85},[1526,1535],{"nctId":1527,"briefTitle":1528,"status":114,"phases":1529,"primaryCompletion":1530,"completion":1530,"start":378,"enrollment":1531,"conditions":1532,"interventions":1533},"NCT01018914","A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients",[77],"2010-12",44,[35],[912,876,1534],"Myfortic",{"nctId":1536,"briefTitle":1537,"status":114,"phases":1538,"primaryCompletion":1539,"completion":1539,"start":1540,"enrollment":1541,"conditions":1542,"interventions":1543},"NCT01339468","A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation",[77],"2014-05-27","2011-04-27",100,[35],[876,912,912],{"trials":1545,"activeCount":85},[],{"intervention":1547,"totalTrials":1191,"cells":1548},"tacrolimus ointment",{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1555,"PHASE4":1596,"NA":1628},{"trials":1550,"activeCount":85},[],{"trials":1552,"activeCount":85},[],{"trials":1554,"activeCount":85},[],{"trials":1556,"activeCount":85},[1557,1566,1573,1580,1589],{"nctId":1558,"briefTitle":1559,"status":114,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":1562,"enrollment":1327,"conditions":1563,"interventions":1565},"NCT00691145","Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis",[76],"2005-02","2002-10",[1564],"Dermatitis, Atopic",[1547],{"nctId":1567,"briefTitle":1568,"status":114,"phases":1569,"primaryCompletion":1561,"completion":1561,"start":1402,"enrollment":1570,"conditions":1571,"interventions":1572},"NCT00691262","Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis",[76],166,[1564],[1547],{"nctId":1574,"briefTitle":1575,"status":114,"phases":1576,"primaryCompletion":928,"completion":928,"start":1076,"enrollment":1577,"conditions":1578,"interventions":1579},"NCT00480610","Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment",[76],226,[1564],[1547],{"nctId":1581,"briefTitle":1582,"status":114,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1588},"NCT00523952","Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients",[76],"2005-09","2004-01",303,[1564],[1547],{"nctId":1590,"briefTitle":1591,"status":114,"phases":1592,"primaryCompletion":928,"completion":928,"start":1067,"enrollment":1593,"conditions":1594,"interventions":1595},"NCT00480896","Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment",[76],250,[1564],[1547],{"trials":1597,"activeCount":85},[1598,1606,1613,1621],{"nctId":1599,"briefTitle":1600,"status":114,"phases":1601,"primaryCompletion":1602,"completion":1602,"start":1250,"enrollment":1577,"conditions":1603,"interventions":1604},"NCT00666159","Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis",[77],"2003-05",[1564],[1547,1605],"pimecrolimus cream",{"nctId":1607,"briefTitle":1608,"status":114,"phases":1609,"primaryCompletion":1288,"completion":1288,"start":1436,"enrollment":1420,"conditions":1610,"interventions":1612},"NCT00667056","Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis",[77],[1611],"Dermatitis",[1547],{"nctId":1614,"briefTitle":1615,"status":114,"phases":1616,"primaryCompletion":1617,"completion":1617,"start":1250,"enrollment":1618,"conditions":1619,"interventions":1620},"NCT00667160","Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis",[77],"2003-11",426,[1564],[1547,1605],{"nctId":1622,"briefTitle":1623,"status":114,"phases":1624,"primaryCompletion":1617,"completion":1617,"start":1562,"enrollment":1625,"conditions":1626,"interventions":1627},"NCT00666302","A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis",[77],413,[1564],[1547,1605],{"trials":1629,"activeCount":85},[],{"intervention":876,"totalTrials":8,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1642,"PHASE4":1648,"NA":1675},{"trials":1633,"activeCount":85},[],{"trials":1635,"activeCount":85},[],{"trials":1637,"activeCount":85},[1638],{"nctId":1452,"briefTitle":1453,"status":114,"phases":1639,"primaryCompletion":1455,"completion":1455,"start":1010,"enrollment":31,"conditions":1640,"interventions":1641},[75],[887,1457,1458],[876,912],{"trials":1643,"activeCount":85},[1644],{"nctId":868,"briefTitle":869,"status":114,"phases":1645,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":1646,"interventions":1647},[76],[35],[876,798,877,829],{"trials":1649,"activeCount":85},[1650,1654,1663,1667,1671],{"nctId":936,"briefTitle":937,"status":114,"phases":1651,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":1652,"interventions":1653},[77],[21],[876,798,944,829],{"nctId":1655,"briefTitle":1656,"status":114,"phases":1657,"primaryCompletion":1658,"completion":1658,"start":1659,"enrollment":1660,"conditions":1661,"interventions":1662},"NCT02432053","A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India",[77],"2013-05","2012-03",92,[21,35],[876],{"nctId":1527,"briefTitle":1528,"status":114,"phases":1664,"primaryCompletion":1530,"completion":1530,"start":378,"enrollment":1531,"conditions":1665,"interventions":1666},[77],[35],[912,876,1534],{"nctId":1536,"briefTitle":1537,"status":114,"phases":1668,"primaryCompletion":1539,"completion":1539,"start":1540,"enrollment":1541,"conditions":1669,"interventions":1670},[77],[35],[876,912,912],{"nctId":988,"briefTitle":989,"status":114,"phases":1672,"primaryCompletion":991,"completion":991,"start":992,"enrollment":993,"conditions":1673,"interventions":1674},[77],[21],[876,798,996,829],{"trials":1676,"activeCount":85},[],{"intervention":1090,"totalTrials":8,"cells":1678},{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1685,"PHASE4":1724,"NA":1747},{"trials":1680,"activeCount":85},[],{"trials":1682,"activeCount":85},[],{"trials":1684,"activeCount":85},[],{"trials":1686,"activeCount":85},[1687,1691,1695,1705,1715],{"nctId":1082,"briefTitle":1083,"status":114,"phases":1688,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1689,"interventions":1690},[76],[33],[1080,1090],{"nctId":1092,"briefTitle":1093,"status":114,"phases":1692,"primaryCompletion":860,"completion":860,"start":1095,"enrollment":1096,"conditions":1693,"interventions":1694},[76],[33],[1000,1099],{"nctId":1696,"briefTitle":1697,"status":114,"phases":1698,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1701,"conditions":1702,"interventions":1703},"NCT00688688","Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",[76],"2010-05-06","2008-04-25",2792,[33],[1704,1090],"Mirabegron",{"nctId":1706,"briefTitle":1707,"status":114,"phases":1708,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":1711,"conditions":1712,"interventions":1713},"NCT00966004","A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder",[76],"2010-02-15","2009-07-24",1139,[33],[1714,1099],"YM178",{"nctId":1716,"briefTitle":1717,"status":114,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT00689104","Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",[76],"2009-03-24","2008-04-28",2336,[33],[1704,1090],{"trials":1725,"activeCount":85},[1726,1739],{"nctId":1727,"briefTitle":1728,"status":114,"phases":1729,"primaryCompletion":1730,"completion":1730,"start":1731,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT02294396","Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.",[77],"2016-09-07","2014-10-28",649,[1734],"Overactive Bladder (OAB)",[1704,1736,1737,1738,1090],"Solifenacin","Propiverine","Imidafenacin",{"nctId":1740,"briefTitle":1741,"status":114,"phases":1742,"primaryCompletion":1743,"completion":1743,"start":307,"enrollment":118,"conditions":1744,"interventions":1746},"NCT01964183","Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine",[77],"2013-08",[1745,15],"Pharmacokinetics of Mirabegron and Tolterodine",[1099,1027],{"trials":1748,"activeCount":85},[],{"intervention":829,"totalTrials":1750,"cells":1751},6,{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1762,"PHASE4":1780,"NA":1798},{"trials":1753,"activeCount":85},[],{"trials":1755,"activeCount":85},[],{"trials":1757,"activeCount":85},[1758],{"nctId":817,"briefTitle":818,"status":114,"phases":1759,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":1760,"interventions":1761},[75],[21],[825,826,827,828,829],{"trials":1763,"activeCount":85},[1764,1768],{"nctId":868,"briefTitle":869,"status":114,"phases":1765,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":1766,"interventions":1767},[76],[35],[876,798,877,829],{"nctId":1769,"briefTitle":1770,"status":114,"phases":1771,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":730,"conditions":1775,"interventions":1776},"NCT00933231","Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)\u002FAngiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts",[76],"2015-05-11","2018-04-03","2009-08-17",[21],[826,826,944,1777,829,1778,1779],"Cellcept","Ramipril","Irbesartan",{"trials":1781,"activeCount":85},[1782,1786,1794],{"nctId":936,"briefTitle":937,"status":114,"phases":1783,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":1784,"interventions":1785},[77],[21],[876,798,944,829],{"nctId":1787,"briefTitle":1788,"status":114,"phases":1789,"primaryCompletion":1436,"completion":1790,"start":1791,"enrollment":908,"conditions":1792,"interventions":1793},"NCT00885820","Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection",[77],"2006-01","2001-09",[21],[852,1480,829],{"nctId":988,"briefTitle":989,"status":114,"phases":1795,"primaryCompletion":991,"completion":991,"start":992,"enrollment":993,"conditions":1796,"interventions":1797},[77],[21],[876,798,996,829],{"trials":1799,"activeCount":85},[],{"intervention":326,"totalTrials":1750,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1816,"PHASE4":1833,"NA":1843},{"trials":1803,"activeCount":85},[],{"trials":1805,"activeCount":85},[],{"trials":1807,"activeCount":85},[1808,1812],{"nctId":315,"briefTitle":316,"status":114,"phases":1809,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":1810,"interventions":1811},[74,75],[322,323],[325,274,326],{"nctId":831,"briefTitle":832,"status":114,"phases":1813,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":1814,"interventions":1815},[75],[35],[826,839,840,841],{"trials":1817,"activeCount":85},[1818,1822],{"nctId":879,"briefTitle":880,"status":114,"phases":1819,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":1820,"interventions":1821},[76],[886,887],[852,889,840,890,326],{"nctId":1823,"briefTitle":1824,"status":353,"phases":1825,"primaryCompletion":1658,"completion":1658,"start":1826,"enrollment":263,"conditions":1827,"interventions":1829},"NCT01342016","A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients",[76],"2011-04",[1828],"Lupus Nephritis",[826,1830,1831,1832,841],"tacrolimus placebo","leflunomide","leflunomide placebo",{"trials":1834,"activeCount":85},[1835,1839],{"nctId":968,"briefTitle":969,"status":114,"phases":1836,"primaryCompletion":971,"completion":971,"start":319,"enrollment":972,"conditions":1837,"interventions":1838},[77],[21,974,975],[852,798,977,326],{"nctId":979,"briefTitle":980,"status":353,"phases":1840,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":1841,"interventions":1842},[77],[21],[852,828,326],{"trials":1844,"activeCount":85},[],{"intervention":866,"totalTrials":1846,"cells":1847},5,{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1858,"PHASE4":1868,"NA":1884},{"trials":1849,"activeCount":85},[],{"trials":1851,"activeCount":85},[],{"trials":1853,"activeCount":85},[1854],{"nctId":843,"briefTitle":844,"status":114,"phases":1855,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":1856,"interventions":1857},[75],[850],[825,852,798,853],{"trials":1859,"activeCount":85},[1860,1864],{"nctId":857,"briefTitle":858,"status":114,"phases":1861,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":1862,"interventions":1863},[76],[864],[826,828,866],{"nctId":925,"briefTitle":926,"status":114,"phases":1865,"primaryCompletion":821,"completion":821,"start":928,"enrollment":929,"conditions":1866,"interventions":1867},[76],[21],[826,828,932,866],{"trials":1869,"activeCount":85},[1870,1874],{"nctId":958,"briefTitle":959,"status":114,"phases":1871,"primaryCompletion":896,"completion":896,"start":961,"enrollment":962,"conditions":1872,"interventions":1873},[77],[21],[827,965,826,966,828,866],{"nctId":1875,"briefTitle":1876,"status":114,"phases":1877,"primaryCompletion":847,"completion":847,"start":1878,"enrollment":1879,"conditions":1880,"interventions":1882},"NCT00650468","A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients",[77],"1999-11",397,[1881],"Renal Transplantation",[826,1883,866],"CellCept",{"trials":1885,"activeCount":85},[],{"intervention":1887,"totalTrials":275,"cells":1888},"Regadenoson",{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1905,"PHASE4":1916,"NA":1936},{"trials":1890,"activeCount":85},[],{"trials":1892,"activeCount":85},[],{"trials":1894,"activeCount":85},[1895],{"nctId":1896,"briefTitle":1897,"status":114,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":749,"conditions":1901,"interventions":1903},"NCT01334918","A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)",[75],"2012-07-02","2011-04-26",[1902],"Coronary Artery Disease (CAD)",[1904],"regadenoson",{"trials":1906,"activeCount":85},[1907],{"nctId":1908,"briefTitle":1909,"status":114,"phases":1910,"primaryCompletion":1911,"completion":1911,"start":1719,"enrollment":1912,"conditions":1913,"interventions":1914},"NCT00826280","Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)",[76],"2010-07-15",347,[1902],[1904,1915],"overencapsulated caffeine",{"trials":1917,"activeCount":85},[1918,1928],{"nctId":1919,"briefTitle":1920,"status":114,"phases":1921,"primaryCompletion":356,"completion":356,"start":378,"enrollment":1922,"conditions":1923,"interventions":1927},"NCT00862641","A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease",[77],1009,[1924,1925,1926],"Asthma","Coronary Artery Disease","Pulmonary Disease, Chronic Obstructive",[1887],{"nctId":1929,"briefTitle":1930,"status":114,"phases":1931,"primaryCompletion":308,"completion":308,"start":378,"enrollment":1932,"conditions":1933,"interventions":1935},"NCT00863707","A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment",[77],511,[1934,1925],"Kidney Diseases",[1887],{"trials":1937,"activeCount":85},[],{"intervention":1939,"totalTrials":275,"cells":1940},"Zolpidem MR",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1970,"NA":1989},{"trials":1942,"activeCount":85},[],{"trials":1944,"activeCount":85},[],{"trials":1946,"activeCount":85},[],{"trials":1948,"activeCount":85},[1949,1961],{"nctId":1950,"briefTitle":1951,"status":114,"phases":1952,"primaryCompletion":1953,"completion":1498,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1958},"NCT00374777","A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients",[76],"2008-05","2006-08",450,[1957],"Sleep Initiation and Maintenance Disorders",[1959,1960],"zolpidem MR","nitrazepam",{"nctId":1962,"briefTitle":1963,"status":114,"phases":1964,"primaryCompletion":1210,"completion":1210,"start":1485,"enrollment":1965,"conditions":1966,"interventions":1968},"NCT00283946","A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia",[76],876,[1957,1967],"Sleep Disorders",[1939,1969],"Zolpidem",{"trials":1971,"activeCount":85},[1972,1981],{"nctId":1973,"briefTitle":1974,"status":114,"phases":1975,"primaryCompletion":1826,"completion":1826,"start":356,"enrollment":1976,"conditions":1977,"interventions":1979},"NCT01181232","A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients",[77],132,[1957,1978],"Primary Insomnia",[1939,1980],"Zolpidem IR",{"nctId":1982,"briefTitle":1983,"status":114,"phases":1984,"primaryCompletion":1985,"completion":1985,"start":809,"enrollment":1211,"conditions":1986,"interventions":1987},"NCT00956319","A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients",[77],"2010-11",[1957,1978],[1939,1988],"Estazolam",{"trials":1990,"activeCount":85},[],{"intervention":1969,"totalTrials":275,"cells":1992},{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":1999,"PHASE4":2014,"NA":2032},{"trials":1994,"activeCount":85},[],{"trials":1996,"activeCount":85},[],{"trials":1998,"activeCount":85},[],{"trials":2000,"activeCount":85},[2001,2005],{"nctId":1962,"briefTitle":1963,"status":114,"phases":2002,"primaryCompletion":1210,"completion":1210,"start":1485,"enrollment":1965,"conditions":2003,"interventions":2004},[76],[1957,1967],[1939,1969],{"nctId":2006,"briefTitle":2007,"status":114,"phases":2008,"primaryCompletion":907,"completion":907,"start":2009,"enrollment":2010,"conditions":2011,"interventions":2012},"NCT00999219","A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia",[76],"2006-03",55,[1957],[2013,1969],"FK199B",{"trials":2015,"activeCount":85},[2016,2025],{"nctId":2017,"briefTitle":2018,"status":114,"phases":2019,"primaryCompletion":318,"completion":318,"start":2020,"enrollment":12,"conditions":2021,"interventions":2023},"NCT00653562","Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography",[77],"2006-11",[2022,1957],"Insomnia",[2024],"zolpidem",{"nctId":2026,"briefTitle":2027,"status":114,"phases":2028,"primaryCompletion":1169,"completion":1169,"start":1338,"enrollment":2029,"conditions":2030,"interventions":2031},"NCT00432198","Zolpidem Postmarketing Study in Adolescent Patients With Insomnia",[77],122,[2022],[1969],{"trials":2033,"activeCount":85},[],{"intervention":1143,"totalTrials":275,"cells":2035},{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2049,"PHASE3":2063,"PHASE4":2065,"NA":2080},{"trials":2037,"activeCount":85},[],{"trials":2039,"activeCount":85},[2040],{"nctId":2041,"briefTitle":2042,"status":114,"phases":2043,"primaryCompletion":820,"completion":820,"start":2044,"enrollment":1474,"conditions":2045,"interventions":2048},"NCT01489696","A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin",[74],"2010-08",[2046,18,2047],"Cardiovascular","Pharmacokinetics",[1027,1143],{"trials":2050,"activeCount":85},[2051],{"nctId":2052,"briefTitle":2053,"status":114,"phases":2054,"primaryCompletion":2055,"completion":2055,"start":2056,"enrollment":2057,"conditions":2058,"interventions":2060},"NCT02038868","A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia",[75],"2014-04-04","2013-07-22",320,[2059],"Benign Prostate Hyperplasia",[2061,2062],"ASP4901","Tamsulosin",{"trials":2064,"activeCount":85},[],{"trials":2066,"activeCount":85},[2067,2071],{"nctId":1136,"briefTitle":1137,"status":114,"phases":2068,"primaryCompletion":1055,"completion":1055,"start":1139,"enrollment":1140,"conditions":2069,"interventions":2070},[77],[1133],[1000,1143],{"nctId":2072,"briefTitle":2073,"status":114,"phases":2074,"primaryCompletion":2075,"completion":2075,"start":2076,"enrollment":2077,"conditions":2078,"interventions":2079},"NCT02656173","A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)",[77],"2017-07-21","2016-01-25",568,[24],[1704,2062],{"trials":2081,"activeCount":85},[],{"intervention":2083,"totalTrials":105,"cells":2084},"Voriconazole",{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2113,"NA":2119},{"trials":2086,"activeCount":85},[],{"trials":2088,"activeCount":85},[],{"trials":2090,"activeCount":85},[],{"trials":2092,"activeCount":85},[2093,2104],{"nctId":2094,"briefTitle":2095,"status":114,"phases":2096,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2100,"interventions":2102},"NCT00412893","Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis",[76],"2013-03-28","2007-03-07",527,[1252,2101],"Invasive Fungal Infection",[2103,2083],"Isavuconazole",{"nctId":2105,"briefTitle":2106,"status":114,"phases":2107,"primaryCompletion":2108,"completion":2108,"start":2109,"enrollment":1955,"conditions":2110,"interventions":2112},"NCT00413218","Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections",[76],"2015-03-03","2007-03-08",[2111,1196,1233],"Candidiasis, Invasive",[2103,1283,2083],{"trials":2114,"activeCount":85},[2115],{"nctId":1334,"briefTitle":1335,"status":1336,"phases":2116,"start":1338,"enrollment":85,"conditions":2117,"interventions":2118},[77],[1340,1341],[1235,1343],{"trials":2120,"activeCount":85},[],{"intervention":944,"totalTrials":105,"cells":2122},{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2129,"PHASE4":2135,"NA":2145},{"trials":2124,"activeCount":85},[],{"trials":2126,"activeCount":85},[],{"trials":2128,"activeCount":85},[],{"trials":2130,"activeCount":85},[2131],{"nctId":1769,"briefTitle":1770,"status":114,"phases":2132,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":730,"conditions":2133,"interventions":2134},[76],[21],[826,826,944,1777,829,1778,1779],{"trials":2136,"activeCount":85},[2137,2141],{"nctId":936,"briefTitle":937,"status":114,"phases":2138,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":2139,"interventions":2140},[77],[21],[876,798,944,829],{"nctId":946,"briefTitle":947,"status":114,"phases":2142,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":2143,"interventions":2144},[77],[21],[954,955,798,944,956],{"trials":2146,"activeCount":85},[],{"intervention":827,"totalTrials":105,"cells":2148},{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2159,"PHASE4":2165,"NA":2171},{"trials":2150,"activeCount":85},[],{"trials":2152,"activeCount":85},[],{"trials":2154,"activeCount":85},[2155],{"nctId":817,"briefTitle":818,"status":114,"phases":2156,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":2157,"interventions":2158},[75],[21],[825,826,827,828,829],{"trials":2160,"activeCount":85},[2161],{"nctId":868,"briefTitle":869,"status":114,"phases":2162,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":2163,"interventions":2164},[76],[35],[876,798,877,829],{"trials":2166,"activeCount":85},[2167],{"nctId":958,"briefTitle":959,"status":114,"phases":2168,"primaryCompletion":896,"completion":896,"start":961,"enrollment":962,"conditions":2169,"interventions":2170},[77],[21],[827,965,826,966,828,866],{"trials":2172,"activeCount":85},[],{"intervention":1605,"totalTrials":105,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2183,"NA":2197},{"trials":2176,"activeCount":85},[],{"trials":2178,"activeCount":85},[],{"trials":2180,"activeCount":85},[],{"trials":2182,"activeCount":85},[],{"trials":2184,"activeCount":85},[2185,2189,2193],{"nctId":1599,"briefTitle":1600,"status":114,"phases":2186,"primaryCompletion":1602,"completion":1602,"start":1250,"enrollment":1577,"conditions":2187,"interventions":2188},[77],[1564],[1547,1605],{"nctId":1614,"briefTitle":1615,"status":114,"phases":2190,"primaryCompletion":1617,"completion":1617,"start":1250,"enrollment":1618,"conditions":2191,"interventions":2192},[77],[1564],[1547,1605],{"nctId":1622,"briefTitle":1623,"status":114,"phases":2194,"primaryCompletion":1617,"completion":1617,"start":1562,"enrollment":1625,"conditions":2195,"interventions":2196},[77],[1564],[1547,1605],{"trials":2198,"activeCount":85},[],{"intervention":1480,"totalTrials":105,"cells":2200},{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2205,"PHASE3":2207,"PHASE4":2217,"NA":2223},{"trials":2202,"activeCount":85},[],{"trials":2204,"activeCount":85},[],{"trials":2206,"activeCount":85},[],{"trials":2208,"activeCount":85},[2209,2213],{"nctId":1471,"briefTitle":1472,"status":114,"phases":2210,"primaryCompletion":846,"completion":846,"start":847,"enrollment":1474,"conditions":2211,"interventions":2212},[76],[35,1476,1477],[1479,912,1480],{"nctId":1503,"briefTitle":1504,"status":114,"phases":2214,"primaryCompletion":355,"completion":355,"start":847,"enrollment":1506,"conditions":2215,"interventions":2216},[76],[21,1476,1477],[1479,912,1480],{"trials":2218,"activeCount":85},[2219],{"nctId":1787,"briefTitle":1788,"status":114,"phases":2220,"primaryCompletion":1436,"completion":1790,"start":1791,"enrollment":908,"conditions":2221,"interventions":2222},[77],[21],[852,1480,829],{"trials":2224,"activeCount":85},[],{"intervention":2226,"totalTrials":105,"cells":2227},"QUTENZA",{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2232,"PHASE3":2234,"PHASE4":2246,"NA":2270},{"trials":2229,"activeCount":85},[],{"trials":2231,"activeCount":85},[],{"trials":2233,"activeCount":85},[],{"trials":2235,"activeCount":85},[2236],{"nctId":2237,"briefTitle":2238,"status":114,"phases":2239,"primaryCompletion":2240,"completion":2240,"start":2241,"enrollment":2242,"conditions":2243,"interventions":2245},"NCT01478607","A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients",[76],"2014-02","2011-11",468,[2244],"Painful Diabetic Peripheral Neuropathy (PDPN)",[2226],{"trials":2247,"activeCount":85},[2248,2258],{"nctId":2249,"briefTitle":2250,"status":114,"phases":2251,"primaryCompletion":2252,"completion":2252,"start":2253,"enrollment":2254,"conditions":2255,"interventions":2257},"NCT01252160","Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage",[77],"2013-09-26","2010-10-28",306,[2256],"Neuralgia, Postherpetic",[2226],{"nctId":2259,"briefTitle":2260,"status":114,"phases":2261,"primaryCompletion":2262,"completion":2262,"start":2263,"enrollment":2029,"conditions":2264,"interventions":2267},"NCT01416116","Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch",[77],"2012-04-25","2011-07-06",[2265,2266],"or Peripheral Nerve Injury (PNI)","Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)",[2226,2268,2269],"Lidocaine","Tramadol",{"trials":2271,"activeCount":85},[],{"intervention":889,"totalTrials":105,"cells":2273},{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2287,"PHASE3":2289,"PHASE4":2295,"NA":2306},{"trials":2275,"activeCount":85},[],{"trials":2277,"activeCount":85},[2278],{"nctId":2279,"briefTitle":2280,"status":114,"phases":2281,"primaryCompletion":2282,"completion":2282,"start":2241,"enrollment":118,"conditions":2283,"interventions":2284},"NCT01494597","Drug Interaction Study of Isavuconazole and Cyclosporine",[74],"2011-12",[15],[2285,2286],"isavuconazole","cyclosporine",{"trials":2288,"activeCount":85},[],{"trials":2290,"activeCount":85},[2291],{"nctId":879,"briefTitle":880,"status":114,"phases":2292,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":2293,"interventions":2294},[76],[886,887],[852,889,840,890,326],{"trials":2296,"activeCount":85},[2297],{"nctId":2298,"briefTitle":2299,"status":114,"phases":2300,"primaryCompletion":1485,"completion":1485,"start":2301,"enrollment":2302,"conditions":2303,"interventions":2305},"NCT00637143","Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)",[77],"1999-04",107,[1881,2304],"Chronic Renal Allograft Failure",[852,889],{"trials":2307,"activeCount":85},[],{"intervention":1049,"totalTrials":105,"cells":2309},{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2314,"PHASE3":2324,"PHASE4":2326,"NA":2332},{"trials":2311,"activeCount":85},[],{"trials":2313,"activeCount":85},[],{"trials":2315,"activeCount":85},[2316,2320],{"nctId":1039,"briefTitle":1040,"status":114,"phases":2317,"primaryCompletion":1042,"completion":1042,"start":1043,"enrollment":1044,"conditions":2318,"interventions":2319},[75],[1046,1047],[1000,1049],{"nctId":1051,"briefTitle":1052,"status":114,"phases":2321,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":2322,"interventions":2323},[75],[1046,1058],[1049,1000],{"trials":2325,"activeCount":85},[],{"trials":2327,"activeCount":85},[2328],{"nctId":1166,"briefTitle":1167,"status":114,"phases":2329,"primaryCompletion":1169,"completion":1169,"start":971,"enrollment":1170,"conditions":2330,"interventions":2331},[77],[1172,1173,24],[1175,1080],{"trials":2333,"activeCount":85},[],{"intervention":955,"totalTrials":158,"cells":2335},{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2344,"NA":2358},{"trials":2337,"activeCount":85},[],{"trials":2339,"activeCount":85},[],{"trials":2341,"activeCount":85},[],{"trials":2343,"activeCount":85},[],{"trials":2345,"activeCount":85},[2346,2350],{"nctId":946,"briefTitle":947,"status":114,"phases":2347,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":2348,"interventions":2349},[77],[21],[954,955,798,944,956],{"nctId":2351,"briefTitle":2352,"status":114,"phases":2353,"primaryCompletion":2354,"completion":2354,"start":2355,"enrollment":1506,"conditions":2356,"interventions":2357},"NCT02161237","Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation",[77],"2016-12-22","2014-06-26",[21],[955],{"trials":2359,"activeCount":85},[],{"intervention":1883,"totalTrials":158,"cells":2361},{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2368,"PHASE4":2374,"NA":2380},{"trials":2363,"activeCount":85},[],{"trials":2365,"activeCount":85},[],{"trials":2367,"activeCount":85},[],{"trials":2369,"activeCount":85},[2370],{"nctId":1769,"briefTitle":1770,"status":114,"phases":2371,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":730,"conditions":2372,"interventions":2373},[76],[21],[826,826,944,1777,829,1778,1779],{"trials":2375,"activeCount":85},[2376],{"nctId":1875,"briefTitle":1876,"status":114,"phases":2377,"primaryCompletion":847,"completion":847,"start":1878,"enrollment":1879,"conditions":2378,"interventions":2379},[77],[1881],[826,1883,866],{"trials":2381,"activeCount":85},[],{"intervention":2383,"totalTrials":158,"cells":2384},"Tamsulosin OCAS",{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2393,"NA":2411},{"trials":2386,"activeCount":85},[],{"trials":2388,"activeCount":85},[],{"trials":2390,"activeCount":85},[],{"trials":2392,"activeCount":85},[],{"trials":2394,"activeCount":85},[2395,2404],{"nctId":2396,"briefTitle":2397,"status":114,"phases":2398,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":1541,"conditions":2401,"interventions":2403},"NCT02180789","A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation",[77],"2015-01","2013-03",[2402],"Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)",[2383],{"nctId":2405,"briefTitle":2406,"status":114,"phases":2407,"primaryCompletion":2020,"completion":2020,"start":1075,"enrollment":2408,"conditions":2409,"interventions":2410},"NCT00379067","A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.",[77],882,[1172],[2383],{"trials":2412,"activeCount":85},[],{"intervention":2414,"totalTrials":158,"cells":2415},"Gabapentin enacarbil",{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2422,"PHASE4":2424,"NA":2445},{"trials":2417,"activeCount":85},[],{"trials":2419,"activeCount":85},[],{"trials":2421,"activeCount":85},[],{"trials":2423,"activeCount":85},[],{"trials":2425,"activeCount":85},[2426,2436],{"nctId":2427,"briefTitle":2428,"status":114,"phases":2429,"primaryCompletion":2430,"completion":2430,"start":2431,"enrollment":2432,"conditions":2433,"interventions":2435},"NCT01981941","Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment",[77],"2015-05-13","2013-11-05",19,[2434],"Restless Legs Syndrome (RLS)",[2414],{"nctId":2437,"briefTitle":2438,"status":114,"phases":2439,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":2442,"conditions":2443,"interventions":2444},"NCT03053427","A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients",[77],"2018-06-25","2017-03-30",375,[2434],[2414],{"trials":2446,"activeCount":85},[],{"intervention":954,"totalTrials":81,"cells":2448},{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2457,"NA":2463},{"trials":2450,"activeCount":85},[],{"trials":2452,"activeCount":85},[],{"trials":2454,"activeCount":85},[],{"trials":2456,"activeCount":85},[],{"trials":2458,"activeCount":85},[2459],{"nctId":946,"briefTitle":947,"status":114,"phases":2460,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":2461,"interventions":2462},[77],[21],[954,955,798,944,956],{"trials":2464,"activeCount":85},[],{"intervention":956,"totalTrials":81,"cells":2466},{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2473,"PHASE4":2475,"NA":2481},{"trials":2468,"activeCount":85},[],{"trials":2470,"activeCount":85},[],{"trials":2472,"activeCount":85},[],{"trials":2474,"activeCount":85},[],{"trials":2476,"activeCount":85},[2477],{"nctId":946,"briefTitle":947,"status":114,"phases":2478,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":2479,"interventions":2480},[77],[21],[954,955,798,944,956],{"trials":2482,"activeCount":85},[],{"intervention":965,"totalTrials":81,"cells":2484},{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2499},{"trials":2486,"activeCount":85},[],{"trials":2488,"activeCount":85},[],{"trials":2490,"activeCount":85},[],{"trials":2492,"activeCount":85},[],{"trials":2494,"activeCount":85},[2495],{"nctId":958,"briefTitle":959,"status":114,"phases":2496,"primaryCompletion":896,"completion":896,"start":961,"enrollment":962,"conditions":2497,"interventions":2498},[77],[21],[827,965,826,966,828,866],{"trials":2500,"activeCount":85},[],{"intervention":966,"totalTrials":81,"cells":2502},{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2509,"PHASE4":2511,"NA":2517},{"trials":2504,"activeCount":85},[],{"trials":2506,"activeCount":85},[],{"trials":2508,"activeCount":85},[],{"trials":2510,"activeCount":85},[],{"trials":2512,"activeCount":85},[2513],{"nctId":958,"briefTitle":959,"status":114,"phases":2514,"primaryCompletion":896,"completion":896,"start":961,"enrollment":962,"conditions":2515,"interventions":2516},[77],[21],[827,965,826,966,828,866],{"trials":2518,"activeCount":85},[],{"intervention":2520,"totalTrials":81,"cells":2521},"Androgen deprivation therapy",{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2543},{"trials":2523,"activeCount":85},[],{"trials":2525,"activeCount":85},[],{"trials":2527,"activeCount":85},[],{"trials":2529,"activeCount":85},[],{"trials":2531,"activeCount":85},[2532],{"nctId":2533,"briefTitle":2534,"status":114,"phases":2535,"primaryCompletion":2536,"completion":2536,"start":2537,"enrollment":2538,"conditions":2539,"interventions":2541},"NCT03641560","A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy",[77],"2024-02-20","2018-09-19",52,[2540],"Metastatic Castration Resistant Prostate Cancer",[2542,2520],"Enzalutamide",{"trials":2544,"activeCount":85},[],{"intervention":2546,"totalTrials":81,"cells":2547},"Tacrolimus, Prograf®",{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2552,"PHASE3":2554,"PHASE4":2556,"NA":2564},{"trials":2549,"activeCount":85},[],{"trials":2551,"activeCount":85},[],{"trials":2553,"activeCount":85},[],{"trials":2555,"activeCount":85},[],{"trials":2557,"activeCount":85},[2558],{"nctId":2559,"briefTitle":2560,"status":114,"phases":2561,"completion":2009,"start":1262,"enrollment":822,"conditions":2562,"interventions":2563},"NCT00297765","Optimizing Prograf® Therapy in Renal Transplant Patients",[77],[1881],[2546],{"trials":2565,"activeCount":85},[],{"intervention":2567,"totalTrials":81,"cells":2568},"Insulin",{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2573,"PHASE3":2575,"PHASE4":2577,"NA":2589},{"trials":2570,"activeCount":85},[],{"trials":2572,"activeCount":85},[],{"trials":2574,"activeCount":85},[],{"trials":2576,"activeCount":85},[],{"trials":2578,"activeCount":85},[2579],{"nctId":2580,"briefTitle":2581,"status":114,"phases":2582,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":2585,"conditions":2586,"interventions":2587},"NCT02847091","Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy",[77],"2017-11-09","2016-07-29",103,[27],[2588,2567],"Ipragliflozin",{"trials":2590,"activeCount":85},[],{"intervention":2592,"totalTrials":81,"cells":2593},"Beraprost",{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2602,"NA":2614},{"trials":2595,"activeCount":85},[],{"trials":2597,"activeCount":85},[],{"trials":2599,"activeCount":85},[],{"trials":2601,"activeCount":85},[],{"trials":2603,"activeCount":85},[2604],{"nctId":2605,"briefTitle":2606,"status":353,"phases":2607,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":2611,"interventions":2612},"NCT02786979","Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients",[77],"2013-01","2010-07",190,[27],[2592,2613],"Aspirin",{"trials":2615,"activeCount":85},[],{"intervention":2613,"totalTrials":81,"cells":2617},{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2622,"PHASE3":2624,"PHASE4":2626,"NA":2632},{"trials":2619,"activeCount":85},[],{"trials":2621,"activeCount":85},[],{"trials":2623,"activeCount":85},[],{"trials":2625,"activeCount":85},[],{"trials":2627,"activeCount":85},[2628],{"nctId":2605,"briefTitle":2606,"status":353,"phases":2629,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":2630,"interventions":2631},[77],[27],[2592,2613],{"trials":2633,"activeCount":85},[],{"intervention":2635,"totalTrials":81,"cells":2636},"Tacrolimus 0.03%",{"EARLY_PHASE1":2637,"PHASE1":2639,"PHASE2":2641,"PHASE3":2643,"PHASE4":2645,"NA":2655},{"trials":2638,"activeCount":85},[],{"trials":2640,"activeCount":85},[],{"trials":2642,"activeCount":85},[],{"trials":2644,"activeCount":85},[],{"trials":2646,"activeCount":85},[2647],{"nctId":2648,"briefTitle":2649,"status":114,"phases":2650,"primaryCompletion":1066,"completion":1066,"start":1308,"enrollment":2651,"conditions":2652,"interventions":2653},"NCT00689832","Protopic Ointment in Children Atopic Eczema",[77],487,[1564],[2635,2654],"Fluticasone 0.005%",{"trials":2656,"activeCount":85},[],{"intervention":2654,"totalTrials":81,"cells":2658},{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2665,"PHASE4":2667,"NA":2673},{"trials":2660,"activeCount":85},[],{"trials":2662,"activeCount":85},[],{"trials":2664,"activeCount":85},[],{"trials":2666,"activeCount":85},[],{"trials":2668,"activeCount":85},[2669],{"nctId":2648,"briefTitle":2649,"status":114,"phases":2670,"primaryCompletion":1066,"completion":1066,"start":1308,"enrollment":2651,"conditions":2671,"interventions":2672},[77],[1564],[2635,2654],{"trials":2674,"activeCount":85},[],{"intervention":2676,"totalTrials":81,"cells":2677},"tacrolimus 0.1%",{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2684,"PHASE4":2686,"NA":2696},{"trials":2679,"activeCount":85},[],{"trials":2681,"activeCount":85},[],{"trials":2683,"activeCount":85},[],{"trials":2685,"activeCount":85},[],{"trials":2687,"activeCount":85},[2688],{"nctId":2689,"briefTitle":2690,"status":114,"phases":2691,"primaryCompletion":983,"completion":983,"start":1308,"enrollment":2692,"conditions":2693,"interventions":2694},"NCT00690105","Protopic Ointment in Adult Atopic Eczema of the Face",[77],577,[1564],[2676,2695],"fluticasone 0.005 %",{"trials":2697,"activeCount":85},[],{"intervention":2695,"totalTrials":81,"cells":2699},{"EARLY_PHASE1":2700,"PHASE1":2702,"PHASE2":2704,"PHASE3":2706,"PHASE4":2708,"NA":2714},{"trials":2701,"activeCount":85},[],{"trials":2703,"activeCount":85},[],{"trials":2705,"activeCount":85},[],{"trials":2707,"activeCount":85},[],{"trials":2709,"activeCount":85},[2710],{"nctId":2689,"briefTitle":2690,"status":114,"phases":2711,"primaryCompletion":983,"completion":983,"start":1308,"enrollment":2692,"conditions":2712,"interventions":2713},[77],[1564],[2676,2695],{"trials":2715,"activeCount":85},[],{"intervention":977,"totalTrials":81,"cells":2717},{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2724,"PHASE4":2726,"NA":2732},{"trials":2719,"activeCount":85},[],{"trials":2721,"activeCount":85},[],{"trials":2723,"activeCount":85},[],{"trials":2725,"activeCount":85},[],{"trials":2727,"activeCount":85},[2728],{"nctId":968,"briefTitle":969,"status":114,"phases":2729,"primaryCompletion":971,"completion":971,"start":319,"enrollment":972,"conditions":2730,"interventions":2731},[77],[21,974,975],[852,798,977,326],{"trials":2733,"activeCount":85},[],{"intervention":1737,"totalTrials":81,"cells":2735},{"EARLY_PHASE1":2736,"PHASE1":2738,"PHASE2":2740,"PHASE3":2742,"PHASE4":2744,"NA":2750},{"trials":2737,"activeCount":85},[],{"trials":2739,"activeCount":85},[],{"trials":2741,"activeCount":85},[],{"trials":2743,"activeCount":85},[],{"trials":2745,"activeCount":85},[2746],{"nctId":1727,"briefTitle":1728,"status":114,"phases":2747,"primaryCompletion":1730,"completion":1730,"start":1731,"enrollment":1732,"conditions":2748,"interventions":2749},[77],[1734],[1704,1736,1737,1738,1090],{"trials":2751,"activeCount":85},[],{"intervention":1738,"totalTrials":81,"cells":2753},{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2762,"NA":2768},{"trials":2755,"activeCount":85},[],{"trials":2757,"activeCount":85},[],{"trials":2759,"activeCount":85},[],{"trials":2761,"activeCount":85},[],{"trials":2763,"activeCount":85},[2764],{"nctId":1727,"briefTitle":1728,"status":114,"phases":2765,"primaryCompletion":1730,"completion":1730,"start":1731,"enrollment":1732,"conditions":2766,"interventions":2767},[77],[1734],[1704,1736,1737,1738,1090],{"trials":2769,"activeCount":85},[],{"intervention":2771,"totalTrials":81,"cells":2772},"ATG-F",{"EARLY_PHASE1":2773,"PHASE1":2775,"PHASE2":2777,"PHASE3":2779,"PHASE4":2781,"NA":2793},{"trials":2774,"activeCount":85},[],{"trials":2776,"activeCount":85},[],{"trials":2778,"activeCount":85},[],{"trials":2780,"activeCount":85},[],{"trials":2782,"activeCount":85},[2783],{"nctId":2784,"briefTitle":2785,"status":114,"phases":2786,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":2789,"conditions":2790,"interventions":2792},"NCT02267512","Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients",[77],"2015-12-31","2012-07-31",280,[2791],"De Novo Kidney Transplant Patients",[2771],{"trials":2794,"activeCount":85},[],{"intervention":1431,"totalTrials":81,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2805,"NA":2811},{"trials":2798,"activeCount":85},[],{"trials":2800,"activeCount":85},[],{"trials":2802,"activeCount":85},[],{"trials":2804,"activeCount":85},[],{"trials":2806,"activeCount":85},[2807],{"nctId":1425,"briefTitle":1426,"status":114,"phases":2808,"primaryCompletion":1120,"completion":1120,"start":907,"enrollment":1428,"conditions":2809,"interventions":2810},[77],[1396],[1347,1431],{"trials":2812,"activeCount":85},[],{"intervention":2814,"totalTrials":81,"cells":2815},"Zotepine",{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2822,"PHASE4":2824,"NA":2835},{"trials":2817,"activeCount":85},[],{"trials":2819,"activeCount":85},[],{"trials":2821,"activeCount":85},[],{"trials":2823,"activeCount":85},[],{"trials":2825,"activeCount":85},[2826],{"nctId":2827,"briefTitle":2828,"status":353,"phases":2829,"primaryCompletion":308,"completion":308,"start":982,"enrollment":2830,"conditions":2831,"interventions":2833},"NCT00418873","Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward",[77],39,[2832],"Schizophrenia",[2814,2834],"Risperidone",{"trials":2836,"activeCount":85},[],{"intervention":2834,"totalTrials":81,"cells":2838},{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2845,"PHASE4":2847,"NA":2853},{"trials":2840,"activeCount":85},[],{"trials":2842,"activeCount":85},[],{"trials":2844,"activeCount":85},[],{"trials":2846,"activeCount":85},[],{"trials":2848,"activeCount":85},[2849],{"nctId":2827,"briefTitle":2828,"status":353,"phases":2850,"primaryCompletion":308,"completion":308,"start":982,"enrollment":2830,"conditions":2851,"interventions":2852},[77],[2832],[2814,2834],{"trials":2854,"activeCount":85},[],{"intervention":2856,"totalTrials":81,"cells":2857},"oxybutynin immediate release",{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2862,"PHASE3":2864,"PHASE4":2866,"NA":2876},{"trials":2859,"activeCount":85},[],{"trials":2861,"activeCount":85},[],{"trials":2863,"activeCount":85},[],{"trials":2865,"activeCount":85},[],{"trials":2867,"activeCount":85},[2868],{"nctId":2869,"briefTitle":2870,"status":114,"phases":2871,"primaryCompletion":821,"completion":821,"start":2872,"enrollment":1976,"conditions":2873,"interventions":2874},"NCT00431041","Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)",[77],"2006-12",[24],[2875,2856],"solifenacin",{"trials":2877,"activeCount":85},[],{"intervention":2879,"totalTrials":81,"cells":2880},"atorvastatin, Lipitor",{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2885,"PHASE3":2887,"PHASE4":2889,"NA":2898},{"trials":2882,"activeCount":85},[],{"trials":2884,"activeCount":85},[],{"trials":2886,"activeCount":85},[],{"trials":2888,"activeCount":85},[],{"trials":2890,"activeCount":85},[2891],{"nctId":2892,"briefTitle":2893,"status":114,"phases":2894,"enrollment":972,"conditions":2895,"interventions":2897},"NCT00408382","Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque",[77],[2896,1925],"Hypercholesteremia",[2879],{"trials":2899,"activeCount":85},[],{"intervention":1534,"totalTrials":81,"cells":2901},{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2916},{"trials":2903,"activeCount":85},[],{"trials":2905,"activeCount":85},[],{"trials":2907,"activeCount":85},[],{"trials":2909,"activeCount":85},[],{"trials":2911,"activeCount":85},[2912],{"nctId":1527,"briefTitle":1528,"status":114,"phases":2913,"primaryCompletion":1530,"completion":1530,"start":378,"enrollment":1531,"conditions":2914,"interventions":2915},[77],[35],[912,876,1534],{"trials":2917,"activeCount":85},[],{"intervention":2268,"totalTrials":81,"cells":2919},{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2928,"NA":2934},{"trials":2921,"activeCount":85},[],{"trials":2923,"activeCount":85},[],{"trials":2925,"activeCount":85},[],{"trials":2927,"activeCount":85},[],{"trials":2929,"activeCount":85},[2930],{"nctId":2259,"briefTitle":2260,"status":114,"phases":2931,"primaryCompletion":2262,"completion":2262,"start":2263,"enrollment":2029,"conditions":2932,"interventions":2933},[77],[2265,2266],[2226,2268,2269],{"trials":2935,"activeCount":85},[],{"intervention":2269,"totalTrials":81,"cells":2937},{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2944,"PHASE4":2946,"NA":2952},{"trials":2939,"activeCount":85},[],{"trials":2941,"activeCount":85},[],{"trials":2943,"activeCount":85},[],{"trials":2945,"activeCount":85},[],{"trials":2947,"activeCount":85},[2948],{"nctId":2259,"briefTitle":2260,"status":114,"phases":2949,"primaryCompletion":2262,"completion":2262,"start":2263,"enrollment":2029,"conditions":2950,"interventions":2951},[77],[2265,2266],[2226,2268,2269],{"trials":2953,"activeCount":85},[],{"intervention":996,"totalTrials":81,"cells":2955},{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2960,"PHASE3":2962,"PHASE4":2964,"NA":2970},{"trials":2957,"activeCount":85},[],{"trials":2959,"activeCount":85},[],{"trials":2961,"activeCount":85},[],{"trials":2963,"activeCount":85},[],{"trials":2965,"activeCount":85},[2966],{"nctId":988,"briefTitle":989,"status":114,"phases":2967,"primaryCompletion":991,"completion":991,"start":992,"enrollment":993,"conditions":2968,"interventions":2969},[77],[21],[876,798,996,829],{"trials":2971,"activeCount":85},[],{"intervention":1156,"totalTrials":81,"cells":2973},{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2978,"PHASE3":2980,"PHASE4":2982,"NA":2988},{"trials":2975,"activeCount":85},[],{"trials":2977,"activeCount":85},[],{"trials":2979,"activeCount":85},[],{"trials":2981,"activeCount":85},[],{"trials":2983,"activeCount":85},[2984],{"nctId":1145,"briefTitle":1146,"status":114,"phases":2985,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":2986,"interventions":2987},[77],[1152,1153,1154],[1017,1017,1156],{"trials":2989,"activeCount":85},[],{"intervention":2991,"totalTrials":81,"cells":2992},"Flutamide",{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3001,"NA":3012},{"trials":2994,"activeCount":85},[],{"trials":2996,"activeCount":85},[],{"trials":2998,"activeCount":85},[],{"trials":3000,"activeCount":85},[],{"trials":3002,"activeCount":85},[3003],{"nctId":3004,"briefTitle":3005,"status":114,"phases":3006,"primaryCompletion":3007,"completion":3007,"start":3008,"enrollment":3009,"conditions":3010,"interventions":3011},"NCT02918968","Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer",[77],"2020-03-27","2016-11-02",206,[322],[2542,2991],{"trials":3013,"activeCount":85},[],{"intervention":3015,"totalTrials":81,"cells":3016},"Protopic",{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3021,"PHASE3":3023,"PHASE4":3025,"NA":3035},{"trials":3018,"activeCount":85},[],{"trials":3020,"activeCount":85},[],{"trials":3022,"activeCount":85},[],{"trials":3024,"activeCount":85},[],{"trials":3026,"activeCount":85},[3027],{"nctId":3028,"briefTitle":3029,"status":114,"phases":3030,"primaryCompletion":1317,"completion":1317,"start":1085,"enrollment":3031,"conditions":3032,"interventions":3033},"NCT00106496","A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis",[77],410,[1564],[3015,3034],"Corticosteroid",{"trials":3036,"activeCount":85},[],{"intervention":3034,"totalTrials":81,"cells":3038},{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3045,"PHASE4":3047,"NA":3053},{"trials":3040,"activeCount":85},[],{"trials":3042,"activeCount":85},[],{"trials":3044,"activeCount":85},[],{"trials":3046,"activeCount":85},[],{"trials":3048,"activeCount":85},[3049],{"nctId":3028,"briefTitle":3029,"status":114,"phases":3050,"primaryCompletion":1317,"completion":1317,"start":1085,"enrollment":3031,"conditions":3051,"interventions":3052},[77],[1564],[3015,3034],{"trials":3054,"activeCount":85},[],{"intervention":1980,"totalTrials":81,"cells":3056},{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3063,"PHASE4":3065,"NA":3071},{"trials":3058,"activeCount":85},[],{"trials":3060,"activeCount":85},[],{"trials":3062,"activeCount":85},[],{"trials":3064,"activeCount":85},[],{"trials":3066,"activeCount":85},[3067],{"nctId":1973,"briefTitle":1974,"status":114,"phases":3068,"primaryCompletion":1826,"completion":1826,"start":356,"enrollment":1976,"conditions":3069,"interventions":3070},[77],[1957,1978],[1939,1980],{"trials":3072,"activeCount":85},[],{"intervention":3074,"totalTrials":81,"cells":3075},"Oxybutynin",{"EARLY_PHASE1":3076,"PHASE1":3078,"PHASE2":3080,"PHASE3":3082,"PHASE4":3084,"NA":3093},{"trials":3077,"activeCount":85},[],{"trials":3079,"activeCount":85},[],{"trials":3081,"activeCount":85},[],{"trials":3083,"activeCount":85},[],{"trials":3085,"activeCount":85},[3086],{"nctId":3087,"briefTitle":3088,"status":114,"phases":3089,"primaryCompletion":1530,"completion":1530,"start":355,"enrollment":11,"conditions":3090,"interventions":3092},"NCT01126424","A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability",[77],[3091],"Cognition",[1736,3074],{"trials":3094,"activeCount":85},[],{"intervention":1988,"totalTrials":81,"cells":3096},{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3101,"PHASE3":3103,"PHASE4":3105,"NA":3111},{"trials":3098,"activeCount":85},[],{"trials":3100,"activeCount":85},[],{"trials":3102,"activeCount":85},[],{"trials":3104,"activeCount":85},[],{"trials":3106,"activeCount":85},[3107],{"nctId":1982,"briefTitle":1983,"status":114,"phases":3108,"primaryCompletion":1985,"completion":1985,"start":809,"enrollment":1211,"conditions":3109,"interventions":3110},[77],[1957,1978],[1939,1988],{"trials":3112,"activeCount":85},[],{"intervention":3114,"totalTrials":3115,"cells":3116},"ASP1941",23,{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3261,"PHASE3":3282,"PHASE4":3314,"NA":3316},{"trials":3118,"activeCount":85},[],{"trials":3120,"activeCount":85},[3121,3129,3138,3144,3153,3159,3167,3177,3184,3192,3200,3211,3218,3227,3234,3241,3247,3254],{"nctId":3122,"briefTitle":3123,"status":114,"phases":3124,"primaryCompletion":331,"completion":331,"start":820,"enrollment":3125,"conditions":3126,"interventions":3128},"NCT01373060","A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ASP1941 in Healthy Male Taiwanese Subjects",[74],56,[15,3127],"Pharmacokinetics of ASP1941",[3114],{"nctId":3130,"briefTitle":3131,"status":114,"phases":3132,"primaryCompletion":3133,"completion":3133,"start":3134,"enrollment":320,"conditions":3135,"interventions":3137},"NCT01972880","A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets",[74],"2014-01","2013-09",[15,3136],"Plasma Concentration of ASP1941",[3114],{"nctId":3139,"briefTitle":3140,"status":114,"phases":3141,"primaryCompletion":860,"completion":860,"start":319,"enrollment":1474,"conditions":3142,"interventions":3143},"NCT01288898","Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941",[74],[15],[3114],{"nctId":3145,"briefTitle":3146,"status":114,"phases":3147,"primaryCompletion":3148,"completion":3148,"start":3149,"enrollment":3150,"conditions":3151,"interventions":3152},"NCT01097681","A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment",[74],"2010-06-18","2010-02-16",25,[27],[3114],{"nctId":3154,"briefTitle":3155,"status":114,"phases":3156,"primaryCompletion":907,"completion":907,"start":2872,"enrollment":263,"conditions":3157,"interventions":3158},"NCT01121198","A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects",[74],[711,3127],[3114],{"nctId":3160,"briefTitle":3161,"status":114,"phases":3162,"primaryCompletion":3163,"completion":3163,"start":3164,"enrollment":1372,"conditions":3165,"interventions":3166},"NCT01023945","A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus",[74],"2010-03-26","2009-11-07",[27],[3114],{"nctId":3168,"briefTitle":3169,"status":114,"phases":3170,"primaryCompletion":820,"completion":820,"start":3171,"enrollment":3172,"conditions":3173,"interventions":3175},"NCT01232413","A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects",[74],"2010-09",88,[18,3174],"Cardiac Repolarization",[3114,3176],"Moxifloxacin",{"nctId":3178,"briefTitle":3179,"status":114,"phases":3180,"primaryCompletion":319,"completion":319,"start":2020,"enrollment":3181,"conditions":3182,"interventions":3183},"NCT01288885","First in Men Study of Single Oral Doses of ASP1941 in Healthy Subjects",[74],76,[15],[3114],{"nctId":3185,"briefTitle":3186,"status":114,"phases":3187,"primaryCompletion":2044,"completion":2044,"start":3188,"enrollment":1180,"conditions":3189,"interventions":3191},"NCT01187186","A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941",[74],"2010-05",[3190],"Liver Disease",[3114],{"nctId":3193,"briefTitle":3194,"status":114,"phases":3195,"primaryCompletion":355,"completion":355,"start":3196,"enrollment":1372,"conditions":3197,"interventions":3198},"NCT01099839","A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol",[74],"2010-02",[30,3127],[3114,3199],"Miglitol",{"nctId":3201,"briefTitle":3202,"status":114,"phases":3203,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":3206,"conditions":3207,"interventions":3209},"NCT01403818","A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration",[74],"2011-08","2011-06",60,[15,3127,3208],"Pharmacokinetics of Mitiglinide",[3114,3210],"Mitiglinide calcium hydrate",{"nctId":3212,"briefTitle":3213,"status":114,"phases":3214,"primaryCompletion":308,"completion":308,"start":333,"enrollment":334,"conditions":3215,"interventions":3216},"NCT01088919","A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects",[74],[15,3127],[3114,3217],"pioglitazone hydrochloride",{"nctId":3219,"briefTitle":3220,"status":114,"phases":3221,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":3224,"conditions":3225,"interventions":3226},"NCT01302145","Drug to Drug Interaction Study With ASP1941 and Metformin",[74],"2009-12-09","2009-02-25",36,[27],[3114,690],{"nctId":3228,"briefTitle":3229,"status":114,"phases":3230,"primaryCompletion":1530,"completion":1530,"start":3231,"enrollment":1372,"conditions":3232,"interventions":3233},"NCT01674777","A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941",[74],"2010-10",[15,3127],[3114],{"nctId":3235,"briefTitle":3236,"status":114,"phases":3237,"primaryCompletion":318,"completion":318,"start":3196,"enrollment":334,"conditions":3238,"interventions":3239},"NCT01104532","A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects",[74],[15,3127],[3114,3240],"sitagliptin",{"nctId":3242,"briefTitle":3243,"status":114,"phases":3244,"primaryCompletion":971,"completion":971,"start":1953,"enrollment":1750,"conditions":3245,"interventions":3246},"NCT01302132","Mass Balance Study of ASP1941",[74],[18],[3114],{"nctId":3248,"briefTitle":3249,"status":114,"phases":3250,"primaryCompletion":3251,"completion":3251,"start":696,"enrollment":719,"conditions":3252,"interventions":3253},"NCT01302028","Renal Impairment Study With ASP1941",[74],"2010-06-26",[27],[3114],{"nctId":3255,"briefTitle":3256,"status":114,"phases":3257,"primaryCompletion":355,"completion":355,"start":308,"enrollment":2538,"conditions":3258,"interventions":3259},"NCT01302158","Drug-drug Interaction Study With ASP1941 and Glimepiride",[74],[18],[3114,3260],"Glimepiride",{"trials":3262,"activeCount":85},[3263,3272],{"nctId":3264,"briefTitle":3265,"status":114,"phases":3266,"primaryCompletion":3267,"completion":3267,"start":3268,"enrollment":1428,"conditions":3269,"interventions":3271},"NCT02529449","Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus",[75],"2016-03-19","2015-09-01",[3270],"Type 1 Diabetes Mellitus",[3114],{"nctId":3273,"briefTitle":3274,"status":114,"phases":3275,"primaryCompletion":3276,"completion":3276,"start":3277,"enrollment":3278,"conditions":3279,"interventions":3281},"NCT00790660","A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.",[75],"2009-03-06","2008-10-23",61,[3280],"Diabetes Mellitus, Type 2",[3114],{"trials":3283,"activeCount":85},[3284,3295,3304],{"nctId":3285,"briefTitle":3286,"status":114,"phases":3287,"primaryCompletion":3288,"completion":3288,"start":3289,"enrollment":3290,"conditions":3291,"interventions":3293},"NCT01505426","A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients",[76],"2013-01-14","2011-11-28",171,[3292],"Type II Diabetes Mellitus",[3114,3294],"metformin",{"nctId":3296,"briefTitle":3297,"status":114,"phases":3298,"primaryCompletion":3299,"completion":3299,"start":3300,"enrollment":3301,"conditions":3302,"interventions":3303},"NCT01316094","A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment",[76],"2012-11-28","2011-01-18",165,[27],[3114],{"nctId":3305,"briefTitle":3306,"status":353,"phases":3307,"primaryCompletion":3308,"completion":3308,"start":3309,"enrollment":3310,"conditions":3311,"interventions":3312},"NCT01514838","A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus",[76],"2012-10-19","2012-04-23",46,[3292],[3114,3313],"acarbose",{"trials":3315,"activeCount":85},[],{"trials":3317,"activeCount":85},[],{"intervention":3319,"totalTrials":1180,"cells":3320},"YM150",{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3360,"PHASE3":3403,"PHASE4":3447,"NA":3449},{"trials":3322,"activeCount":85},[],{"trials":3324,"activeCount":85},[3325,3332,3340,3348,3354],{"nctId":3326,"briefTitle":3327,"status":114,"phases":3328,"primaryCompletion":1169,"completion":1169,"start":333,"enrollment":118,"conditions":3329,"interventions":3331},"NCT01118559","A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150",[74],[15,3330],"Pharmacokinetics of YM150",[3319],{"nctId":3333,"briefTitle":3334,"status":114,"phases":3335,"primaryCompletion":1279,"completion":1279,"start":1485,"enrollment":118,"conditions":3336,"interventions":3338},"NCT01514812","A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects",[74],[15,3337],"Pharmacokinetic of Digoxin",[3319,3339],"digoxin",{"nctId":3341,"briefTitle":3342,"status":114,"phases":3343,"primaryCompletion":1338,"completion":1338,"start":2020,"enrollment":3224,"conditions":3344,"interventions":3347},"NCT01514825","A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects",[74],[3345,3346],"Healthy Elderly Subject","Pharmacokinetic of YM150",[3319],{"nctId":3349,"briefTitle":3350,"status":114,"phases":3351,"primaryCompletion":355,"completion":355,"start":3196,"enrollment":118,"conditions":3352,"interventions":3353},"NCT01125670","A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet",[74],[711,3330],[3319],{"nctId":3355,"briefTitle":3356,"status":114,"phases":3357,"primaryCompletion":318,"completion":318,"start":3196,"enrollment":1531,"conditions":3358,"interventions":3359},"NCT01125657","A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B",[74],[711,3330],[3319],{"trials":3361,"activeCount":85},[3362,3370,3379,3387,3395],{"nctId":3363,"briefTitle":3364,"status":114,"phases":3365,"primaryCompletion":1121,"completion":1121,"start":1241,"enrollment":3366,"conditions":3367,"interventions":3369},"NCT00353678","Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)",[75],1141,[3368],"Thromboembolism",[3319],{"nctId":3371,"briefTitle":3372,"status":114,"phases":3373,"primaryCompletion":809,"completion":809,"start":1953,"enrollment":3374,"conditions":3375,"interventions":3377},"NCT00595426","A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery",[75],685,[3376],"Arthroplasty, Replacement, Knee",[3319,3378],"Warfarin",{"nctId":3380,"briefTitle":3381,"status":114,"phases":3382,"primaryCompletion":3171,"completion":3171,"start":808,"enrollment":3383,"conditions":3384,"interventions":3386},"NCT00938730","A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation",[75],1280,[3385],"Atrial Fibrillation",[3319,3378],{"nctId":3388,"briefTitle":3389,"status":114,"phases":3390,"primaryCompletion":896,"completion":896,"start":2872,"enrollment":3391,"conditions":3392,"interventions":3393},"NCT00408239","Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement",[75],367,[3368],[3319,3394],"enoxaparin",{"nctId":3396,"briefTitle":3397,"status":114,"phases":3398,"primaryCompletion":971,"completion":971,"start":982,"enrollment":3399,"conditions":3400,"interventions":3401},"NCT00448214","Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation",[75],448,[3385],[3319,3402],"warfarin",{"trials":3404,"activeCount":85},[3405,3414,3420,3427,3433,3440],{"nctId":3406,"briefTitle":3407,"status":114,"phases":3408,"primaryCompletion":318,"completion":318,"start":809,"enrollment":3409,"conditions":3410,"interventions":3412},"NCT00913120","Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery",[75,76],610,[3411],"Venous Thromboembolism",[3319,3413],"Enoxaparin",{"nctId":3415,"briefTitle":3416,"status":114,"phases":3417,"primaryCompletion":355,"completion":355,"start":808,"enrollment":309,"conditions":3418,"interventions":3419},"NCT00937911","Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities",[76],[3411],[3319],{"nctId":3421,"briefTitle":3422,"status":114,"phases":3423,"primaryCompletion":1530,"completion":1530,"start":808,"enrollment":3424,"conditions":3425,"interventions":3426},"NCT00937820","Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism",[76],87,[3411],[3319],{"nctId":3428,"briefTitle":3429,"status":114,"phases":3430,"primaryCompletion":355,"completion":355,"start":809,"enrollment":2538,"conditions":3431,"interventions":3432},"NCT01028950","YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness",[76],[3411],[3319],{"nctId":3434,"briefTitle":3435,"status":114,"phases":3436,"primaryCompletion":355,"completion":355,"start":808,"enrollment":3437,"conditions":3438,"interventions":3439},"NCT00942435","A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery",[76],156,[3411],[3319],{"nctId":3441,"briefTitle":3442,"status":114,"phases":3443,"primaryCompletion":1169,"completion":1169,"start":809,"enrollment":3444,"conditions":3445,"interventions":3446},"NCT00917254","Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery",[75,76],369,[3411],[3319,3413],{"trials":3448,"activeCount":85},[],{"trials":3450,"activeCount":85},[],{"intervention":3452,"totalTrials":3453,"cells":3454},"ASP1585",12,{"EARLY_PHASE1":3455,"PHASE1":3457,"PHASE2":3500,"PHASE3":3518,"PHASE4":3560,"NA":3562},{"trials":3456,"activeCount":85},[],{"trials":3458,"activeCount":85},[3459,3468,3476,3484,3492],{"nctId":3460,"briefTitle":3461,"status":114,"phases":3462,"primaryCompletion":3463,"completion":3463,"start":3464,"enrollment":3206,"conditions":3465,"interventions":3467},"NCT02531204","A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules",[74],"2015-02","2014-08",[15,3466],"Urine Phosphorus Excretion",[3452],{"nctId":3469,"briefTitle":3470,"status":114,"phases":3471,"primaryCompletion":355,"completion":355,"start":318,"enrollment":118,"conditions":3472,"interventions":3474},"NCT01115972","A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers",[74],[15,3473],"Pharmacokinetics of Valsartan",[3452,3475],"valsartan",{"nctId":3477,"briefTitle":3478,"status":114,"phases":3479,"primaryCompletion":3188,"completion":3188,"start":355,"enrollment":3453,"conditions":3480,"interventions":3482},"NCT01124747","A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug",[74],[15,3481],"Pharmacokinetics of ASP1585",[3452,3483],"14C-Labeled ASP1585",{"nctId":3485,"briefTitle":3486,"status":114,"phases":3487,"primaryCompletion":355,"completion":355,"start":318,"enrollment":118,"conditions":3488,"interventions":3490},"NCT01115985","A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers",[74],[15,3489],"Pharmacokinetics of Atorvastatin",[3452,3491],"atorvastatin",{"nctId":3493,"briefTitle":3494,"status":114,"phases":3495,"primaryCompletion":355,"completion":355,"start":318,"enrollment":118,"conditions":3496,"interventions":3498},"NCT01115946","A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers",[74],[15,3497],"Pharmacokinetics of Enalapril",[3452,3499],"enalapril",{"trials":3501,"activeCount":85},[3502,3511],{"nctId":3503,"briefTitle":3504,"status":114,"phases":3505,"primaryCompletion":1240,"completion":1240,"start":1190,"enrollment":3437,"conditions":3506,"interventions":3509},"NCT00505037","A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis",[75],[3507,3508],"Hyperphosphatemia","Chronic Kidney Disease",[3452,3510],"Sevelamer hydrochloride",{"nctId":3512,"briefTitle":3513,"status":114,"phases":3514,"primaryCompletion":1498,"completion":1498,"start":1513,"enrollment":1506,"conditions":3515,"interventions":3517},"NCT02753894","Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia",[75],[3516],"Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia",[3452],{"trials":3519,"activeCount":85},[3520,3529,3538,3545,3552],{"nctId":3521,"briefTitle":3522,"status":114,"phases":3523,"primaryCompletion":3171,"completion":3171,"start":1169,"enrollment":3524,"conditions":3525,"interventions":3528},"NCT01057407","A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis",[76],110,[3508,3526,3527],"Renal Dialysis","Renal Insufficiency",[3452,3510],{"nctId":3530,"briefTitle":3531,"status":114,"phases":3532,"primaryCompletion":3533,"completion":3533,"start":3534,"enrollment":3535,"conditions":3536,"interventions":3537},"NCT01742585","A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis",[76],"2014-05","2012-10",163,[3508,3527,3507],[3452],{"nctId":3539,"briefTitle":3540,"status":114,"phases":3541,"primaryCompletion":3171,"completion":3171,"start":333,"enrollment":3542,"conditions":3543,"interventions":3544},"NCT01017276","A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis",[76],35,[3508,3526,3527],[3452],{"nctId":3546,"briefTitle":3547,"status":114,"phases":3548,"primaryCompletion":3171,"completion":3171,"start":809,"enrollment":3549,"conditions":3550,"interventions":3551},"NCT00892749","Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis",[76],248,[3508,3526,3527,3507],[3452],{"nctId":3553,"briefTitle":3554,"status":114,"phases":3555,"primaryCompletion":3556,"completion":3556,"start":2400,"enrollment":3557,"conditions":3558,"interventions":3559},"NCT01742611","Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis",[76],"2015-04",105,[3508,3527,3507],[3452],{"trials":3561,"activeCount":85},[],{"trials":3563,"activeCount":85},[],{"intervention":1714,"totalTrials":1466,"cells":3565},{"EARLY_PHASE1":3566,"PHASE1":3568,"PHASE2":3605,"PHASE3":3623,"PHASE4":3646,"NA":3648},{"trials":3567,"activeCount":85},[],{"trials":3569,"activeCount":85},[3570,3577,3585,3592,3599],{"nctId":3571,"briefTitle":3572,"status":114,"phases":3573,"primaryCompletion":3574,"completion":3574,"start":1240,"enrollment":118,"conditions":3575,"interventions":3576},"NCT00856570","A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects",[74],"2008-12",[24,2047],[3402,1714],{"nctId":3578,"briefTitle":3579,"status":114,"phases":3580,"primaryCompletion":846,"completion":846,"start":1240,"enrollment":3581,"conditions":3582,"interventions":3584},"NCT00750620","A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment",[74],33,[3583],"Renal Impairment",[1714],{"nctId":3586,"briefTitle":3587,"status":114,"phases":3588,"primaryCompletion":3205,"completion":3205,"start":331,"enrollment":3453,"conditions":3589,"interventions":3591},"NCT01334905","A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers",[74],[711,3590],"Pharmacokinetics of YM178",[1714],{"nctId":3593,"briefTitle":3594,"status":114,"phases":3595,"primaryCompletion":3534,"completion":3534,"start":332,"enrollment":118,"conditions":3596,"interventions":3598},"NCT01747564","A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects",[74],[18,3597],"Plasma Concentration of Mirabegron",[1714],{"nctId":3600,"briefTitle":3601,"status":114,"phases":3602,"primaryCompletion":846,"completion":846,"start":1022,"enrollment":708,"conditions":3603,"interventions":3604},"NCT00965926","A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers",[74],[711,3590],[1714],{"trials":3606,"activeCount":85},[3607,3614],{"nctId":3608,"briefTitle":3609,"status":114,"phases":3610,"primaryCompletion":982,"completion":982,"enrollment":3611,"conditions":3612,"interventions":3613},"NCT00337090","A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)",[75],1108,[24],[1714],{"nctId":3615,"briefTitle":3616,"status":114,"phases":3617,"primaryCompletion":3618,"completion":3618,"start":3619,"enrollment":3620,"conditions":3621,"interventions":3622},"NCT00527033","A Study of YM178 in Patients With Symptomatic Overactive Bladder",[75],"2008-04-03","2007-09-11",842,[33],[1714],{"trials":3624,"activeCount":85},[3625,3635,3642],{"nctId":3626,"briefTitle":3627,"status":114,"phases":3628,"primaryCompletion":3629,"completion":3629,"start":3630,"enrollment":3631,"conditions":3632,"interventions":3633},"NCT01043666","A Study of YM178 in Subjects With Symptoms of Overactive Bladder",[76],"2011-09-16","2009-12-21",1126,[33],[1714,3634],"tolterodine ER",{"nctId":3636,"briefTitle":3637,"status":114,"phases":3638,"primaryCompletion":318,"completion":318,"start":3574,"enrollment":3639,"conditions":3640,"interventions":3641},"NCT00840645","A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients",[76],204,[33],[1714],{"nctId":1706,"briefTitle":1707,"status":114,"phases":3643,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":1711,"conditions":3644,"interventions":3645},[76],[33],[1714,1099],{"trials":3647,"activeCount":85},[],{"trials":3649,"activeCount":85},[],{"intervention":3651,"totalTrials":1191,"cells":3652},"FK949E",{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3702,"PHASE3":3704,"PHASE4":3736,"NA":3738},{"trials":3654,"activeCount":85},[],{"trials":3656,"activeCount":85},[3657,3665,3671,3679,3686,3694],{"nctId":3658,"briefTitle":3659,"status":114,"phases":3660,"primaryCompletion":3661,"completion":3661,"start":3196,"enrollment":1180,"conditions":3662,"interventions":3664},"NCT01903200","Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder",[74],"2011-09",[3663],"Major Depressive Disorder Patients",[3651],{"nctId":3666,"briefTitle":3667,"status":114,"phases":3668,"primaryCompletion":318,"completion":318,"start":809,"enrollment":1180,"conditions":3669,"interventions":3670},"NCT01871974","Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder",[74],[3663],[3651],{"nctId":3672,"briefTitle":3673,"status":114,"phases":3674,"primaryCompletion":3204,"completion":3204,"start":1010,"enrollment":118,"conditions":3675,"interventions":3677},"NCT01908296","Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers",[74],[15,3676],"Pharmacokinetics of Quetiapine",[3651,3678],"fluvoxamine",{"nctId":3680,"briefTitle":3681,"status":114,"phases":3682,"primaryCompletion":1011,"completion":1011,"start":1985,"enrollment":320,"conditions":3683,"interventions":3685},"NCT01924520","Oral Multiple-dose Study in Patients With Major Depressive Disorder",[74],[3684],"Major Depressive Disorder",[3651],{"nctId":3687,"briefTitle":3688,"status":114,"phases":3689,"primaryCompletion":3690,"completion":3690,"start":3691,"enrollment":1180,"conditions":3692,"interventions":3693},"NCT01919008","Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder",[74],"2012-06-22","2012-03-26",[3684],[3651],{"nctId":3695,"briefTitle":3696,"status":114,"phases":3697,"primaryCompletion":3698,"completion":3698,"start":808,"enrollment":118,"conditions":3699,"interventions":3701},"NCT01871987","Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers",[74],"2009-08",[15,3700],"Plasma Concentration Change of Quetiapine",[3651],{"trials":3703,"activeCount":85},[],{"trials":3705,"activeCount":85},[3706,3716,3726],{"nctId":3707,"briefTitle":3708,"status":114,"phases":3709,"primaryCompletion":3710,"completion":3710,"start":3711,"enrollment":28,"conditions":3712,"interventions":3715},"NCT01737268","Long-term Study of FK949E in Elderly Bipolar Disorder Patients",[76],"2016-06-29","2012-10-29",[3713,3714],"Bipolar Disorder","Elderly",[3651],{"nctId":3717,"briefTitle":3718,"status":114,"phases":3719,"primaryCompletion":3720,"completion":3721,"start":3722,"enrollment":3723,"conditions":3724,"interventions":3725},"NCT01725308","A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes",[75,76],"2015-08-01","2016-07-11","2012-02-07",431,[3713],[3651],{"nctId":3727,"briefTitle":3728,"status":114,"phases":3729,"primaryCompletion":3730,"completion":3730,"start":3731,"enrollment":3732,"conditions":3733,"interventions":3735},"NCT02362412","Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes",[76],"2016-02-06","2015-02-18",22,[3734],"Bipolar Depression",[3651],{"trials":3737,"activeCount":85},[],{"trials":3739,"activeCount":85},[],{"intervention":776,"totalTrials":3741,"cells":3742},8,{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3751,"PHASE3":3770,"PHASE4":3803,"NA":3805},{"trials":3744,"activeCount":85},[],{"trials":3746,"activeCount":85},[3747],{"nctId":692,"briefTitle":693,"status":114,"phases":3748,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":3749,"interventions":3750},[74],[699],[676,701],{"trials":3752,"activeCount":85},[3753,3762,3766],{"nctId":3754,"briefTitle":3755,"status":114,"phases":3756,"primaryCompletion":3757,"completion":144,"start":3758,"enrollment":708,"conditions":3759,"interventions":3760},"NCT02884635","A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate",[75],"2017-10-18","2016-09-16",[699],[3761,776],"ASP1707",{"nctId":735,"briefTitle":736,"status":114,"phases":3763,"primaryCompletion":738,"completion":738,"start":739,"enrollment":740,"conditions":3764,"interventions":3765},[75],[732],[676,701],{"nctId":1380,"briefTitle":1381,"status":114,"phases":3767,"primaryCompletion":895,"completion":895,"start":1383,"enrollment":1384,"conditions":3768,"interventions":3769},[75],[1386],[825,776],{"trials":3771,"activeCount":85},[3772,3780,3788,3792],{"nctId":3773,"briefTitle":3774,"status":114,"phases":3775,"completion":1585,"start":3776,"enrollment":3777,"conditions":3778,"interventions":3779},"NCT00036153","Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis",[76],"2002-03",210,[699],[852,776],{"nctId":3781,"briefTitle":3782,"status":114,"phases":3783,"primaryCompletion":307,"completion":307,"start":896,"enrollment":3784,"conditions":3785,"interventions":3786},"NCT00851318","Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients",[76],285,[699],[3787,776],"Certolizumab pegol",{"nctId":767,"briefTitle":768,"status":114,"phases":3789,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":3790,"interventions":3791},[76],[699],[46,776],{"nctId":3793,"briefTitle":3794,"status":114,"phases":3795,"primaryCompletion":3796,"completion":3797,"start":3798,"enrollment":3799,"conditions":3800,"interventions":3801},"NCT01451203","Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis",[76],"2013-08-28","2014-10-20","2011-10-11",319,[699],[3802,701],"CZP",{"trials":3804,"activeCount":85},[],{"trials":3806,"activeCount":85},[],{"intervention":3808,"totalTrials":3741,"cells":3809},"OSI-906",{"EARLY_PHASE1":3810,"PHASE1":3812,"PHASE2":3841,"PHASE3":3886,"PHASE4":3899,"NA":3901},{"trials":3811,"activeCount":85},[],{"trials":3813,"activeCount":85},[3814,3824,3833],{"nctId":3815,"briefTitle":3816,"status":114,"phases":3817,"primaryCompletion":3818,"completion":3818,"start":3277,"enrollment":3819,"conditions":3820,"interventions":3822},"NCT00739453","A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)",[74],"2012-03-03",95,[3821],"Advanced Solid Tumors",[3808,3823],"erlotinib",{"nctId":3825,"briefTitle":3826,"status":114,"phases":3827,"primaryCompletion":3828,"completion":3828,"start":3829,"enrollment":3830,"conditions":3831,"interventions":3832},"NCT00514306","Study of Intermittent OSI-906 Dosing",[74],"2010-09-20","2007-07-05",79,[3821],[3808],{"nctId":3834,"briefTitle":3835,"status":114,"phases":3836,"primaryCompletion":3837,"completion":3837,"start":3838,"enrollment":3819,"conditions":3839,"interventions":3840},"NCT00514007","Study of Continuous OSI-906 Dosing",[74],"2012-03-19","2007-06-18",[3821],[3808],{"trials":3842,"activeCount":85},[3843,3853,3864,3874],{"nctId":3844,"briefTitle":3845,"status":353,"phases":3846,"primaryCompletion":3847,"completion":3848,"start":3849,"enrollment":3115,"conditions":3850,"interventions":3852},"NCT01101906","A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC",[75],"2011-11-04","2011-12-28","2011-01-10",[3851],"Advanced Hepatocellular Carcinoma (HCC)",[3808],{"nctId":3854,"briefTitle":3855,"status":114,"phases":3856,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":920,"conditions":3860,"interventions":3862},"NCT00889382","A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)",[74,75],"2014-08-01","2014-08-25","2009-08-05",[359,3861],"Solid Tumors",[3808,3863],"Paclitaxel",{"nctId":3865,"briefTitle":3866,"status":114,"phases":3867,"primaryCompletion":3868,"completion":3869,"start":3870,"enrollment":379,"conditions":3871,"interventions":3873},"NCT01186861","Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy",[75],"2013-07-01","2015-03-11","2011-03-04",[3872],"Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy",[3808,3823],{"nctId":3875,"briefTitle":3876,"status":114,"phases":3877,"primaryCompletion":3878,"completion":3879,"start":3880,"enrollment":3172,"conditions":3881,"interventions":3884},"NCT01221077","Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene",[75],"2013-03-01","2014-09-01","2011-04-08",[3882,3883],"NSCLC","Non Small Cell Lung Cancer",[3808,3885],"Erlotinib",{"trials":3887,"activeCount":85},[3888],{"nctId":3889,"briefTitle":3890,"status":114,"phases":3891,"primaryCompletion":3892,"completion":3893,"start":3894,"enrollment":3895,"conditions":3896,"interventions":3898},"NCT00924989","A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma",[76],"2012-07-11","2012-10-08","2009-12-01",139,[3897],"Adrenocortical Carcinoma",[3808],{"trials":3900,"activeCount":85},[],{"trials":3902,"activeCount":85},[],{"intervention":3904,"totalTrials":8,"cells":3905},"YM060",{"EARLY_PHASE1":3906,"PHASE1":3908,"PHASE2":3923,"PHASE3":3941,"PHASE4":3965,"NA":3967},{"trials":3907,"activeCount":85},[],{"trials":3909,"activeCount":85},[3910,3917],{"nctId":3911,"briefTitle":3912,"status":114,"phases":3913,"primaryCompletion":3204,"completion":3204,"start":1010,"enrollment":3224,"conditions":3914,"interventions":3916},"NCT01394653","A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake",[74],[15,3915],"Plasma Concentration of YM060",[3904],{"nctId":3918,"briefTitle":3919,"status":114,"phases":3920,"primaryCompletion":1011,"completion":1011,"start":1826,"enrollment":3224,"conditions":3921,"interventions":3922},"NCT01392794","A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet",[74],[15,3915],[3904],{"trials":3924,"activeCount":85},[3925,3934],{"nctId":3926,"briefTitle":3927,"status":114,"phases":3928,"primaryCompletion":3929,"completion":3929,"start":1985,"enrollment":3930,"conditions":3931,"interventions":3933},"NCT01274000","A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients",[75],"2011-10",409,[3932],"Irritable Bowel Syndrome",[3904],{"nctId":3935,"briefTitle":3936,"status":114,"phases":3937,"primaryCompletion":1261,"completion":1261,"start":895,"enrollment":3938,"conditions":3939,"interventions":3940},"NCT00189813","A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)",[75],691,[3932],[3904],{"trials":3942,"activeCount":85},[3943,3951,3957],{"nctId":3944,"briefTitle":3945,"status":114,"phases":3946,"primaryCompletion":2240,"completion":2240,"start":3947,"enrollment":2692,"conditions":3948,"interventions":3950},"NCT01870895","A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)",[76],"2013-02",[3949],"Diarrhea-predominant Irritable Bowel Syndrome",[3904],{"nctId":3952,"briefTitle":3953,"status":114,"phases":3954,"conditions":3955,"interventions":3956},"NCT00189696","Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)",[76],[3932],[3904],{"nctId":3958,"briefTitle":3959,"status":114,"phases":3960,"primaryCompletion":3533,"completion":3533,"start":3961,"enrollment":3962,"conditions":3963,"interventions":3964},"NCT01736423","A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome",[76],"2012-09",151,[3949],[3904],{"trials":3966,"activeCount":85},[],{"trials":3968,"activeCount":85},[],{"intervention":690,"totalTrials":8,"cells":3970},{"EARLY_PHASE1":3971,"PHASE1":3973,"PHASE2":3983,"PHASE3":4012,"PHASE4":4026,"NA":4028},{"trials":3972,"activeCount":85},[],{"trials":3974,"activeCount":85},[3975,3979],{"nctId":683,"briefTitle":684,"status":114,"phases":3976,"primaryCompletion":686,"completion":686,"start":687,"enrollment":118,"conditions":3977,"interventions":3978},[74],[18],[676,690],{"nctId":3219,"briefTitle":3220,"status":114,"phases":3980,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":3224,"conditions":3981,"interventions":3982},[74],[27],[3114,690],{"trials":3984,"activeCount":85},[3985,3995,4003],{"nctId":3986,"briefTitle":3987,"status":114,"phases":3988,"primaryCompletion":3989,"completion":3989,"start":3990,"enrollment":3991,"conditions":3992,"interventions":3993},"NCT01071850","A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus",[75],"2011-04-11","2010-03-03",412,[3280],[3994,690],"ipragliflozin",{"nctId":3996,"briefTitle":3997,"status":114,"phases":3998,"primaryCompletion":1498,"completion":1498,"start":1338,"enrollment":131,"conditions":3999,"interventions":4001},"NCT00454233","A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects",[75],[4000],"Diabetes Mellitus Type 2",[4002,690],"YM543",{"nctId":4004,"briefTitle":4005,"status":114,"phases":4006,"primaryCompletion":4007,"completion":4007,"start":4008,"enrollment":4009,"conditions":4010,"interventions":4011},"NCT01117584","A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus",[75],"2011-04-01","2010-04-06",343,[27],[3994,690],{"trials":4013,"activeCount":85},[4014,4018],{"nctId":3285,"briefTitle":3286,"status":114,"phases":4015,"primaryCompletion":3288,"completion":3288,"start":3289,"enrollment":3290,"conditions":4016,"interventions":4017},[76],[3292],[3114,3294],{"nctId":4019,"briefTitle":4020,"status":114,"phases":4021,"primaryCompletion":3289,"completion":3289,"start":4022,"enrollment":4023,"conditions":4024,"interventions":4025},"NCT01135433","A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients",[76],"2010-05-15",168,[27],[3994,3294],{"trials":4027,"activeCount":85},[],{"trials":4029,"activeCount":85},[],{"intervention":2103,"totalTrials":8,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4066,"PHASE3":4068,"PHASE4":4088,"NA":4090},{"trials":4033,"activeCount":85},[],{"trials":4035,"activeCount":85},[4036,4045,4053,4062],{"nctId":4037,"briefTitle":4038,"status":114,"phases":4039,"primaryCompletion":3205,"completion":3205,"start":1011,"enrollment":118,"conditions":4040,"interventions":4043},"NCT01406171","Drug Interaction Study of Isavuconazole and Midazolam",[74],[4041,4042,30],"Pharmacokinetics of Isavuconazole","Pharmacokinetics of Midazolam",[2103,4044],"Midazolam",{"nctId":4046,"briefTitle":4047,"status":114,"phases":4048,"primaryCompletion":4049,"completion":4049,"start":2282,"enrollment":118,"conditions":4050,"interventions":4052},"NCT01535547","Drug Interaction Study of Isavuconazole and Tacrolimus",[74],"2012-01",[4041,4051,30],"Pharmacokinetics of Tacrolimus",[2285,826],{"nctId":4054,"briefTitle":4055,"status":114,"phases":4056,"primaryCompletion":4057,"completion":4057,"start":332,"enrollment":3224,"conditions":4058,"interventions":4061},"NCT01555918","A Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers",[74],"2012-11",[4059,4060,30],"Pharmacokinetics of BAL4815","Pharmacokinetics of BAL8728",[2103,2103],{"nctId":2279,"briefTitle":2280,"status":114,"phases":4063,"primaryCompletion":2282,"completion":2282,"start":2241,"enrollment":118,"conditions":4064,"interventions":4065},[74],[15],[2285,2286],{"trials":4067,"activeCount":85},[],{"trials":4069,"activeCount":85},[4070,4074,4078],{"nctId":2094,"briefTitle":2095,"status":114,"phases":4071,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":4072,"interventions":4073},[76],[1252,2101],[2103,2083],{"nctId":2105,"briefTitle":2106,"status":114,"phases":4075,"primaryCompletion":2108,"completion":2108,"start":2109,"enrollment":1955,"conditions":4076,"interventions":4077},[76],[2111,1196,1233],[2103,1283,2083],{"nctId":4079,"briefTitle":4080,"status":114,"phases":4081,"primaryCompletion":4082,"completion":4083,"start":4084,"enrollment":4085,"conditions":4086,"interventions":4087},"NCT00634049","Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi",[76],"2014-01-03","2016-05-05","2008-04-22",149,[1252,1273],[2285],{"trials":4089,"activeCount":85},[],{"trials":4091,"activeCount":85},[],{"intervention":4093,"totalTrials":1846,"cells":4094},"ASP8825",{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4115,"PHASE3":4133,"PHASE4":4142,"NA":4144},{"trials":4096,"activeCount":85},[],{"trials":4098,"activeCount":85},[4099,4107],{"nctId":4100,"briefTitle":4101,"status":114,"phases":4102,"primaryCompletion":971,"completion":971,"start":821,"enrollment":4103,"conditions":4104,"interventions":4106},"NCT02629224","ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis",[74],18,[4105],"Patients With Impaired Renal Function and Haemodialysis",[4093],{"nctId":4108,"briefTitle":4109,"status":114,"phases":4110,"primaryCompletion":4111,"completion":4111,"start":4112,"enrollment":4103,"conditions":4113,"interventions":4114},"NCT02632331","ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825",[74],"2009-02","2009-01",[30],[4093],{"trials":4116,"activeCount":85},[4117,4125],{"nctId":4118,"briefTitle":4119,"status":353,"phases":4120,"primaryCompletion":1298,"completion":1298,"start":907,"enrollment":4121,"conditions":4122,"interventions":4124},"NCT00508430","ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy",[75],199,[4123],"Diabetic Neuropathies",[4093],{"nctId":4126,"briefTitle":4127,"status":114,"phases":4128,"primaryCompletion":4112,"completion":4112,"start":1054,"enrollment":4129,"conditions":4130,"interventions":4132},"NCT00530530","ASP8825 - Study in Patients With Restless Legs Syndrome",[75],474,[4131],"Restless Legs Syndrome",[4093],{"trials":4134,"activeCount":85},[4135],{"nctId":4136,"briefTitle":4137,"status":114,"phases":4138,"primaryCompletion":378,"completion":378,"start":847,"enrollment":4139,"conditions":4140,"interventions":4141},"NCT02658188","Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients",[76],182,[4131],[4093],{"trials":4143,"activeCount":85},[],{"trials":4145,"activeCount":85},[],{"intervention":1283,"totalTrials":275,"cells":4147},{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4154,"PHASE4":4172,"NA":4174},{"trials":4149,"activeCount":85},[],{"trials":4151,"activeCount":85},[],{"trials":4153,"activeCount":85},[],{"trials":4155,"activeCount":85},[4156,4160,4164,4168],{"nctId":2105,"briefTitle":2106,"status":114,"phases":4157,"primaryCompletion":2108,"completion":2108,"start":2109,"enrollment":1955,"conditions":4158,"interventions":4159},[76],[2111,1196,1233],[2103,1283,2083],{"nctId":1276,"briefTitle":1277,"status":114,"phases":4161,"primaryCompletion":1279,"completion":1279,"start":861,"enrollment":1280,"conditions":4162,"interventions":4163},[76],[1265,1196],[1179,1283],{"nctId":1285,"briefTitle":1286,"status":114,"phases":4165,"primaryCompletion":1288,"completion":1288,"start":1067,"enrollment":1289,"conditions":4166,"interventions":4167},[76],[1291],[1235,1293],{"nctId":1322,"briefTitle":1323,"status":114,"phases":4169,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":4170,"interventions":4171},[76],[35,1233],[1235,1320,1330,1293],{"trials":4173,"activeCount":85},[],{"trials":4175,"activeCount":85},[],{"intervention":901,"totalTrials":275,"cells":4177},{"EARLY_PHASE1":4178,"PHASE1":4180,"PHASE2":4182,"PHASE3":4205,"PHASE4":4211,"NA":4213},{"trials":4179,"activeCount":85},[],{"trials":4181,"activeCount":85},[],{"trials":4183,"activeCount":85},[4184,4192,4199],{"nctId":4185,"briefTitle":4186,"status":114,"phases":4187,"primaryCompletion":971,"completion":971,"start":4188,"enrollment":4189,"conditions":4190,"interventions":4191},"NCT00282568","A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients",[75],"2002-08",70,[21],[901,826],{"nctId":4193,"briefTitle":4194,"status":114,"phases":4195,"primaryCompletion":971,"completion":971,"start":1585,"enrollment":2432,"conditions":4196,"interventions":4197},"NCT00282256","A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients",[75],[35],[4198,826],"tacrolimus modified release",{"nctId":4200,"briefTitle":4201,"status":114,"phases":4202,"primaryCompletion":971,"completion":971,"start":919,"enrollment":4189,"conditions":4203,"interventions":4204},"NCT00282243","A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients",[75],[35],[4198,826],{"trials":4206,"activeCount":85},[4207],{"nctId":892,"briefTitle":893,"status":114,"phases":4208,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":4209,"interventions":4210},[76],[21],[901,852,902,828],{"trials":4212,"activeCount":85},[],{"trials":4214,"activeCount":85},[],{"intervention":1254,"totalTrials":105,"cells":4216},{"EARLY_PHASE1":4217,"PHASE1":4219,"PHASE2":4221,"PHASE3":4227,"PHASE4":4237,"NA":4239},{"trials":4218,"activeCount":85},[],{"trials":4220,"activeCount":85},[],{"trials":4222,"activeCount":85},[4223],{"nctId":1247,"briefTitle":1248,"status":353,"phases":4224,"primaryCompletion":919,"completion":919,"start":1250,"enrollment":158,"conditions":4225,"interventions":4226},[75],[1252],[1179,1254],{"trials":4228,"activeCount":85},[4229,4233],{"nctId":1258,"briefTitle":1259,"status":114,"phases":4230,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":1263,"conditions":4231,"interventions":4232},[76],[1265],[1179,1254],{"nctId":1322,"briefTitle":1323,"status":114,"phases":4234,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":4235,"interventions":4236},[76],[35,1233],[1235,1320,1330,1293],{"trials":4238,"activeCount":85},[],{"trials":4240,"activeCount":85},[],{"intervention":3413,"totalTrials":105,"cells":4242},{"EARLY_PHASE1":4243,"PHASE1":4245,"PHASE2":4247,"PHASE3":4253,"PHASE4":4263,"NA":4265},{"trials":4244,"activeCount":85},[],{"trials":4246,"activeCount":85},[],{"trials":4248,"activeCount":85},[4249],{"nctId":3388,"briefTitle":3389,"status":114,"phases":4250,"primaryCompletion":896,"completion":896,"start":2872,"enrollment":3391,"conditions":4251,"interventions":4252},[75],[3368],[3319,3394],{"trials":4254,"activeCount":85},[4255,4259],{"nctId":3406,"briefTitle":3407,"status":114,"phases":4256,"primaryCompletion":318,"completion":318,"start":809,"enrollment":3409,"conditions":4257,"interventions":4258},[75,76],[3411],[3319,3413],{"nctId":3441,"briefTitle":3442,"status":114,"phases":4260,"primaryCompletion":1169,"completion":1169,"start":809,"enrollment":3444,"conditions":4261,"interventions":4262},[75,76],[3411],[3319,3413],{"trials":4264,"activeCount":85},[],{"trials":4266,"activeCount":85},[],{"intervention":4268,"totalTrials":105,"cells":4269},"RSD1235",{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4274,"PHASE3":4276,"PHASE4":4299,"NA":4301},{"trials":4271,"activeCount":85},[],{"trials":4273,"activeCount":85},[],{"trials":4275,"activeCount":85},[],{"trials":4277,"activeCount":85},[4278,4285,4293],{"nctId":4279,"briefTitle":4280,"status":114,"phases":4281,"primaryCompletion":1055,"completion":1055,"start":1075,"enrollment":4282,"conditions":4283,"interventions":4284},"NCT00281554","Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation",[76],254,[3385],[4268],{"nctId":4286,"briefTitle":4287,"status":114,"phases":4288,"primaryCompletion":4289,"completion":4289,"start":1067,"enrollment":145,"conditions":4290,"interventions":4292},"NCT00115791","Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter",[76],"2005-06",[4291,3385],"Atrial Flutter",[4268],{"nctId":4294,"briefTitle":4295,"status":114,"phases":4296,"primaryCompletion":1338,"completion":1338,"start":1067,"enrollment":2610,"conditions":4297,"interventions":4298},"NCT00125320","Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery",[76],[3385,4291],[4268],{"trials":4300,"activeCount":85},[],{"trials":4302,"activeCount":85},[],{"intervention":4304,"totalTrials":105,"cells":4305},"Fezolinetant",{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4323,"PHASE4":4343,"NA":4345},{"trials":4307,"activeCount":85},[],{"trials":4309,"activeCount":85},[],{"trials":4311,"activeCount":85},[4312],{"nctId":4313,"briefTitle":4314,"status":114,"phases":4315,"primaryCompletion":4316,"completion":4317,"start":4318,"enrollment":4319,"conditions":4320,"interventions":4322},"NCT05034042","A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause",[75],"2022-11-11","2022-12-23","2021-11-17",147,[4321],"Hot Flashes",[4304],{"trials":4324,"activeCount":85},[4325,4334],{"nctId":4326,"briefTitle":4327,"status":114,"phases":4328,"primaryCompletion":4329,"completion":4329,"start":4330,"enrollment":4331,"conditions":4332,"interventions":4333},"NCT06206421","A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause",[76],"2026-03-19","2024-02-22",277,[4321],[4304],{"nctId":4335,"briefTitle":4336,"status":114,"phases":4337,"primaryCompletion":4338,"completion":4339,"start":4340,"enrollment":3031,"conditions":4341,"interventions":4342},"NCT06206408","A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause",[76],"2025-10-22","2025-12-18","2024-02-16",[4321],[4304],{"trials":4344,"activeCount":85},[],{"trials":4346,"activeCount":85},[],{"intervention":4348,"totalTrials":105,"cells":4349},"YM443",{"EARLY_PHASE1":4350,"PHASE1":4352,"PHASE2":4362,"PHASE3":4375,"PHASE4":4384,"NA":4386},{"trials":4351,"activeCount":85},[],{"trials":4353,"activeCount":85},[4354],{"nctId":4355,"briefTitle":4356,"status":114,"phases":4357,"primaryCompletion":378,"completion":378,"start":4111,"enrollment":4358,"conditions":4359,"interventions":4361},"NCT00850746","A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults",[74],80,[4360],"Functional Dyspepsia",[4348,3176],{"trials":4363,"activeCount":85},[4364],{"nctId":4365,"briefTitle":4366,"status":114,"phases":4367,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":4370,"conditions":4371,"interventions":4374},"NCT00102310","YM443 in Subjects With Functional Dyspepsia",[75],"2006-03-11","2004-03-10",416,[4372,4373],"Indigestion","Nausea",[4348],{"trials":4376,"activeCount":85},[4377],{"nctId":4378,"briefTitle":4379,"status":114,"phases":4380,"primaryCompletion":308,"completion":308,"start":1042,"enrollment":3991,"conditions":4381,"interventions":4383},"NCT00764374","A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia",[76],[4382,4360],"Dyspepsia",[4348],{"trials":4385,"activeCount":85},[],{"trials":4387,"activeCount":85},[],{"intervention":1320,"totalTrials":105,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4410,"NA":4412},{"trials":4391,"activeCount":85},[],{"trials":4393,"activeCount":85},[],{"trials":4395,"activeCount":85},[],{"trials":4397,"activeCount":85},[4398,4402,4406],{"nctId":1305,"briefTitle":1306,"status":114,"phases":4399,"primaryCompletion":1308,"completion":1308,"start":1309,"enrollment":6,"conditions":4400,"interventions":4401},[76],[1291],[1179,1312],{"nctId":1314,"briefTitle":1315,"status":114,"phases":4403,"primaryCompletion":1317,"completion":1317,"start":918,"enrollment":118,"conditions":4404,"interventions":4405},[76],[1193,1196],[1179,1320],{"nctId":1322,"briefTitle":1323,"status":114,"phases":4407,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":4408,"interventions":4409},[76],[35,1233],[1235,1320,1330,1293],{"trials":4411,"activeCount":85},[],{"trials":4413,"activeCount":85},[],{"intervention":4415,"totalTrials":158,"cells":4416},"Tacrolimus Cream",{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4423,"PHASE4":4438,"NA":4440},{"trials":4418,"activeCount":85},[],{"trials":4420,"activeCount":85},[],{"trials":4422,"activeCount":85},[],{"trials":4424,"activeCount":85},[4425,4432],{"nctId":4426,"briefTitle":4427,"status":114,"phases":4428,"completion":1055,"enrollment":4429,"conditions":4430,"interventions":4431},"NCT00293891","A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis",[76],658,[751],[4415],{"nctId":4433,"briefTitle":4434,"status":114,"phases":4435,"primaryCompletion":1121,"completion":1121,"start":1790,"enrollment":4429,"conditions":4436,"interventions":4437},"NCT00293917","A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis",[76],[751],[4415],{"trials":4439,"activeCount":85},[],{"trials":4441,"activeCount":85},[],{"intervention":3510,"totalTrials":158,"cells":4443},{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4454,"PHASE4":4460,"NA":4462},{"trials":4445,"activeCount":85},[],{"trials":4447,"activeCount":85},[],{"trials":4449,"activeCount":85},[4450],{"nctId":3503,"briefTitle":3504,"status":114,"phases":4451,"primaryCompletion":1240,"completion":1240,"start":1190,"enrollment":3437,"conditions":4452,"interventions":4453},[75],[3507,3508],[3452,3510],{"trials":4455,"activeCount":85},[4456],{"nctId":3521,"briefTitle":3522,"status":114,"phases":4457,"primaryCompletion":3171,"completion":3171,"start":1169,"enrollment":3524,"conditions":4458,"interventions":4459},[76],[3508,3526,3527],[3452,3510],{"trials":4461,"activeCount":85},[],{"trials":4463,"activeCount":85},[],{"intervention":4465,"totalTrials":158,"cells":4466},"FK506",{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4473,"PHASE4":4490,"NA":4492},{"trials":4468,"activeCount":85},[],{"trials":4470,"activeCount":85},[],{"trials":4472,"activeCount":85},[],{"trials":4474,"activeCount":85},[4475,4483],{"nctId":4476,"briefTitle":4477,"status":114,"phases":4478,"completion":861,"start":1308,"enrollment":3125,"conditions":4479,"interventions":4482},"NCT00567762","Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis",[76],[4480,4481],"Keratoconjunctivitis","Conjunctivitis",[4465],{"nctId":4484,"briefTitle":4485,"status":114,"phases":4486,"primaryCompletion":1513,"completion":1513,"start":4487,"enrollment":2538,"conditions":4488,"interventions":4489},"NCT00567918","Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis",[76],"2004-05",[4480,4481],[4465],{"trials":4491,"activeCount":85},[],{"trials":4493,"activeCount":85},[],{"intervention":4495,"totalTrials":158,"cells":4496},"Darbepoetin alfa",{"EARLY_PHASE1":4497,"PHASE1":4499,"PHASE2":4501,"PHASE3":4514,"PHASE4":4526,"NA":4528},{"trials":4498,"activeCount":85},[],{"trials":4500,"activeCount":85},[],{"trials":4502,"activeCount":85},[4503],{"nctId":4504,"briefTitle":4505,"status":114,"phases":4506,"primaryCompletion":4507,"completion":4507,"start":2097,"enrollment":4508,"conditions":4509,"interventions":4511},"NCT01888445","A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug",[75],"2014-09-15",130,[4510],"Renal Anemia Associated With Chronic Renal Failure (CRF)",[4512,4513],"roxadustat","darbepoetin alfa",{"trials":4515,"activeCount":85},[4516],{"nctId":4517,"briefTitle":4518,"status":114,"phases":4519,"primaryCompletion":4520,"completion":4521,"start":4522,"enrollment":1586,"conditions":4523,"interventions":4525},"NCT02952092","A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia",[76],"2018-03-13","2018-03-15","2016-11-30",[4524],"Hemodialysis Chronic Kidney Disease Patients With Anemia",[4512,4495],{"trials":4527,"activeCount":85},[],{"trials":4529,"activeCount":85},[],{"intervention":4531,"totalTrials":158,"cells":4532},"degarelix",{"EARLY_PHASE1":4533,"PHASE1":4535,"PHASE2":4537,"PHASE3":4549,"PHASE4":4562,"NA":4564},{"trials":4534,"activeCount":85},[],{"trials":4536,"activeCount":85},[],{"trials":4538,"activeCount":85},[4539],{"nctId":4540,"briefTitle":4541,"status":114,"phases":4542,"primaryCompletion":4543,"completion":4543,"start":4544,"enrollment":4545,"conditions":4546,"interventions":4548},"NCT01261572","Study to Find Maintenance Dose for Periodic Administration of ASP3550",[75],"2012-04-24","2010-10-12",155,[4547],"Prostatic Neoplasms",[4531],{"trials":4550,"activeCount":85},[4551],{"nctId":4552,"briefTitle":4553,"status":114,"phases":4554,"primaryCompletion":4555,"completion":4556,"start":4557,"enrollment":4558,"conditions":4559,"interventions":4560},"NCT01964170","A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer",[76],"2015-06-05","2016-08-08","2013-08-13",234,[322],[4531,4561],"Goserelin",{"trials":4563,"activeCount":85},[],{"trials":4565,"activeCount":85},[],{"intervention":1479,"totalTrials":158,"cells":4567},{"EARLY_PHASE1":4568,"PHASE1":4570,"PHASE2":4572,"PHASE3":4574,"PHASE4":4584,"NA":4586},{"trials":4569,"activeCount":85},[],{"trials":4571,"activeCount":85},[],{"trials":4573,"activeCount":85},[],{"trials":4575,"activeCount":85},[4576,4580],{"nctId":1471,"briefTitle":1472,"status":114,"phases":4577,"primaryCompletion":846,"completion":846,"start":847,"enrollment":1474,"conditions":4578,"interventions":4579},[76],[35,1476,1477],[1479,912,1480],{"nctId":1503,"briefTitle":1504,"status":114,"phases":4581,"primaryCompletion":355,"completion":355,"start":847,"enrollment":1506,"conditions":4582,"interventions":4583},[76],[21,1476,1477],[1479,912,1480],{"trials":4585,"activeCount":85},[],{"trials":4587,"activeCount":85},[],{"intervention":4589,"totalTrials":158,"cells":4590},"Exisulind",{"EARLY_PHASE1":4591,"PHASE1":4593,"PHASE2":4595,"PHASE3":4604,"PHASE4":4615,"NA":4617},{"trials":4592,"activeCount":85},[],{"trials":4594,"activeCount":85},[],{"trials":4596,"activeCount":85},[4597],{"nctId":4598,"briefTitle":4599,"status":114,"phases":4600,"completion":1309,"start":4601,"enrollment":2538,"conditions":4602,"interventions":4603},"NCT00072618","Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients",[74,75],"2001-10",[3882],[4589],{"trials":4605,"activeCount":85},[4606],{"nctId":4607,"briefTitle":4608,"status":114,"phases":4609,"completion":1288,"start":4610,"enrollment":4611,"conditions":4612,"interventions":4614},"NCT00085826","A Phase III Study of the Efficacy of Taxotere\u002FAptosyn Versus Taxotere\u002FPlacebo in Non-Small Cell Lung Cancer Patients",[76],"2001-04",600,[4613],"Non-Small Cell Lung Cancer",[4589],{"trials":4616,"activeCount":85},[],{"trials":4618,"activeCount":85},[],{"intervention":4620,"totalTrials":158,"cells":4621},"Tacrolimus ointment 0.1%",{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4626,"PHASE3":4638,"PHASE4":4649,"NA":4651},{"trials":4623,"activeCount":85},[],{"trials":4625,"activeCount":85},[],{"trials":4627,"activeCount":85},[4628],{"nctId":4629,"briefTitle":4630,"status":114,"phases":4631,"primaryCompletion":4632,"completion":4632,"start":4633,"enrollment":4634,"conditions":4635,"interventions":4636},"NCT00534508","Distribution of Tacrolimus in Skin, Atopic Dermatitis",[75],"2001-07","2000-12",14,[1564],[4637],"Tacrolimus Ointment 0.1%",{"trials":4639,"activeCount":85},[4640],{"nctId":4641,"briefTitle":4642,"status":114,"phases":4643,"completion":4289,"start":4644,"enrollment":4645,"conditions":4646,"interventions":4648},"NCT00560378","Long-term Safety of Protopic in Atopic Eczema",[76],"1998-06",789,[1564,4647],"Eczema, Atopic",[4620],{"trials":4650,"activeCount":85},[],{"trials":4652,"activeCount":85},[],{"intervention":4654,"totalTrials":158,"cells":4655},"nateglinide",{"EARLY_PHASE1":4656,"PHASE1":4658,"PHASE2":4660,"PHASE3":4662,"PHASE4":4678,"NA":4680},{"trials":4657,"activeCount":85},[],{"trials":4659,"activeCount":85},[],{"trials":4661,"activeCount":85},[],{"trials":4663,"activeCount":85},[4664,4671],{"nctId":4665,"briefTitle":4666,"status":114,"phases":4667,"conditions":4668,"interventions":4670},"NCT00189774","Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients",[75,76],[27,4669],"Diabetes Mellitus, Type II",[4654],{"nctId":4672,"briefTitle":4673,"status":114,"phases":4674,"primaryCompletion":3308,"completion":3308,"start":4675,"enrollment":2029,"conditions":4676,"interventions":4677},"NCT01316107","A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients",[76],"2011-01-15",[27],[3994,4654],{"trials":4679,"activeCount":85},[],{"trials":4681,"activeCount":85},[],{"intervention":890,"totalTrials":158,"cells":4683},{"EARLY_PHASE1":4684,"PHASE1":4686,"PHASE2":4688,"PHASE3":4690,"PHASE4":4700,"NA":4702},{"trials":4685,"activeCount":85},[],{"trials":4687,"activeCount":85},[],{"trials":4689,"activeCount":85},[],{"trials":4691,"activeCount":85},[4692,4696],{"nctId":879,"briefTitle":880,"status":114,"phases":4693,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":4694,"interventions":4695},[76],[886,887],[852,889,840,890,326],{"nctId":904,"briefTitle":905,"status":114,"phases":4697,"primaryCompletion":896,"completion":896,"start":907,"enrollment":908,"conditions":4698,"interventions":4699},[76],[21],[911,912,798,890,913],{"trials":4701,"activeCount":85},[],{"trials":4703,"activeCount":85},[],{"intervention":3787,"totalTrials":158,"cells":4705},{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4712,"PHASE4":4725,"NA":4727},{"trials":4707,"activeCount":85},[],{"trials":4709,"activeCount":85},[],{"trials":4711,"activeCount":85},[],{"trials":4713,"activeCount":85},[4714,4718],{"nctId":3781,"briefTitle":3782,"status":114,"phases":4715,"primaryCompletion":307,"completion":307,"start":896,"enrollment":3784,"conditions":4716,"interventions":4717},[76],[699],[3787,776],{"nctId":4719,"briefTitle":4720,"status":114,"phases":4721,"primaryCompletion":1658,"completion":1658,"start":896,"enrollment":4722,"conditions":4723,"interventions":4724},"NCT00850343","Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients",[76],208,[699],[3787],{"trials":4726,"activeCount":85},[],{"trials":4728,"activeCount":85},[],{"intervention":1489,"totalTrials":158,"cells":4730},{"EARLY_PHASE1":4731,"PHASE1":4733,"PHASE2":4735,"PHASE3":4737,"PHASE4":4747,"NA":4749},{"trials":4732,"activeCount":85},[],{"trials":4734,"activeCount":85},[],{"trials":4736,"activeCount":85},[],{"trials":4738,"activeCount":85},[4739,4743],{"nctId":1482,"briefTitle":1483,"status":114,"phases":4740,"primaryCompletion":860,"completion":860,"start":1485,"enrollment":1486,"conditions":4741,"interventions":4742},[76],[21],[912,1489],{"nctId":1495,"briefTitle":1496,"status":114,"phases":4744,"primaryCompletion":1498,"completion":1498,"start":1485,"enrollment":1499,"conditions":4745,"interventions":4746},[76],[35],[912,1489],{"trials":4748,"activeCount":85},[],{"trials":4750,"activeCount":85},[],{"intervention":911,"totalTrials":158,"cells":4752},{"EARLY_PHASE1":4753,"PHASE1":4755,"PHASE2":4757,"PHASE3":4759,"PHASE4":4769,"NA":4771},{"trials":4754,"activeCount":85},[],{"trials":4756,"activeCount":85},[],{"trials":4758,"activeCount":85},[],{"trials":4760,"activeCount":85},[4761,4765],{"nctId":904,"briefTitle":905,"status":114,"phases":4762,"primaryCompletion":896,"completion":896,"start":907,"enrollment":908,"conditions":4763,"interventions":4764},[76],[21],[911,912,798,890,913],{"nctId":1510,"briefTitle":1511,"status":114,"phases":4766,"primaryCompletion":896,"completion":896,"start":1513,"enrollment":1514,"conditions":4767,"interventions":4768},[76],[35],[912,911],{"trials":4770,"activeCount":85},[],{"trials":4772,"activeCount":85},[],{"intervention":765,"totalTrials":81,"cells":4774},{"EARLY_PHASE1":4775,"PHASE1":4777,"PHASE2":4779,"PHASE3":4781,"PHASE4":4787,"NA":4789},{"trials":4776,"activeCount":85},[],{"trials":4778,"activeCount":85},[],{"trials":4780,"activeCount":85},[],{"trials":4782,"activeCount":85},[4783],{"nctId":756,"briefTitle":757,"status":114,"phases":4784,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":4785,"interventions":4786},[76],[699],[46,765],{"trials":4788,"activeCount":85},[],{"trials":4790,"activeCount":85},[],{"intervention":1960,"totalTrials":81,"cells":4792},{"EARLY_PHASE1":4793,"PHASE1":4795,"PHASE2":4797,"PHASE3":4799,"PHASE4":4805,"NA":4807},{"trials":4794,"activeCount":85},[],{"trials":4796,"activeCount":85},[],{"trials":4798,"activeCount":85},[],{"trials":4800,"activeCount":85},[4801],{"nctId":1950,"briefTitle":1951,"status":114,"phases":4802,"primaryCompletion":1953,"completion":1498,"start":1954,"enrollment":1955,"conditions":4803,"interventions":4804},[76],[1957],[1959,1960],{"trials":4806,"activeCount":85},[],{"trials":4808,"activeCount":85},[],{"intervention":4810,"totalTrials":81,"cells":4811},"Tacrolimus, modified release",{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4818,"PHASE4":4827,"NA":4829},{"trials":4813,"activeCount":85},[],{"trials":4815,"activeCount":85},[],{"trials":4817,"activeCount":85},[],{"trials":4819,"activeCount":85},[4820],{"nctId":4821,"briefTitle":4822,"status":114,"phases":4823,"primaryCompletion":847,"completion":847,"start":1054,"enrollment":4824,"conditions":4825,"interventions":4826},"NCT00865137","An Open Study Assessing Bioavailability of a Modified Formulation of Tacrolimus in Kidney Transplant Recipients",[76],27,[21],[4810],{"trials":4828,"activeCount":85},[],{"trials":4830,"activeCount":85},[],{"intervention":4832,"totalTrials":81,"cells":4833},"YM529 \u002F ONO-5920",{"EARLY_PHASE1":4834,"PHASE1":4836,"PHASE2":4838,"PHASE3":4840,"PHASE4":4851,"NA":4853},{"trials":4835,"activeCount":85},[],{"trials":4837,"activeCount":85},[],{"trials":4839,"activeCount":85},[],{"trials":4841,"activeCount":85},[4842],{"nctId":4843,"briefTitle":4844,"status":114,"phases":4845,"primaryCompletion":355,"completion":355,"start":1298,"enrollment":4846,"conditions":4847,"interventions":4850},"NCT00794443","ONO-5920\u002FYM529 Confirmatory Study in Involutional Osteoporosis Patients",[75,76],692,[4848,4849],"Osteoporosis","Bone Loss, Age-Related",[4832],{"trials":4852,"activeCount":85},[],{"trials":4854,"activeCount":85},[],{"intervention":4856,"totalTrials":81,"cells":4857},"Tamuslosin",{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4862,"PHASE3":4864,"PHASE4":4873,"NA":4875},{"trials":4859,"activeCount":85},[],{"trials":4861,"activeCount":85},[],{"trials":4863,"activeCount":85},[],{"trials":4865,"activeCount":85},[4866],{"nctId":4867,"briefTitle":4868,"status":114,"phases":4869,"conditions":4870,"interventions":4872},"NCT00239265","Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome",[76],[4871],"Urinary Tract Diseases",[4856],{"trials":4874,"activeCount":85},[],{"trials":4876,"activeCount":85},[],{"intervention":4878,"totalTrials":81,"cells":4879},"DA",{"EARLY_PHASE1":4880,"PHASE1":4882,"PHASE2":4884,"PHASE3":4886,"PHASE4":4898,"NA":4900},{"trials":4881,"activeCount":85},[],{"trials":4883,"activeCount":85},[],{"trials":4885,"activeCount":85},[],{"trials":4887,"activeCount":85},[4888],{"nctId":4889,"briefTitle":4890,"status":114,"phases":4891,"primaryCompletion":4892,"completion":4893,"start":4894,"enrollment":4895,"conditions":4896,"interventions":4897},"NCT02988973","A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia",[76],"2019-09-13","2020-03-26","2017-01-12",334,[3508],[4512,4878],{"trials":4899,"activeCount":85},[],{"trials":4901,"activeCount":85},[],{"intervention":4903,"totalTrials":81,"cells":4904},"YM177",{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4909,"PHASE3":4911,"PHASE4":4922,"NA":4924},{"trials":4906,"activeCount":85},[],{"trials":4908,"activeCount":85},[],{"trials":4910,"activeCount":85},[],{"trials":4912,"activeCount":85},[4913],{"nctId":4914,"briefTitle":4915,"status":114,"phases":4916,"primaryCompletion":1985,"completion":1985,"start":3196,"enrollment":4917,"conditions":4918,"interventions":4920},"NCT01118572","A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients",[76],616,[4919],"Post Operative Pain",[4903,4921],"etodolac",{"trials":4923,"activeCount":85},[],{"trials":4925,"activeCount":85},[],{"intervention":4921,"totalTrials":81,"cells":4927},{"EARLY_PHASE1":4928,"PHASE1":4930,"PHASE2":4932,"PHASE3":4934,"PHASE4":4940,"NA":4942},{"trials":4929,"activeCount":85},[],{"trials":4931,"activeCount":85},[],{"trials":4933,"activeCount":85},[],{"trials":4935,"activeCount":85},[4936],{"nctId":4914,"briefTitle":4915,"status":114,"phases":4937,"primaryCompletion":1985,"completion":1985,"start":3196,"enrollment":4917,"conditions":4938,"interventions":4939},[76],[4919],[4903,4921],{"trials":4941,"activeCount":85},[],{"trials":4943,"activeCount":85},[],{"intervention":4945,"totalTrials":81,"cells":4946},"alpha glucosidase inhibitor",{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4953,"PHASE4":4964,"NA":4966},{"trials":4948,"activeCount":85},[],{"trials":4950,"activeCount":85},[],{"trials":4952,"activeCount":85},[],{"trials":4954,"activeCount":85},[4955],{"nctId":4956,"briefTitle":4957,"status":114,"phases":4958,"primaryCompletion":4959,"completion":4959,"start":4960,"enrollment":4961,"conditions":4962,"interventions":4963},"NCT01242202","A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients",[76],"2012-05-25","2010-10-21",113,[27],[3994,4945],{"trials":4965,"activeCount":85},[],{"trials":4967,"activeCount":85},[],{"intervention":3313,"totalTrials":81,"cells":4969},{"EARLY_PHASE1":4970,"PHASE1":4972,"PHASE2":4974,"PHASE3":4976,"PHASE4":4982,"NA":4984},{"trials":4971,"activeCount":85},[],{"trials":4973,"activeCount":85},[],{"trials":4975,"activeCount":85},[],{"trials":4977,"activeCount":85},[4978],{"nctId":3305,"briefTitle":3306,"status":353,"phases":4979,"primaryCompletion":3308,"completion":3308,"start":3309,"enrollment":3310,"conditions":4980,"interventions":4981},[76],[3292],[3114,3313],{"trials":4983,"activeCount":85},[],{"trials":4985,"activeCount":85},[],{"intervention":3634,"totalTrials":81,"cells":4987},{"EARLY_PHASE1":4988,"PHASE1":4990,"PHASE2":4992,"PHASE3":4994,"PHASE4":5000,"NA":5002},{"trials":4989,"activeCount":85},[],{"trials":4991,"activeCount":85},[],{"trials":4993,"activeCount":85},[],{"trials":4995,"activeCount":85},[4996],{"nctId":3626,"briefTitle":3627,"status":114,"phases":4997,"primaryCompletion":3629,"completion":3629,"start":3630,"enrollment":3631,"conditions":4998,"interventions":4999},[76],[33],[1714,3634],{"trials":5001,"activeCount":85},[],{"trials":5003,"activeCount":85},[],{"intervention":1469,"totalTrials":81,"cells":5005},{"EARLY_PHASE1":5006,"PHASE1":5008,"PHASE2":5010,"PHASE3":5012,"PHASE4":5018,"NA":5020},{"trials":5007,"activeCount":85},[],{"trials":5009,"activeCount":85},[],{"trials":5011,"activeCount":85},[],{"trials":5013,"activeCount":85},[5014],{"nctId":1463,"briefTitle":1464,"status":114,"phases":5015,"primaryCompletion":318,"completion":318,"start":378,"enrollment":1466,"conditions":5016,"interventions":5017},[76],[35],[1469,912],{"trials":5019,"activeCount":85},[],{"trials":5021,"activeCount":85},[],{"intervention":5023,"totalTrials":81,"cells":5024},"OPT-80",{"EARLY_PHASE1":5025,"PHASE1":5027,"PHASE2":5029,"PHASE3":5031,"PHASE4":5043,"NA":5045},{"trials":5026,"activeCount":85},[],{"trials":5028,"activeCount":85},[],{"trials":5030,"activeCount":85},[],{"trials":5032,"activeCount":85},[5033],{"nctId":5034,"briefTitle":5035,"status":114,"phases":5036,"primaryCompletion":5037,"completion":5037,"start":5038,"enrollment":3777,"conditions":5039,"interventions":5041},"NCT02179658","A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",[76],"2016-09-08","2014-06-23",[5040],"Clostridium Difficile",[5023,5042],"vancomycin",{"trials":5044,"activeCount":85},[],{"trials":5046,"activeCount":85},[],{"intervention":5042,"totalTrials":81,"cells":5048},{"EARLY_PHASE1":5049,"PHASE1":5051,"PHASE2":5053,"PHASE3":5055,"PHASE4":5061,"NA":5063},{"trials":5050,"activeCount":85},[],{"trials":5052,"activeCount":85},[],{"trials":5054,"activeCount":85},[],{"trials":5056,"activeCount":85},[5057],{"nctId":5034,"briefTitle":5035,"status":114,"phases":5058,"primaryCompletion":5037,"completion":5037,"start":5038,"enrollment":3777,"conditions":5059,"interventions":5060},[76],[5040],[5023,5042],{"trials":5062,"activeCount":85},[],{"trials":5064,"activeCount":85},[],{"intervention":5066,"totalTrials":81,"cells":5067},"Granisetron",{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5072,"PHASE3":5074,"PHASE4":5085,"NA":5087},{"trials":5069,"activeCount":85},[],{"trials":5071,"activeCount":85},[],{"trials":5073,"activeCount":85},[],{"trials":5075,"activeCount":85},[5076],{"nctId":5077,"briefTitle":5078,"status":114,"phases":5079,"primaryCompletion":847,"completion":860,"start":1790,"enrollment":5080,"conditions":5081,"interventions":5083},"NCT00272285","A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea",[76],287,[5082,4373],"Vomiting",[5084,5066],"Ramosetron",{"trials":5086,"activeCount":85},[],{"trials":5088,"activeCount":85},[],{"intervention":4561,"totalTrials":81,"cells":5090},{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5095,"PHASE3":5097,"PHASE4":5103,"NA":5105},{"trials":5092,"activeCount":85},[],{"trials":5094,"activeCount":85},[],{"trials":5096,"activeCount":85},[],{"trials":5098,"activeCount":85},[5099],{"nctId":4552,"briefTitle":4553,"status":114,"phases":5100,"primaryCompletion":4555,"completion":4556,"start":4557,"enrollment":4558,"conditions":5101,"interventions":5102},[76],[322],[4531,4561],{"trials":5104,"activeCount":85},[],{"trials":5106,"activeCount":85},[],{"intervention":5108,"totalTrials":81,"cells":5109},"CDP870",{"EARLY_PHASE1":5110,"PHASE1":5112,"PHASE2":5114,"PHASE3":5116,"PHASE4":5127,"NA":5129},{"trials":5111,"activeCount":85},[],{"trials":5113,"activeCount":85},[],{"trials":5115,"activeCount":85},[],{"trials":5117,"activeCount":85},[5118],{"nctId":5119,"briefTitle":5120,"status":114,"phases":5121,"primaryCompletion":1658,"completion":1658,"start":5122,"enrollment":5123,"conditions":5124,"interventions":5126},"NCT02586246","Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870",[76],"2011-01",86,[5125],"Active Rheumatoid Arthritis",[5108],{"trials":5128,"activeCount":85},[],{"trials":5130,"activeCount":85},[],{"intervention":5132,"totalTrials":81,"cells":5133},"ASP8597",{"EARLY_PHASE1":5134,"PHASE1":5136,"PHASE2":5138,"PHASE3":5140,"PHASE4":5149,"NA":5151},{"trials":5135,"activeCount":85},[],{"trials":5137,"activeCount":85},[],{"trials":5139,"activeCount":85},[],{"trials":5141,"activeCount":85},[5142],{"nctId":5143,"briefTitle":5144,"status":353,"phases":5145,"primaryCompletion":5146,"completion":5146,"start":2282,"enrollment":25,"conditions":5147,"interventions":5148},"NCT01442337","A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients",[75,76],"2013-07",[21],[5132],{"trials":5150,"activeCount":85},[],{"trials":5152,"activeCount":85},[],{"intervention":1303,"totalTrials":81,"cells":5154},{"EARLY_PHASE1":5155,"PHASE1":5157,"PHASE2":5159,"PHASE3":5161,"PHASE4":5167,"NA":5169},{"trials":5156,"activeCount":85},[],{"trials":5158,"activeCount":85},[],{"trials":5160,"activeCount":85},[],{"trials":5162,"activeCount":85},[5163],{"nctId":1295,"briefTitle":1296,"status":114,"phases":5164,"primaryCompletion":333,"completion":333,"start":1298,"enrollment":1299,"conditions":5165,"interventions":5166},[76],[1301,1213],[1235,1303],{"trials":5168,"activeCount":85},[],{"trials":5170,"activeCount":85},[],{"intervention":5172,"totalTrials":81,"cells":5173},"Tamusulosin",{"EARLY_PHASE1":5174,"PHASE1":5176,"PHASE2":5178,"PHASE3":5180,"PHASE4":5188,"NA":5190},{"trials":5175,"activeCount":85},[],{"trials":5177,"activeCount":85},[],{"trials":5179,"activeCount":85},[],{"trials":5181,"activeCount":85},[5182],{"nctId":5183,"briefTitle":5184,"status":114,"phases":5185,"conditions":5186,"interventions":5187},"NCT00239317","Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome",[76],[4871],[5172],{"trials":5189,"activeCount":85},[],{"trials":5191,"activeCount":85},[],{"intervention":902,"totalTrials":81,"cells":5193},{"EARLY_PHASE1":5194,"PHASE1":5196,"PHASE2":5198,"PHASE3":5200,"PHASE4":5206,"NA":5208},{"trials":5195,"activeCount":85},[],{"trials":5197,"activeCount":85},[],{"trials":5199,"activeCount":85},[],{"trials":5201,"activeCount":85},[5202],{"nctId":892,"briefTitle":893,"status":114,"phases":5203,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":5204,"interventions":5205},[76],[21],[901,852,902,828],{"trials":5207,"activeCount":85},[],{"trials":5209,"activeCount":85},[],{"intervention":5211,"totalTrials":81,"cells":5212},"Sulfonylurea",{"EARLY_PHASE1":5213,"PHASE1":5215,"PHASE2":5217,"PHASE3":5219,"PHASE4":5229,"NA":5231},{"trials":5214,"activeCount":85},[],{"trials":5216,"activeCount":85},[],{"trials":5218,"activeCount":85},[],{"trials":5220,"activeCount":85},[5221],{"nctId":5222,"briefTitle":5223,"status":114,"phases":5224,"primaryCompletion":2262,"completion":2262,"start":5225,"enrollment":5226,"conditions":5227,"interventions":5228},"NCT01242215","A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients",[76],"2010-09-17",243,[27],[5211],{"trials":5230,"activeCount":85},[],{"trials":5232,"activeCount":85},[],{"intervention":3802,"totalTrials":81,"cells":5234},{"EARLY_PHASE1":5235,"PHASE1":5237,"PHASE2":5239,"PHASE3":5241,"PHASE4":5247,"NA":5249},{"trials":5236,"activeCount":85},[],{"trials":5238,"activeCount":85},[],{"trials":5240,"activeCount":85},[],{"trials":5242,"activeCount":85},[5243],{"nctId":3793,"briefTitle":3794,"status":114,"phases":5244,"primaryCompletion":3796,"completion":3797,"start":3798,"enrollment":3799,"conditions":5245,"interventions":5246},[76],[699],[3802,701],{"trials":5248,"activeCount":85},[],{"trials":5250,"activeCount":85},[],{"intervention":1915,"totalTrials":81,"cells":5252},{"EARLY_PHASE1":5253,"PHASE1":5255,"PHASE2":5257,"PHASE3":5259,"PHASE4":5265,"NA":5267},{"trials":5254,"activeCount":85},[],{"trials":5256,"activeCount":85},[],{"trials":5258,"activeCount":85},[],{"trials":5260,"activeCount":85},[5261],{"nctId":1908,"briefTitle":1909,"status":114,"phases":5262,"primaryCompletion":1911,"completion":1911,"start":1719,"enrollment":1912,"conditions":5263,"interventions":5264},[76],[1902],[1904,1915],{"trials":5266,"activeCount":85},[],{"trials":5268,"activeCount":85},[],{"intervention":5270,"totalTrials":81,"cells":5271},"Famotidine",{"EARLY_PHASE1":5272,"PHASE1":5274,"PHASE2":5276,"PHASE3":5278,"PHASE4":5288,"NA":5290},{"trials":5273,"activeCount":85},[],{"trials":5275,"activeCount":85},[],{"trials":5277,"activeCount":85},[],{"trials":5279,"activeCount":85},[5280],{"nctId":5281,"briefTitle":5282,"status":114,"phases":5283,"start":1584,"enrollment":5284,"conditions":5285,"interventions":5287},"NCT00141960","Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease",[75,76],480,[5286],"Gastroesophageal Reflux",[5270],{"trials":5289,"activeCount":85},[],{"trials":5291,"activeCount":85},[],{"intervention":913,"totalTrials":81,"cells":5293},{"EARLY_PHASE1":5294,"PHASE1":5296,"PHASE2":5298,"PHASE3":5300,"PHASE4":5306,"NA":5308},{"trials":5295,"activeCount":85},[],{"trials":5297,"activeCount":85},[],{"trials":5299,"activeCount":85},[],{"trials":5301,"activeCount":85},[5302],{"nctId":904,"briefTitle":905,"status":114,"phases":5303,"primaryCompletion":896,"completion":896,"start":907,"enrollment":908,"conditions":5304,"interventions":5305},[76],[21],[911,912,798,890,913],{"trials":5307,"activeCount":85},[],{"trials":5309,"activeCount":85},[],{"intervention":923,"totalTrials":81,"cells":5311},{"EARLY_PHASE1":5312,"PHASE1":5314,"PHASE2":5316,"PHASE3":5318,"PHASE4":5324,"NA":5326},{"trials":5313,"activeCount":85},[],{"trials":5315,"activeCount":85},[],{"trials":5317,"activeCount":85},[],{"trials":5319,"activeCount":85},[5320],{"nctId":915,"briefTitle":916,"status":114,"phases":5321,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":5322,"interventions":5323},[76],[21],[852,798,923],{"trials":5325,"activeCount":85},[],{"trials":5327,"activeCount":85},[],{"intervention":5329,"totalTrials":81,"cells":5330},"VESIcare®",{"EARLY_PHASE1":5331,"PHASE1":5333,"PHASE2":5335,"PHASE3":5337,"PHASE4":5346,"NA":5348},{"trials":5332,"activeCount":85},[],{"trials":5334,"activeCount":85},[],{"trials":5336,"activeCount":85},[],{"trials":5338,"activeCount":85},[5339],{"nctId":5340,"briefTitle":5341,"status":114,"phases":5342,"primaryCompletion":1584,"completion":1584,"start":4487,"enrollment":5343,"conditions":5344,"interventions":5345},"NCT00454896","A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)",[76],739,[33],[5329],{"trials":5347,"activeCount":85},[],{"trials":5349,"activeCount":85},[],{"intervention":932,"totalTrials":81,"cells":5351},{"EARLY_PHASE1":5352,"PHASE1":5354,"PHASE2":5356,"PHASE3":5358,"PHASE4":5364,"NA":5366},{"trials":5353,"activeCount":85},[],{"trials":5355,"activeCount":85},[],{"trials":5357,"activeCount":85},[],{"trials":5359,"activeCount":85},[5360],{"nctId":925,"briefTitle":926,"status":114,"phases":5361,"primaryCompletion":821,"completion":821,"start":928,"enrollment":929,"conditions":5362,"interventions":5363},[76],[21],[826,828,932,866],{"trials":5365,"activeCount":85},[],{"trials":5367,"activeCount":85},[],{"intervention":1778,"totalTrials":81,"cells":5369},{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5382,"NA":5384},{"trials":5371,"activeCount":85},[],{"trials":5373,"activeCount":85},[],{"trials":5375,"activeCount":85},[],{"trials":5377,"activeCount":85},[5378],{"nctId":1769,"briefTitle":1770,"status":114,"phases":5379,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":730,"conditions":5380,"interventions":5381},[76],[21],[826,826,944,1777,829,1778,1779],{"trials":5383,"activeCount":85},[],{"trials":5385,"activeCount":85},[],{"intervention":1779,"totalTrials":81,"cells":5387},{"EARLY_PHASE1":5388,"PHASE1":5390,"PHASE2":5392,"PHASE3":5394,"PHASE4":5400,"NA":5402},{"trials":5389,"activeCount":85},[],{"trials":5391,"activeCount":85},[],{"trials":5393,"activeCount":85},[],{"trials":5395,"activeCount":85},[5396],{"nctId":1769,"briefTitle":1770,"status":114,"phases":5397,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":730,"conditions":5398,"interventions":5399},[76],[21],[826,826,944,1777,829,1778,1779],{"trials":5401,"activeCount":85},[],{"trials":5403,"activeCount":85},[],{"intervention":2013,"totalTrials":81,"cells":5405},{"EARLY_PHASE1":5406,"PHASE1":5408,"PHASE2":5410,"PHASE3":5412,"PHASE4":5418,"NA":5420},{"trials":5407,"activeCount":85},[],{"trials":5409,"activeCount":85},[],{"trials":5411,"activeCount":85},[],{"trials":5413,"activeCount":85},[5414],{"nctId":2006,"briefTitle":2007,"status":114,"phases":5415,"primaryCompletion":907,"completion":907,"start":2009,"enrollment":2010,"conditions":5416,"interventions":5417},[76],[1957],[2013,1969],{"trials":5419,"activeCount":85},[],{"trials":5421,"activeCount":85},[],{"intervention":5423,"totalTrials":81,"cells":5424},"Capsaicin 8%",{"EARLY_PHASE1":5425,"PHASE1":5427,"PHASE2":5429,"PHASE3":5431,"PHASE4":5441,"NA":5443},{"trials":5426,"activeCount":85},[],{"trials":5428,"activeCount":85},[],{"trials":5430,"activeCount":85},[],{"trials":5432,"activeCount":85},[5433],{"nctId":5434,"briefTitle":5435,"status":114,"phases":5436,"primaryCompletion":2240,"completion":2240,"start":1371,"enrollment":3444,"conditions":5437,"interventions":5440},"NCT01533428","A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)",[76],[5438,5439],"Diabetic Peripheral Neuropathy","Pain",[5423],{"trials":5442,"activeCount":85},[],{"trials":5444,"activeCount":85},[],{"intervention":5446,"totalTrials":81,"cells":5447},"leuprorelin acetate",{"EARLY_PHASE1":5448,"PHASE1":5450,"PHASE2":5452,"PHASE3":5454,"PHASE4":5464,"NA":5466},{"trials":5449,"activeCount":85},[],{"trials":5451,"activeCount":85},[],{"trials":5453,"activeCount":85},[],{"trials":5455,"activeCount":85},[5456],{"nctId":5457,"briefTitle":5458,"status":114,"phases":5459,"primaryCompletion":3205,"completion":5460,"start":2009,"enrollment":5461,"conditions":5462,"interventions":5463},"NCT00378690","A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD",[76],"2012-12",706,[322],[5446],{"trials":5465,"activeCount":85},[],{"trials":5467,"activeCount":85},[],{"intervention":5469,"totalTrials":81,"cells":5470},"Pioglitazone",{"EARLY_PHASE1":5471,"PHASE1":5473,"PHASE2":5475,"PHASE3":5477,"PHASE4":5487,"NA":5489},{"trials":5472,"activeCount":85},[],{"trials":5474,"activeCount":85},[],{"trials":5476,"activeCount":85},[],{"trials":5478,"activeCount":85},[5479],{"nctId":5480,"briefTitle":5481,"status":114,"phases":5482,"primaryCompletion":5483,"completion":5483,"start":5484,"enrollment":920,"conditions":5485,"interventions":5486},"NCT01225081","A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients",[76],"2012-04-28","2010-09-15",[27],[3994,5469],{"trials":5488,"activeCount":85},[],{"trials":5490,"activeCount":85},[],{"intervention":5492,"totalTrials":81,"cells":5493},"Interferon alfacon-1",{"EARLY_PHASE1":5494,"PHASE1":5496,"PHASE2":5498,"PHASE3":5500,"PHASE4":5509,"NA":5511},{"trials":5495,"activeCount":85},[],{"trials":5497,"activeCount":85},[],{"trials":5499,"activeCount":85},[],{"trials":5501,"activeCount":85},[5502],{"nctId":5503,"briefTitle":5504,"status":114,"phases":5505,"conditions":5506,"interventions":5508},"NCT00239252","Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C",[76],[5507],"Hepatitis C",[5492],{"trials":5510,"activeCount":85},[],{"trials":5512,"activeCount":85},[],{"intervention":1830,"totalTrials":81,"cells":5514},{"EARLY_PHASE1":5515,"PHASE1":5517,"PHASE2":5519,"PHASE3":5521,"PHASE4":5527,"NA":5529},{"trials":5516,"activeCount":85},[],{"trials":5518,"activeCount":85},[],{"trials":5520,"activeCount":85},[],{"trials":5522,"activeCount":85},[5523],{"nctId":1823,"briefTitle":1824,"status":353,"phases":5524,"primaryCompletion":1658,"completion":1658,"start":1826,"enrollment":263,"conditions":5525,"interventions":5526},[76],[1828],[826,1830,1831,1832,841],{"trials":5528,"activeCount":85},[],{"trials":5530,"activeCount":85},[],{"intervention":1831,"totalTrials":81,"cells":5532},{"EARLY_PHASE1":5533,"PHASE1":5535,"PHASE2":5537,"PHASE3":5539,"PHASE4":5545,"NA":5547},{"trials":5534,"activeCount":85},[],{"trials":5536,"activeCount":85},[],{"trials":5538,"activeCount":85},[],{"trials":5540,"activeCount":85},[5541],{"nctId":1823,"briefTitle":1824,"status":353,"phases":5542,"primaryCompletion":1658,"completion":1658,"start":1826,"enrollment":263,"conditions":5543,"interventions":5544},[76],[1828],[826,1830,1831,1832,841],{"trials":5546,"activeCount":85},[],{"trials":5548,"activeCount":85},[],{"intervention":1832,"totalTrials":81,"cells":5550},{"EARLY_PHASE1":5551,"PHASE1":5553,"PHASE2":5555,"PHASE3":5557,"PHASE4":5563,"NA":5565},{"trials":5552,"activeCount":85},[],{"trials":5554,"activeCount":85},[],{"trials":5556,"activeCount":85},[],{"trials":5558,"activeCount":85},[5559],{"nctId":1823,"briefTitle":1824,"status":353,"phases":5560,"primaryCompletion":1658,"completion":1658,"start":1826,"enrollment":263,"conditions":5561,"interventions":5562},[76],[1828],[826,1830,1831,1832,841],{"trials":5564,"activeCount":85},[],{"trials":5566,"activeCount":85},[],{"intervention":1523,"totalTrials":81,"cells":5568},{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5575,"PHASE4":5581,"NA":5583},{"trials":5570,"activeCount":85},[],{"trials":5572,"activeCount":85},[],{"trials":5574,"activeCount":85},[],{"trials":5576,"activeCount":85},[5577],{"nctId":1518,"briefTitle":1519,"status":114,"phases":5578,"primaryCompletion":896,"completion":896,"start":982,"enrollment":1211,"conditions":5579,"interventions":5580},[76],[35],[1523,912],{"trials":5582,"activeCount":85},[],{"trials":5584,"activeCount":85},[],{"intervention":5586,"totalTrials":81,"cells":5587},"DPP-4 inhibitor",{"EARLY_PHASE1":5588,"PHASE1":5590,"PHASE2":5592,"PHASE3":5594,"PHASE4":5604,"NA":5606},{"trials":5589,"activeCount":85},[],{"trials":5591,"activeCount":85},[],{"trials":5593,"activeCount":85},[],{"trials":5595,"activeCount":85},[5596],{"nctId":5597,"briefTitle":5598,"status":114,"phases":5599,"primaryCompletion":5600,"completion":5600,"start":4960,"enrollment":5601,"conditions":5602,"interventions":5603},"NCT01242228","A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients",[76],"2012-06-06",106,[27],[3994,5586],{"trials":5605,"activeCount":85},[],{"trials":5607,"activeCount":85},[],{"intervention":313,"totalTrials":1191,"cells":5609},{"EARLY_PHASE1":5610,"PHASE1":5612,"PHASE2":5621,"PHASE3":5681,"PHASE4":5683,"NA":5685},{"trials":5611,"activeCount":85},[],{"trials":5613,"activeCount":85},[5614],{"nctId":5615,"briefTitle":5616,"status":114,"phases":5617,"primaryCompletion":318,"completion":318,"start":333,"enrollment":1750,"conditions":5618,"interventions":5620},"NCT01023386","A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer",[74],[5619],"Cancer",[313],{"trials":5622,"activeCount":85},[5623,5632,5636,5645,5651,5657,5665,5669],{"nctId":5624,"briefTitle":5625,"status":114,"phases":5626,"primaryCompletion":2400,"completion":5627,"start":333,"enrollment":1428,"conditions":5628,"interventions":5630},"NCT01007292","A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment",[75],"2015-06",[5629],"Non-Hodgkin's Lymphoma",[313,5631],"Rituximab",{"nctId":303,"briefTitle":304,"status":114,"phases":5633,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":5634,"interventions":5635},[75],[311],[313,274],{"nctId":5637,"briefTitle":5638,"status":114,"phases":5639,"completion":982,"conditions":5640,"interventions":5644},"NCT00257478","A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy",[75],[322,5641,5642,5643],"Cancer of Prostate","Prostatic Cancer","Cancer of the Prostate",[313],{"nctId":5646,"briefTitle":5647,"status":114,"phases":5648,"primaryCompletion":331,"completion":332,"start":1485,"enrollment":1466,"conditions":5649,"interventions":5650},"NCT00818480","An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155",[75],[322,336,5629],[313],{"nctId":5652,"briefTitle":5653,"status":114,"phases":5654,"completion":1043,"start":928,"enrollment":19,"conditions":5655,"interventions":5656},"NCT00281541","A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma",[75],[336],[313],{"nctId":5658,"briefTitle":5659,"status":353,"phases":5660,"primaryCompletion":378,"completion":378,"start":1043,"enrollment":1023,"conditions":5661,"interventions":5664},"NCT00498914","Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects",[75],[5662,5663],"Lymphoma, Large-Cell, Diffuse","Lymphoma, B-Cell Refractory",[313],{"nctId":328,"briefTitle":329,"status":114,"phases":5666,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":5667,"interventions":5668},[75],[336],[313,274],{"nctId":5670,"briefTitle":5671,"status":114,"phases":5672,"primaryCompletion":982,"completion":982,"start":2872,"enrollment":5673,"conditions":5674,"interventions":5680},"NCT00328588","LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy",[75],37,[5675,5676,5677,5678,5679],"Lung Cancer","Cancer of Lung","Cancer of the Lung","Non-Small Cell Lung Carcinoma","Carcinoma, Non-Small Cell Lung",[313],{"trials":5682,"activeCount":85},[],{"trials":5684,"activeCount":85},[],{"trials":5686,"activeCount":85},[],{"intervention":5688,"totalTrials":1846,"cells":5689},"CP-461",{"EARLY_PHASE1":5690,"PHASE1":5692,"PHASE2":5702,"PHASE3":5733,"PHASE4":5735,"NA":5737},{"trials":5691,"activeCount":85},[],{"trials":5693,"activeCount":85},[5694],{"nctId":5695,"briefTitle":5696,"status":114,"phases":5697,"completion":5698,"start":3776,"enrollment":697,"conditions":5699,"interventions":5701},"NCT00036257","Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia",[74],"2003-04",[5700],"Chronic Lymphocytic Leukemia",[5688],{"trials":5703,"activeCount":85},[5704,5712,5719,5726],{"nctId":5705,"briefTitle":5706,"status":114,"phases":5707,"completion":1383,"start":5708,"enrollment":1372,"conditions":5709,"interventions":5711},"NCT00042055","CP-461 for the Treatment of Crohn's Disease",[75],"2002-07",[5710],"Crohn's Disease",[5688],{"nctId":5713,"briefTitle":5714,"status":114,"phases":5715,"completion":1261,"start":5716,"enrollment":3150,"conditions":5717,"interventions":5718},"NCT00036075","Study Using CP-461 to Treat Advanced Prostate Cancer",[75],"2001-08",[322],[5688],{"nctId":5720,"briefTitle":5721,"status":353,"phases":5722,"completion":1288,"start":1262,"enrollment":3542,"conditions":5723,"interventions":5725},"NCT00060710","CP-461 in the Treatment of Patients With Advanced Melanoma",[75],[5724],"Malignant Melanoma",[5688],{"nctId":5727,"briefTitle":5728,"status":114,"phases":5729,"completion":1086,"start":4632,"enrollment":4634,"conditions":5730,"interventions":5732},"NCT00036036","Study of CP-461 in Patients With Advanced Renal Cell Cancer",[75],[5731],"Renal Cell Carcinoma",[5688],{"trials":5734,"activeCount":85},[],{"trials":5736,"activeCount":85},[],{"trials":5738,"activeCount":85},[],{"intervention":5740,"totalTrials":1846,"cells":5741},"ASP1517",{"EARLY_PHASE1":5742,"PHASE1":5744,"PHASE2":5779,"PHASE3":5791,"PHASE4":5793,"NA":5795},{"trials":5743,"activeCount":85},[],{"trials":5745,"activeCount":85},[5746,5755,5762,5770],{"nctId":5747,"briefTitle":5748,"status":114,"phases":5749,"primaryCompletion":5750,"completion":5750,"start":5751,"enrollment":4103,"conditions":5752,"interventions":5753},"NCT02952040","A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate",[74],"2016-12","2016-11",[18],[5740,5754],"Lanthanum carbonate hydrate",{"nctId":5756,"briefTitle":5757,"status":114,"phases":5758,"primaryCompletion":5759,"completion":5759,"start":846,"enrollment":1541,"conditions":5760,"interventions":5761},"NCT00978198","Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers",[74],"2010-06",[30],[5740],{"nctId":5763,"briefTitle":5764,"status":114,"phases":5765,"primaryCompletion":5766,"completion":5766,"start":5767,"enrollment":1180,"conditions":5768,"interventions":5769},"NCT02805374","A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517",[74],"2016-08","2016-07",[18],[5740],{"nctId":5771,"briefTitle":5772,"status":114,"phases":5773,"primaryCompletion":5774,"completion":5774,"start":5775,"enrollment":16,"conditions":5776,"interventions":5777},"NCT02693613","Pharmacokinetic Study of ASP1517 With Kremezin®",[74],"2016-04","2016-02",[30],[5740,5778],"Kremezin®",{"trials":5780,"activeCount":85},[5781],{"nctId":5782,"briefTitle":5783,"status":114,"phases":5784,"primaryCompletion":5785,"completion":5786,"start":5787,"enrollment":2302,"conditions":5788,"interventions":5790},"NCT01964196","ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-",[75],"2015-07-06","2015-12-01","2013-09-17",[5789],"Anemia in Chronic Kidney Disease Patients Not on Dialysis",[5740],{"trials":5792,"activeCount":85},[],{"trials":5794,"activeCount":85},[],{"trials":5796,"activeCount":85},[],{"intervention":5798,"totalTrials":275,"cells":5799},"ASP2151",{"EARLY_PHASE1":5800,"PHASE1":5802,"PHASE2":5820,"PHASE3":5844,"PHASE4":5846,"NA":5848},{"trials":5801,"activeCount":85},[],{"trials":5803,"activeCount":85},[5804,5813],{"nctId":5805,"briefTitle":5806,"status":353,"phases":5807,"primaryCompletion":355,"completion":355,"start":896,"enrollment":5808,"conditions":5809,"interventions":5811},"NCT00870441","Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers",[74],442,[5810],"Safety of ASP2151",[5798,5812],"Valacyclovir",{"nctId":5814,"briefTitle":5815,"status":114,"phases":5816,"primaryCompletion":5817,"completion":5817,"start":1317,"enrollment":3224,"conditions":5818,"interventions":5819},"NCT02796118","Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects",[74],"2006-10",[18],[5798],{"trials":5821,"activeCount":85},[5822,5833],{"nctId":5823,"briefTitle":5824,"status":114,"phases":5825,"primaryCompletion":5826,"completion":5826,"start":5827,"enrollment":5828,"conditions":5829,"interventions":5831},"NCT00486200","A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes",[75],"2008-08-12","2007-06-21",695,[5830],"Herpes Genitalis",[5798,5832],"valacyclovir",{"nctId":5834,"briefTitle":5835,"status":114,"phases":5836,"primaryCompletion":5837,"completion":5837,"start":5838,"enrollment":5839,"conditions":5840,"interventions":5842},"NCT00487682","Dose-finding Study of ASP2151 in Subjects With Herpes Zoster",[75],"2008-09-01","2007-11-13",403,[5841],"Herpes Zoster",[5798,5843],"Valacyclovir hydrochloride",{"trials":5845,"activeCount":85},[],{"trials":5847,"activeCount":85},[],{"trials":5849,"activeCount":85},[],{"intervention":3402,"totalTrials":275,"cells":5851},{"EARLY_PHASE1":5852,"PHASE1":5854,"PHASE2":5860,"PHASE3":5874,"PHASE4":5876,"NA":5878},{"trials":5853,"activeCount":85},[],{"trials":5855,"activeCount":85},[5856],{"nctId":3571,"briefTitle":3572,"status":114,"phases":5857,"primaryCompletion":3574,"completion":3574,"start":1240,"enrollment":118,"conditions":5858,"interventions":5859},[74],[24,2047],[3402,1714],{"trials":5861,"activeCount":85},[5862,5866,5870],{"nctId":3371,"briefTitle":3372,"status":114,"phases":5863,"primaryCompletion":809,"completion":809,"start":1953,"enrollment":3374,"conditions":5864,"interventions":5865},[75],[3376],[3319,3378],{"nctId":3380,"briefTitle":3381,"status":114,"phases":5867,"primaryCompletion":3171,"completion":3171,"start":808,"enrollment":3383,"conditions":5868,"interventions":5869},[75],[3385],[3319,3378],{"nctId":3396,"briefTitle":3397,"status":114,"phases":5871,"primaryCompletion":971,"completion":971,"start":982,"enrollment":3399,"conditions":5872,"interventions":5873},[75],[3385],[3319,3402],{"trials":5875,"activeCount":85},[],{"trials":5877,"activeCount":85},[],{"trials":5879,"activeCount":85},[],{"intervention":5881,"totalTrials":275,"cells":5882},"ASP7991",{"EARLY_PHASE1":5883,"PHASE1":5885,"PHASE2":5910,"PHASE3":5923,"PHASE4":5925,"NA":5927},{"trials":5884,"activeCount":85},[],{"trials":5886,"activeCount":85},[5887,5898,5904],{"nctId":5888,"briefTitle":5889,"status":114,"phases":5890,"primaryCompletion":5891,"completion":5891,"start":5892,"enrollment":4634,"conditions":5893,"interventions":5897},"NCT01872026","Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis",[74],"2013-06-26","2012-12-26",[5894,5895,5896],"Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy","Pharmacodynamics of ASP7991","Pharmacokinetics of ASP7991",[5881],{"nctId":5899,"briefTitle":5900,"status":114,"phases":5901,"primaryCompletion":3947,"completion":3947,"start":4057,"enrollment":3224,"conditions":5902,"interventions":5903},"NCT01872013","Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects",[74],[15,5896],[5881],{"nctId":5905,"briefTitle":5906,"status":114,"phases":5907,"primaryCompletion":306,"completion":306,"start":4049,"enrollment":3125,"conditions":5908,"interventions":5909},"NCT01675518","A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers",[74],[15,5896],[5881],{"trials":5911,"activeCount":85},[5912],{"nctId":5913,"briefTitle":5914,"status":114,"phases":5915,"primaryCompletion":5916,"completion":5916,"start":5917,"enrollment":5918,"conditions":5919,"interventions":5921},"NCT02133404","A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis",[75],"2014-11-10","2014-03-14",62,[5920],"Secondary Hyperparathyroidism",[5881,5922],"Cinacalcet",{"trials":5924,"activeCount":85},[],{"trials":5926,"activeCount":85},[],{"trials":5928,"activeCount":85},[],{"intervention":5930,"totalTrials":275,"cells":5931},"FK778",{"EARLY_PHASE1":5932,"PHASE1":5934,"PHASE2":5936,"PHASE3":5969,"PHASE4":5971,"NA":5973},{"trials":5933,"activeCount":85},[],{"trials":5935,"activeCount":85},[],{"trials":5937,"activeCount":85},[5938,5947,5956,5962],{"nctId":5939,"briefTitle":5940,"status":353,"phases":5941,"completion":1954,"start":5942,"enrollment":5943,"conditions":5944,"interventions":5946},"NCT00104338","Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy",[75],"2005-01",45,[5945,1934],"BK Polyomavirus",[5930],{"nctId":5948,"briefTitle":5949,"status":114,"phases":5950,"primaryCompletion":1075,"completion":1075,"start":1383,"enrollment":424,"conditions":5951,"interventions":5955},"NCT00189735","A Study to Evaluate FK778 in Kidney Transplant Patients",[75],[21,1881,5952,5953,5954],"Transplantation, Renal","Transplantation, Kidney","Grafting, Kidney",[5930],{"nctId":5957,"briefTitle":5958,"status":114,"phases":5959,"primaryCompletion":1584,"completion":1584,"start":1562,"enrollment":1586,"conditions":5960,"interventions":5961},"NCT00451932","A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients",[75],[35],[5930],{"nctId":5963,"briefTitle":5964,"status":353,"phases":5965,"completion":1075,"start":1617,"enrollment":5966,"conditions":5967,"interventions":5968},"NCT00282230","A Study to Evaluate the Safety and Efficacy of Prograf\u002FFK778 and Prograf\u002FMMF in de Novo Kidney Transplant Recipients",[75],150,[21],[5930],{"trials":5970,"activeCount":85},[],{"trials":5972,"activeCount":85},[],{"trials":5974,"activeCount":85},[],{"intervention":5976,"totalTrials":105,"cells":5977},"Pudexacianinium chloride",{"EARLY_PHASE1":5978,"PHASE1":5980,"PHASE2":5990,"PHASE3":6013,"PHASE4":6015,"NA":6017},{"trials":5979,"activeCount":85},[],{"trials":5981,"activeCount":85},[5982],{"nctId":5983,"briefTitle":5984,"status":114,"phases":5985,"primaryCompletion":5986,"completion":5986,"start":5987,"enrollment":3453,"conditions":5988,"interventions":5989},"NCT04878471","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants",[74],"2021-07-22","2021-06-02",[30],[5976],{"trials":5991,"activeCount":85},[5992,6003],{"nctId":5993,"briefTitle":5994,"status":353,"phases":5995,"primaryCompletion":5996,"completion":5997,"start":5998,"enrollment":81,"conditions":5999,"interventions":6001},"NCT05457842","A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery",[75],"2022-09-02","2022-09-20","2022-08-10",[6000,311,336],"Sentinel Lymph Node Biopsy",[6002],"pudexacianinium chloride",{"nctId":6004,"briefTitle":6005,"status":114,"phases":6006,"primaryCompletion":6007,"completion":6008,"start":6009,"enrollment":1219,"conditions":6010,"interventions":6012},"NCT04238481","A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic\u002FMinimally Invasive Colorectal Surgery",[75],"2021-11-18","2021-11-29","2020-10-06",[6011],"Laparoscopic\u002FMinimally Invasive Colorectal Surgery",[5976],{"trials":6014,"activeCount":85},[],{"trials":6016,"activeCount":85},[],{"trials":6018,"activeCount":85},[],{"intervention":6020,"totalTrials":105,"cells":6021},"Tacrolimus Ointment 0.03%",{"EARLY_PHASE1":6022,"PHASE1":6024,"PHASE2":6026,"PHASE3":6055,"PHASE4":6057,"NA":6059},{"trials":6023,"activeCount":85},[],{"trials":6025,"activeCount":85},[],{"trials":6027,"activeCount":85},[6028,6042,6049],{"nctId":6029,"briefTitle":6030,"status":114,"phases":6031,"primaryCompletion":1410,"completion":1410,"start":6032,"enrollment":6033,"conditions":6034,"interventions":6036},"NCT00801957","Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis",[75],"2003-03",260,[6035],"Atopic Dermatitis",[6037,6038,6039,6040,6041],"tacrolimus ointment 0.03%","hydrocortisone acetate ointment 1%","hydrocortisone butyrate ointment 0.1%","Meningitec","AC VAX",{"nctId":6043,"briefTitle":6044,"status":114,"phases":6045,"completion":1288,"start":5698,"enrollment":6046,"conditions":6047,"interventions":6048},"NCT00535691","Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis",[75],53,[1564],[6020,6020],{"nctId":6050,"briefTitle":6051,"status":114,"phases":6052,"completion":2872,"start":897,"enrollment":972,"conditions":6053,"interventions":6054},"NCT00560326","Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis",[75],[1564],[6020],{"trials":6056,"activeCount":85},[],{"trials":6058,"activeCount":85},[],{"trials":6060,"activeCount":85},[],{"intervention":3823,"totalTrials":105,"cells":6062},{"EARLY_PHASE1":6063,"PHASE1":6065,"PHASE2":6071,"PHASE3":6081,"PHASE4":6083,"NA":6085},{"trials":6064,"activeCount":85},[],{"trials":6066,"activeCount":85},[6067],{"nctId":3815,"briefTitle":3816,"status":114,"phases":6068,"primaryCompletion":3818,"completion":3818,"start":3277,"enrollment":3819,"conditions":6069,"interventions":6070},[74],[3821],[3808,3823],{"trials":6072,"activeCount":85},[6073,6077],{"nctId":3865,"briefTitle":3866,"status":114,"phases":6074,"primaryCompletion":3868,"completion":3869,"start":3870,"enrollment":379,"conditions":6075,"interventions":6076},[75],[3872],[3808,3823],{"nctId":3875,"briefTitle":3876,"status":114,"phases":6078,"primaryCompletion":3878,"completion":3879,"start":3880,"enrollment":3172,"conditions":6079,"interventions":6080},[75],[3882,3883],[3808,3885],{"trials":6082,"activeCount":85},[],{"trials":6084,"activeCount":85},[],{"trials":6086,"activeCount":85},[],{"intervention":6088,"totalTrials":105,"cells":6089},"ASP0456",{"EARLY_PHASE1":6090,"PHASE1":6092,"PHASE2":6107,"PHASE3":6119,"PHASE4":6121,"NA":6123},{"trials":6091,"activeCount":85},[],{"trials":6093,"activeCount":85},[6094,6101],{"nctId":6095,"briefTitle":6096,"status":114,"phases":6097,"primaryCompletion":3661,"completion":3661,"start":3205,"enrollment":1531,"conditions":6098,"interventions":6100},"NCT01427387","A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects",[74],[15,6099],"Pharmacokinetics of ASP0456",[6088],{"nctId":6102,"briefTitle":6103,"status":114,"phases":6104,"primaryCompletion":5122,"completion":5122,"start":3231,"enrollment":320,"conditions":6105,"interventions":6106},"NCT01279915","A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects",[74],[15,6099],[6088],{"trials":6108,"activeCount":85},[6109],{"nctId":6110,"briefTitle":6111,"status":114,"phases":6112,"primaryCompletion":6113,"completion":6113,"start":6114,"enrollment":6115,"conditions":6116,"interventions":6118},"NCT02425722","A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation",[75],"2015-10-31","2015-04-13",383,[6117],"Chronic Constipation",[6088],{"trials":6120,"activeCount":85},[],{"trials":6122,"activeCount":85},[],{"trials":6124,"activeCount":85},[],{"intervention":5832,"totalTrials":158,"cells":6126},{"EARLY_PHASE1":6127,"PHASE1":6129,"PHASE2":6135,"PHASE3":6141,"PHASE4":6143,"NA":6145},{"trials":6128,"activeCount":85},[],{"trials":6130,"activeCount":85},[6131],{"nctId":5805,"briefTitle":5806,"status":353,"phases":6132,"primaryCompletion":355,"completion":355,"start":896,"enrollment":5808,"conditions":6133,"interventions":6134},[74],[5810],[5798,5812],{"trials":6136,"activeCount":85},[6137],{"nctId":5823,"briefTitle":5824,"status":114,"phases":6138,"primaryCompletion":5826,"completion":5826,"start":5827,"enrollment":5828,"conditions":6139,"interventions":6140},[75],[5830],[5798,5832],{"trials":6142,"activeCount":85},[],{"trials":6144,"activeCount":85},[],{"trials":6146,"activeCount":85},[],{"intervention":6148,"totalTrials":158,"cells":6149},"ASP8273",{"EARLY_PHASE1":6150,"PHASE1":6152,"PHASE2":6154,"PHASE3":6177,"PHASE4":6179,"NA":6181},{"trials":6151,"activeCount":85},[],{"trials":6153,"activeCount":85},[],{"trials":6155,"activeCount":85},[6156,6166],{"nctId":6157,"briefTitle":6158,"status":353,"phases":6159,"primaryCompletion":6160,"completion":6161,"start":6162,"enrollment":749,"conditions":6163,"interventions":6165},"NCT02192697","An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations",[74,75],"2016-01-15","2017-06-14","2014-01-23",[6164],"Non-small Cell Lung Cancer",[6148],{"nctId":6167,"briefTitle":6168,"status":353,"phases":6169,"primaryCompletion":6170,"completion":6170,"start":6171,"enrollment":6172,"conditions":6173,"interventions":6175},"NCT02500927","A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations",[75],"2017-06-09","2015-06-25",31,[6174],"EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations",[6148,6176],"ASP8273 Capsules A",{"trials":6178,"activeCount":85},[],{"trials":6180,"activeCount":85},[],{"trials":6182,"activeCount":85},[],{"intervention":6184,"totalTrials":158,"cells":6185},"ASP4070",{"EARLY_PHASE1":6186,"PHASE1":6188,"PHASE2":6201,"PHASE3":6213,"PHASE4":6215,"NA":6217},{"trials":6187,"activeCount":85},[],{"trials":6189,"activeCount":85},[6190],{"nctId":6191,"briefTitle":6192,"status":114,"phases":6193,"primaryCompletion":6194,"completion":6195,"start":6196,"enrollment":6197,"conditions":6198,"interventions":6200},"NCT02469688","A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy",[74],"2015-11-27","2016-07-26","2015-06-18",66,[6199],"Cedar Pollinosis",[6184],{"trials":6202,"activeCount":85},[6203],{"nctId":6204,"briefTitle":6205,"status":114,"phases":6206,"primaryCompletion":6207,"completion":6208,"start":6209,"enrollment":5966,"conditions":6210,"interventions":6212},"NCT03101267","A Dose-finding Study of ASP4070",[75],"2018-01-26","2018-10-27","2017-04-13",[6211],"Rhinitis, Allergic, Seasonal",[6184],{"trials":6214,"activeCount":85},[],{"trials":6216,"activeCount":85},[],{"trials":6218,"activeCount":85},[],{"intervention":6220,"totalTrials":158,"cells":6221},"YM598",{"EARLY_PHASE1":6222,"PHASE1":6224,"PHASE2":6226,"PHASE3":6241,"PHASE4":6243,"NA":6245},{"trials":6223,"activeCount":85},[],{"trials":6225,"activeCount":85},[],{"trials":6227,"activeCount":85},[6228,6234],{"nctId":6229,"briefTitle":6230,"status":353,"phases":6231,"completion":1308,"conditions":6232,"interventions":6233},"NCT00050297","YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer",[75],[322],[6220],{"nctId":6235,"briefTitle":6236,"status":353,"phases":6237,"completion":1067,"conditions":6238,"interventions":6240},"NCT00048659","YM598 Added to Mitoxantrone\u002FPrednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy",[75],[6239,4547],"Hormone-Refractory Prostate Cancer",[6220],{"trials":6242,"activeCount":85},[],{"trials":6244,"activeCount":85},[],{"trials":6246,"activeCount":85},[],{"intervention":385,"totalTrials":158,"cells":6248},{"EARLY_PHASE1":6249,"PHASE1":6251,"PHASE2":6259,"PHASE3":6265,"PHASE4":6267,"NA":6269},{"trials":6250,"activeCount":85},[],{"trials":6252,"activeCount":85},[6253],{"nctId":6254,"briefTitle":6255,"status":114,"phases":6256,"primaryCompletion":846,"completion":846,"start":1054,"enrollment":1219,"conditions":6257,"interventions":6258},"NCT00519233","AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer",[74],[322],[385],{"trials":6260,"activeCount":85},[6261],{"nctId":374,"briefTitle":375,"status":114,"phases":6262,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":6263,"interventions":6264},[75],[381,382,383],[385,294],{"trials":6266,"activeCount":85},[],{"trials":6268,"activeCount":85},[],{"trials":6270,"activeCount":85},[],{"intervention":6272,"totalTrials":158,"cells":6273},"Enfortumab vedotin",{"EARLY_PHASE1":6274,"PHASE1":6276,"PHASE2":6287,"PHASE3":6306,"PHASE4":6308,"NA":6310},{"trials":6275,"activeCount":85},[],{"trials":6277,"activeCount":85},[6278],{"nctId":6279,"briefTitle":6280,"status":114,"phases":6281,"primaryCompletion":6282,"completion":6282,"start":6283,"enrollment":2432,"conditions":6284,"interventions":6286},"NCT03070990","A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma",[74],"2019-02-25","2017-04-24",[6285],"Metastatic Urothelial Cancer",[6272],{"trials":6288,"activeCount":85},[6289],{"nctId":6290,"briefTitle":6291,"status":114,"phases":6292,"primaryCompletion":6293,"completion":6294,"start":6295,"enrollment":6296,"conditions":6297,"interventions":6305},"NCT03219333","A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",[75],"2020-10-27","2023-07-28","2017-10-08",219,[6298,6299,6300,6301,6302,6303,6304],"Carcinoma, Transitional Cell","Urinary Bladder Neoplasms","Urologic Neoplasms","Renal Pelvis Neoplasms","Urothelial Cancer","Ureteral Neoplasms","Urethral Neoplasms",[6272],{"trials":6307,"activeCount":85},[],{"trials":6309,"activeCount":85},[],{"trials":6311,"activeCount":85},[],{"intervention":6313,"totalTrials":158,"cells":6314},"FK463",{"EARLY_PHASE1":6315,"PHASE1":6317,"PHASE2":6319,"PHASE3":6338,"PHASE4":6340,"NA":6342},{"trials":6316,"activeCount":85},[],{"trials":6318,"activeCount":85},[],{"trials":6320,"activeCount":85},[6321,6330],{"nctId":6322,"briefTitle":6323,"status":114,"phases":6324,"primaryCompletion":6325,"completion":6325,"start":6326,"enrollment":6327,"conditions":6328,"interventions":6329},"NCT00036166","Study of FK463 for the Treatment of Invasive Aspergillosis",[75],"2002-01-31","1999-01-29",326,[1252],[6313],{"nctId":6331,"briefTitle":6332,"status":114,"phases":6333,"primaryCompletion":6334,"completion":6334,"start":6335,"enrollment":1357,"conditions":6336,"interventions":6337},"NCT00036179","Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis",[75],"2002-01-27","1999-02-27",[1265],[6313],{"trials":6339,"activeCount":85},[],{"trials":6341,"activeCount":85},[],{"trials":6343,"activeCount":85},[],{"intervention":6345,"totalTrials":158,"cells":6346},"Bocidelpar",{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6360,"PHASE3":6371,"PHASE4":6373,"NA":6375},{"trials":6348,"activeCount":85},[],{"trials":6350,"activeCount":85},[6351],{"nctId":6352,"briefTitle":6353,"status":353,"phases":6354,"primaryCompletion":6355,"completion":6355,"start":6356,"enrollment":3741,"conditions":6357,"interventions":6359},"NCT04184882","A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)",[74],"2022-09-04","2021-02-24",[6358],"Duchenne Muscular Dystrophy (DMD)",[6345],{"trials":6361,"activeCount":85},[6362],{"nctId":6363,"briefTitle":6364,"status":353,"phases":6365,"primaryCompletion":6366,"completion":6366,"start":6367,"enrollment":16,"conditions":6368,"interventions":6370},"NCT04641962","A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy",[75],"2024-05-08","2021-05-24",[6369],"Primary Mitochondrial Myopathy",[6345],{"trials":6372,"activeCount":85},[],{"trials":6374,"activeCount":85},[],{"trials":6376,"activeCount":85},[],{"intervention":6378,"totalTrials":158,"cells":6379},"YM872",{"EARLY_PHASE1":6380,"PHASE1":6382,"PHASE2":6384,"PHASE3":6400,"PHASE4":6402,"NA":6404},{"trials":6381,"activeCount":85},[],{"trials":6383,"activeCount":85},[],{"trials":6385,"activeCount":85},[6386,6393],{"nctId":6387,"briefTitle":6388,"status":114,"phases":6389,"completion":1262,"start":4633,"conditions":6390,"interventions":6392},"NCT00044070","A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients",[75],[6391],"Cerebrovascular Accident",[6378],{"nctId":6394,"briefTitle":6395,"status":114,"phases":6396,"completion":1262,"start":4633,"conditions":6397,"interventions":6399},"NCT00044057","A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)",[75],[6398],"Acute Ischemic Stroke",[6378],{"trials":6401,"activeCount":85},[],{"trials":6403,"activeCount":85},[],{"trials":6405,"activeCount":85},[],{"intervention":6407,"totalTrials":158,"cells":6408},"OSI-211",{"EARLY_PHASE1":6409,"PHASE1":6411,"PHASE2":6413,"PHASE3":6431,"PHASE4":6433,"NA":6435},{"trials":6410,"activeCount":85},[],{"trials":6412,"activeCount":85},[],{"trials":6414,"activeCount":85},[6415,6425],{"nctId":6416,"briefTitle":6417,"status":114,"phases":6418,"completion":919,"start":6419,"enrollment":6420,"conditions":6421,"interventions":6424},"NCT00046787","Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer",[75],"2002-09",47,[6422,6423],"SCLC","Carcinoma, Small Cell",[6407],{"nctId":6426,"briefTitle":6427,"status":114,"phases":6428,"completion":6032,"start":6419,"enrollment":4358,"conditions":6429,"interventions":6430},"NCT00046800","Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer",[75],[361],[6407],{"trials":6432,"activeCount":85},[],{"trials":6434,"activeCount":85},[],{"trials":6436,"activeCount":85},[],{"intervention":3761,"totalTrials":81,"cells":6438},{"EARLY_PHASE1":6439,"PHASE1":6441,"PHASE2":6443,"PHASE3":6449,"PHASE4":6451,"NA":6453},{"trials":6440,"activeCount":85},[],{"trials":6442,"activeCount":85},[],{"trials":6444,"activeCount":85},[6445],{"nctId":3754,"briefTitle":3755,"status":114,"phases":6446,"primaryCompletion":3757,"completion":144,"start":3758,"enrollment":708,"conditions":6447,"interventions":6448},[75],[699],[3761,776],{"trials":6450,"activeCount":85},[],{"trials":6452,"activeCount":85},[],{"trials":6454,"activeCount":85},[],{"intervention":6456,"totalTrials":81,"cells":6457},"ASK8007",{"EARLY_PHASE1":6458,"PHASE1":6460,"PHASE2":6462,"PHASE3":6471,"PHASE4":6473,"NA":6475},{"trials":6459,"activeCount":85},[],{"trials":6461,"activeCount":85},[],{"trials":6463,"activeCount":85},[6464],{"nctId":6465,"briefTitle":6466,"status":114,"phases":6467,"primaryCompletion":808,"completion":808,"start":1054,"enrollment":6468,"conditions":6469,"interventions":6470},"NCT00411424","Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis",[74,75],54,[699],[6456],{"trials":6472,"activeCount":85},[],{"trials":6474,"activeCount":85},[],{"trials":6476,"activeCount":85},[],{"intervention":136,"totalTrials":81,"cells":6478},{"EARLY_PHASE1":6479,"PHASE1":6481,"PHASE2":6483,"PHASE3":6489,"PHASE4":6491,"NA":6493},{"trials":6480,"activeCount":85},[],{"trials":6482,"activeCount":85},[],{"trials":6484,"activeCount":85},[6485],{"nctId":125,"briefTitle":126,"status":114,"phases":6486,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":6487,"interventions":6488},[74,75],[133,134],[41,136,137],{"trials":6490,"activeCount":85},[],{"trials":6492,"activeCount":85},[],{"trials":6494,"activeCount":85},[],{"intervention":6496,"totalTrials":81,"cells":6497},"bicalutamide",{"EARLY_PHASE1":6498,"PHASE1":6500,"PHASE2":6502,"PHASE3":6514,"PHASE4":6516,"NA":6518},{"trials":6499,"activeCount":85},[],{"trials":6501,"activeCount":85},[],{"trials":6503,"activeCount":85},[6504],{"nctId":6505,"briefTitle":6506,"status":114,"phases":6507,"primaryCompletion":6508,"completion":6509,"start":6510,"enrollment":2442,"conditions":6511,"interventions":6512},"NCT01288911","A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer",[75],"2014-10-19","2017-11-08","2011-03-22",[4547],[6513,6496],"enzalutamide",{"trials":6515,"activeCount":85},[],{"trials":6517,"activeCount":85},[],{"trials":6519,"activeCount":85},[],{"intervention":6038,"totalTrials":81,"cells":6521},{"EARLY_PHASE1":6522,"PHASE1":6524,"PHASE2":6526,"PHASE3":6532,"PHASE4":6534,"NA":6536},{"trials":6523,"activeCount":85},[],{"trials":6525,"activeCount":85},[],{"trials":6527,"activeCount":85},[6528],{"nctId":6029,"briefTitle":6030,"status":114,"phases":6529,"primaryCompletion":1410,"completion":1410,"start":6032,"enrollment":6033,"conditions":6530,"interventions":6531},[75],[6035],[6037,6038,6039,6040,6041],{"trials":6533,"activeCount":85},[],{"trials":6535,"activeCount":85},[],{"trials":6537,"activeCount":85},[],{"intervention":6039,"totalTrials":81,"cells":6539},{"EARLY_PHASE1":6540,"PHASE1":6542,"PHASE2":6544,"PHASE3":6550,"PHASE4":6552,"NA":6554},{"trials":6541,"activeCount":85},[],{"trials":6543,"activeCount":85},[],{"trials":6545,"activeCount":85},[6546],{"nctId":6029,"briefTitle":6030,"status":114,"phases":6547,"primaryCompletion":1410,"completion":1410,"start":6032,"enrollment":6033,"conditions":6548,"interventions":6549},[75],[6035],[6037,6038,6039,6040,6041],{"trials":6551,"activeCount":85},[],{"trials":6553,"activeCount":85},[],{"trials":6555,"activeCount":85},[],{"intervention":6040,"totalTrials":81,"cells":6557},{"EARLY_PHASE1":6558,"PHASE1":6560,"PHASE2":6562,"PHASE3":6568,"PHASE4":6570,"NA":6572},{"trials":6559,"activeCount":85},[],{"trials":6561,"activeCount":85},[],{"trials":6563,"activeCount":85},[6564],{"nctId":6029,"briefTitle":6030,"status":114,"phases":6565,"primaryCompletion":1410,"completion":1410,"start":6032,"enrollment":6033,"conditions":6566,"interventions":6567},[75],[6035],[6037,6038,6039,6040,6041],{"trials":6569,"activeCount":85},[],{"trials":6571,"activeCount":85},[],{"trials":6573,"activeCount":85},[],{"intervention":6041,"totalTrials":81,"cells":6575},{"EARLY_PHASE1":6576,"PHASE1":6578,"PHASE2":6580,"PHASE3":6586,"PHASE4":6588,"NA":6590},{"trials":6577,"activeCount":85},[],{"trials":6579,"activeCount":85},[],{"trials":6581,"activeCount":85},[6582],{"nctId":6029,"briefTitle":6030,"status":114,"phases":6583,"primaryCompletion":1410,"completion":1410,"start":6032,"enrollment":6033,"conditions":6584,"interventions":6585},[75],[6035],[6037,6038,6039,6040,6041],{"trials":6587,"activeCount":85},[],{"trials":6589,"activeCount":85},[],{"trials":6591,"activeCount":85},[],{"intervention":4002,"totalTrials":81,"cells":6593},{"EARLY_PHASE1":6594,"PHASE1":6596,"PHASE2":6598,"PHASE3":6604,"PHASE4":6606,"NA":6608},{"trials":6595,"activeCount":85},[],{"trials":6597,"activeCount":85},[],{"trials":6599,"activeCount":85},[6600],{"nctId":3996,"briefTitle":3997,"status":114,"phases":6601,"primaryCompletion":1498,"completion":1498,"start":1338,"enrollment":131,"conditions":6602,"interventions":6603},[75],[4000],[4002,690],{"trials":6605,"activeCount":85},[],{"trials":6607,"activeCount":85},[],{"trials":6609,"activeCount":85},[],{"intervention":6611,"totalTrials":81,"cells":6612},"Tacrolimus Inhalation Aerosol",{"EARLY_PHASE1":6613,"PHASE1":6615,"PHASE2":6617,"PHASE3":6625,"PHASE4":6627,"NA":6629},{"trials":6614,"activeCount":85},[],{"trials":6616,"activeCount":85},[],{"trials":6618,"activeCount":85},[6619],{"nctId":6620,"briefTitle":6621,"status":114,"phases":6622,"completion":1279,"start":4289,"conditions":6623,"interventions":6624},"NCT00116103","A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma",[75],[1924],[6611],{"trials":6626,"activeCount":85},[],{"trials":6628,"activeCount":85},[],{"trials":6630,"activeCount":85},[],{"intervention":6632,"totalTrials":81,"cells":6633},"steroids, monoclonal anti-IL2R antibody",{"EARLY_PHASE1":6634,"PHASE1":6636,"PHASE2":6638,"PHASE3":6647,"PHASE4":6649,"NA":6651},{"trials":6635,"activeCount":85},[],{"trials":6637,"activeCount":85},[],{"trials":6639,"activeCount":85},[6640],{"nctId":6641,"briefTitle":6642,"status":114,"phases":6643,"primaryCompletion":1498,"completion":1498,"start":4289,"enrollment":6644,"conditions":6645,"interventions":6646},"NCT00295607","Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients",[75],138,[5507,35],[852,6632],{"trials":6648,"activeCount":85},[],{"trials":6650,"activeCount":85},[],{"trials":6652,"activeCount":85},[],{"intervention":6654,"totalTrials":81,"cells":6655},"ASP1128",{"EARLY_PHASE1":6656,"PHASE1":6658,"PHASE2":6660,"PHASE3":6673,"PHASE4":6675,"NA":6677},{"trials":6657,"activeCount":85},[],{"trials":6659,"activeCount":85},[],{"trials":6661,"activeCount":85},[6662],{"nctId":6663,"briefTitle":6664,"status":114,"phases":6665,"primaryCompletion":6666,"completion":6667,"start":6668,"enrollment":6669,"conditions":6670,"interventions":6672},"NCT03941483","Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and\u002For Valve Surgery",[75],"2021-07-26","2021-10-20","2019-11-01",351,[6671],"Acute Kidney Injury (AKI)",[6654],{"trials":6674,"activeCount":85},[],{"trials":6676,"activeCount":85},[],{"trials":6678,"activeCount":85},[],{"intervention":5631,"totalTrials":81,"cells":6680},{"EARLY_PHASE1":6681,"PHASE1":6683,"PHASE2":6685,"PHASE3":6691,"PHASE4":6693,"NA":6695},{"trials":6682,"activeCount":85},[],{"trials":6684,"activeCount":85},[],{"trials":6686,"activeCount":85},[6687],{"nctId":5624,"briefTitle":5625,"status":114,"phases":6688,"primaryCompletion":2400,"completion":5627,"start":333,"enrollment":1428,"conditions":6689,"interventions":6690},[75],[5629],[313,5631],{"trials":6692,"activeCount":85},[],{"trials":6694,"activeCount":85},[],{"trials":6696,"activeCount":85},[],{"intervention":6698,"totalTrials":81,"cells":6699},"VCL-CB01",{"EARLY_PHASE1":6700,"PHASE1":6702,"PHASE2":6704,"PHASE3":6721,"PHASE4":6723,"NA":6725},{"trials":6701,"activeCount":85},[],{"trials":6703,"activeCount":85},[],{"trials":6705,"activeCount":85},[6706],{"nctId":6707,"briefTitle":6708,"status":114,"phases":6709,"primaryCompletion":6710,"completion":6711,"start":6712,"enrollment":6713,"conditions":6714,"interventions":6720},"NCT00285259","Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)",[75],"2009-11-30","2010-11-30","2006-01-31",112,[6715,6716,6717,6718,5629,6719],"Acute Lymphoblastic Leukemia","Chronic Myelogenous Leukemia","Acute Myelogenous Leukemia","Hodgkin's Lymphoma","Myelodysplastic Syndrome",[6698],{"trials":6722,"activeCount":85},[],{"trials":6724,"activeCount":85},[],{"trials":6726,"activeCount":85},[],{"intervention":6728,"totalTrials":81,"cells":6729},"MDV3100",{"EARLY_PHASE1":6730,"PHASE1":6732,"PHASE2":6734,"PHASE3":6747,"PHASE4":6749,"NA":6751},{"trials":6731,"activeCount":85},[],{"trials":6733,"activeCount":85},[],{"trials":6735,"activeCount":85},[6736],{"nctId":6737,"briefTitle":6738,"status":114,"phases":6739,"primaryCompletion":6740,"completion":6741,"start":6742,"enrollment":6420,"conditions":6743,"interventions":6746},"NCT01284920","A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients",[74,75],"2012-07-12","2014-07-02","2010-11-02",[322,6744,6745],"Prostate Neoplasms","Castration Resistant Prostate Cancer (CRPC)",[6728],{"trials":6748,"activeCount":85},[],{"trials":6750,"activeCount":85},[],{"trials":6752,"activeCount":85},[],{"intervention":6176,"totalTrials":81,"cells":6754},{"EARLY_PHASE1":6755,"PHASE1":6757,"PHASE2":6759,"PHASE3":6765,"PHASE4":6767,"NA":6769},{"trials":6756,"activeCount":85},[],{"trials":6758,"activeCount":85},[],{"trials":6760,"activeCount":85},[6761],{"nctId":6167,"briefTitle":6168,"status":353,"phases":6762,"primaryCompletion":6170,"completion":6170,"start":6171,"enrollment":6172,"conditions":6763,"interventions":6764},[75],[6174],[6148,6176],{"trials":6766,"activeCount":85},[],{"trials":6768,"activeCount":85},[],{"trials":6770,"activeCount":85},[],{"intervention":6772,"totalTrials":81,"cells":6773},"FK614",{"EARLY_PHASE1":6774,"PHASE1":6776,"PHASE2":6778,"PHASE3":6789,"PHASE4":6791,"NA":6793},{"trials":6775,"activeCount":85},[],{"trials":6777,"activeCount":85},[],{"trials":6779,"activeCount":85},[6780],{"nctId":6781,"briefTitle":6782,"status":114,"phases":6783,"completion":2009,"start":6784,"enrollment":6785,"conditions":6786,"interventions":6788},"NCT00036192","Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea",[75],"2002-02",200,[6787],"Diabetes Mellitus",[6772],{"trials":6790,"activeCount":85},[],{"trials":6792,"activeCount":85},[],{"trials":6794,"activeCount":85},[],{"intervention":6796,"totalTrials":81,"cells":6797},"FK962",{"EARLY_PHASE1":6798,"PHASE1":6800,"PHASE2":6802,"PHASE3":6812,"PHASE4":6814,"NA":6816},{"trials":6799,"activeCount":85},[],{"trials":6801,"activeCount":85},[],{"trials":6803,"activeCount":85},[6804],{"nctId":6805,"briefTitle":6806,"status":353,"phases":6807,"completion":1095,"start":1436,"enrollment":6808,"conditions":6809,"interventions":6811},"NCT00087724","A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease",[75],510,[6810],"Alzheimer's Disease",[6796],{"trials":6813,"activeCount":85},[],{"trials":6815,"activeCount":85},[],{"trials":6817,"activeCount":85},[],{"intervention":6819,"totalTrials":81,"cells":6820},"OSI-461",{"EARLY_PHASE1":6821,"PHASE1":6823,"PHASE2":6825,"PHASE3":6835,"PHASE4":6837,"NA":6839},{"trials":6822,"activeCount":85},[],{"trials":6824,"activeCount":85},[],{"trials":6826,"activeCount":85},[6827],{"nctId":6828,"briefTitle":6829,"status":114,"phases":6830,"completion":6831,"start":6832,"enrollment":3115,"conditions":6833,"interventions":6834},"NCT00073489","A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)",[75],"2003-12","2001-05",[5700],[6819],{"trials":6836,"activeCount":85},[],{"trials":6838,"activeCount":85},[],{"trials":6840,"activeCount":85},[],{"intervention":6842,"totalTrials":81,"cells":6843},"ASP9521",{"EARLY_PHASE1":6844,"PHASE1":6846,"PHASE2":6848,"PHASE3":6857,"PHASE4":6859,"NA":6861},{"trials":6845,"activeCount":85},[],{"trials":6847,"activeCount":85},[],{"trials":6849,"activeCount":85},[6850],{"nctId":6851,"briefTitle":6852,"status":353,"phases":6853,"primaryCompletion":3961,"completion":3961,"start":331,"enrollment":1219,"conditions":6854,"interventions":6856},"NCT01352208","Phase I\u002FII Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients",[74,75],[6855],"Castrate Resistant Prostate Cancer",[6842],{"trials":6858,"activeCount":85},[],{"trials":6860,"activeCount":85},[],{"trials":6862,"activeCount":85},[],{"intervention":3863,"totalTrials":81,"cells":6864},{"EARLY_PHASE1":6865,"PHASE1":6867,"PHASE2":6869,"PHASE3":6875,"PHASE4":6877,"NA":6879},{"trials":6866,"activeCount":85},[],{"trials":6868,"activeCount":85},[],{"trials":6870,"activeCount":85},[6871],{"nctId":3854,"briefTitle":3855,"status":114,"phases":6872,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":920,"conditions":6873,"interventions":6874},[74,75],[359,3861],[3808,3863],{"trials":6876,"activeCount":85},[],{"trials":6878,"activeCount":85},[],{"trials":6880,"activeCount":85},[],{"intervention":5922,"totalTrials":81,"cells":6882},{"EARLY_PHASE1":6883,"PHASE1":6885,"PHASE2":6887,"PHASE3":6893,"PHASE4":6895,"NA":6897},{"trials":6884,"activeCount":85},[],{"trials":6886,"activeCount":85},[],{"trials":6888,"activeCount":85},[6889],{"nctId":5913,"briefTitle":5914,"status":114,"phases":6890,"primaryCompletion":5916,"completion":5916,"start":5917,"enrollment":5918,"conditions":6891,"interventions":6892},[75],[5920],[5881,5922],{"trials":6894,"activeCount":85},[],{"trials":6896,"activeCount":85},[],{"trials":6898,"activeCount":85},[],{"intervention":6900,"totalTrials":81,"cells":6901},"ASP9831",{"EARLY_PHASE1":6902,"PHASE1":6904,"PHASE2":6906,"PHASE3":6916,"PHASE4":6918,"NA":6920},{"trials":6903,"activeCount":85},[],{"trials":6905,"activeCount":85},[],{"trials":6907,"activeCount":85},[6908],{"nctId":6909,"briefTitle":6910,"status":114,"phases":6911,"primaryCompletion":3231,"completion":3231,"start":6912,"enrollment":1437,"conditions":6913,"interventions":6915},"NCT00668070","A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831",[75],"2008-04",[6914],"Non-Alcoholic Steatohepatitis",[6900],{"trials":6917,"activeCount":85},[],{"trials":6919,"activeCount":85},[],{"trials":6921,"activeCount":85},[],{"intervention":2061,"totalTrials":81,"cells":6923},{"EARLY_PHASE1":6924,"PHASE1":6926,"PHASE2":6928,"PHASE3":6934,"PHASE4":6936,"NA":6938},{"trials":6925,"activeCount":85},[],{"trials":6927,"activeCount":85},[],{"trials":6929,"activeCount":85},[6930],{"nctId":2052,"briefTitle":2053,"status":114,"phases":6931,"primaryCompletion":2055,"completion":2055,"start":2056,"enrollment":2057,"conditions":6932,"interventions":6933},[75],[2059],[2061,2062],{"trials":6935,"activeCount":85},[],{"trials":6937,"activeCount":85},[],{"trials":6939,"activeCount":85},[],{"intervention":1245,"totalTrials":81,"cells":6941},{"EARLY_PHASE1":6942,"PHASE1":6944,"PHASE2":6946,"PHASE3":6952,"PHASE4":6954,"NA":6956},{"trials":6943,"activeCount":85},[],{"trials":6945,"activeCount":85},[],{"trials":6947,"activeCount":85},[6948],{"nctId":1237,"briefTitle":1238,"status":353,"phases":6949,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":31,"conditions":6950,"interventions":6951},[75],[1243],[1179,1245],{"trials":6953,"activeCount":85},[],{"trials":6955,"activeCount":85},[],{"trials":6957,"activeCount":85},[],{"intervention":6959,"totalTrials":81,"cells":6960},"ASP3550",{"EARLY_PHASE1":6961,"PHASE1":6963,"PHASE2":6965,"PHASE3":6974,"PHASE4":6976,"NA":6978},{"trials":6962,"activeCount":85},[],{"trials":6964,"activeCount":85},[],{"trials":6966,"activeCount":85},[6967],{"nctId":6968,"briefTitle":6969,"status":114,"phases":6970,"primaryCompletion":356,"completion":356,"start":1190,"enrollment":6971,"conditions":6972,"interventions":6973},"NCT00568516","Phase II Study of ASP3550 in Patients With Prostate Cancer",[75],273,[4547],[6959],{"trials":6975,"activeCount":85},[],{"trials":6977,"activeCount":85},[],{"trials":6979,"activeCount":85},[],{"intervention":325,"totalTrials":81,"cells":6981},{"EARLY_PHASE1":6982,"PHASE1":6984,"PHASE2":6986,"PHASE3":6992,"PHASE4":6994,"NA":6996},{"trials":6983,"activeCount":85},[],{"trials":6985,"activeCount":85},[],{"trials":6987,"activeCount":85},[6988],{"nctId":315,"briefTitle":316,"status":114,"phases":6989,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":6990,"interventions":6991},[74,75],[322,323],[325,274,326],{"trials":6993,"activeCount":85},[],{"trials":6995,"activeCount":85},[],{"trials":6997,"activeCount":85},[],{"intervention":6999,"totalTrials":81,"cells":7000},"ASP0113",{"EARLY_PHASE1":7001,"PHASE1":7003,"PHASE2":7005,"PHASE3":7016,"PHASE4":7018,"NA":7020},{"trials":7002,"activeCount":85},[],{"trials":7004,"activeCount":85},[],{"trials":7006,"activeCount":85},[7007],{"nctId":7008,"briefTitle":7009,"status":114,"phases":7010,"primaryCompletion":7011,"completion":7011,"start":7012,"enrollment":1191,"conditions":7013,"interventions":7015},"NCT01903928","A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant",[75],"2015-01-19","2013-06-20",[7014],"Allogeneic Hematopoietic Cell Transplant",[6999],{"trials":7017,"activeCount":85},[],{"trials":7019,"activeCount":85},[],{"trials":7021,"activeCount":85},[],{"intervention":7023,"totalTrials":81,"cells":7024},"ASP5094",{"EARLY_PHASE1":7025,"PHASE1":7027,"PHASE2":7029,"PHASE3":7039,"PHASE4":7041,"NA":7043},{"trials":7026,"activeCount":85},[],{"trials":7028,"activeCount":85},[],{"trials":7030,"activeCount":85},[7031],{"nctId":7032,"briefTitle":7033,"status":114,"phases":7034,"primaryCompletion":2537,"completion":7035,"start":7036,"enrollment":6197,"conditions":7037,"interventions":7038},"NCT03257852","A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate",[75],"2018-10-16","2017-09-29",[795],[7023],{"trials":7040,"activeCount":85},[],{"trials":7042,"activeCount":85},[],{"trials":7044,"activeCount":85},[],{"intervention":7046,"totalTrials":81,"cells":7047},"FK788",{"EARLY_PHASE1":7048,"PHASE1":7050,"PHASE2":7052,"PHASE3":7060,"PHASE4":7062,"NA":7064},{"trials":7049,"activeCount":85},[],{"trials":7051,"activeCount":85},[],{"trials":7053,"activeCount":85},[7054],{"nctId":7055,"briefTitle":7056,"status":114,"phases":7057,"completion":2009,"start":1562,"enrollment":1474,"conditions":7058,"interventions":7059},"NCT00047814","Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection",[75],[5507],[7046],{"trials":7061,"activeCount":85},[],{"trials":7063,"activeCount":85},[],{"trials":7065,"activeCount":85},[],{"intervention":7067,"totalTrials":81,"cells":7068},"quetiapine extended release",{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7073,"PHASE3":7083,"PHASE4":7085,"NA":7087},{"trials":7070,"activeCount":85},[],{"trials":7072,"activeCount":85},[],{"trials":7074,"activeCount":85},[7075],{"nctId":7076,"briefTitle":7077,"status":114,"phases":7078,"primaryCompletion":7079,"completion":7079,"start":7080,"enrollment":1514,"conditions":7081,"interventions":7082},"NCT01725282","Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder",[75],"2013-08-24","2011-12-14",[3684],[7067],{"trials":7084,"activeCount":85},[],{"trials":7086,"activeCount":85},[],{"trials":7088,"activeCount":85},[],{"intervention":839,"totalTrials":81,"cells":7090},{"EARLY_PHASE1":7091,"PHASE1":7093,"PHASE2":7095,"PHASE3":7101,"PHASE4":7103,"NA":7105},{"trials":7092,"activeCount":85},[],{"trials":7094,"activeCount":85},[],{"trials":7096,"activeCount":85},[7097],{"nctId":831,"briefTitle":832,"status":114,"phases":7098,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":7099,"interventions":7100},[75],[35],[826,839,840,841],{"trials":7102,"activeCount":85},[],{"trials":7104,"activeCount":85},[],{"trials":7106,"activeCount":85},[],{"intervention":5843,"totalTrials":81,"cells":7108},{"EARLY_PHASE1":7109,"PHASE1":7111,"PHASE2":7113,"PHASE3":7119,"PHASE4":7121,"NA":7123},{"trials":7110,"activeCount":85},[],{"trials":7112,"activeCount":85},[],{"trials":7114,"activeCount":85},[7115],{"nctId":5834,"briefTitle":5835,"status":114,"phases":7116,"primaryCompletion":5837,"completion":5837,"start":5838,"enrollment":5839,"conditions":7117,"interventions":7118},[75],[5841],[5798,5843],{"trials":7120,"activeCount":85},[],{"trials":7122,"activeCount":85},[],{"trials":7124,"activeCount":85},[],{"intervention":7126,"totalTrials":81,"cells":7127},"ASP3652",{"EARLY_PHASE1":7128,"PHASE1":7130,"PHASE2":7132,"PHASE3":7143,"PHASE4":7145,"NA":7147},{"trials":7129,"activeCount":85},[],{"trials":7131,"activeCount":85},[],{"trials":7133,"activeCount":85},[7134],{"nctId":7135,"briefTitle":7136,"status":114,"phases":7137,"primaryCompletion":3947,"completion":3947,"start":3205,"enrollment":7138,"conditions":7139,"interventions":7142},"NCT01391338","A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis \u002F Chronic Pelvic Pain Syndrome (CP\u002FCPPS)",[75],239,[7140,7141],"Chronic Abacterial Prostatitis","Chronic Pelvic Pain Syndrome",[7126],{"trials":7144,"activeCount":85},[],{"trials":7146,"activeCount":85},[],{"trials":7148,"activeCount":85},[],{"intervention":813,"totalTrials":3453,"cells":7150},{"EARLY_PHASE1":7151,"PHASE1":7153,"PHASE2":7234,"PHASE3":7236,"PHASE4":7238,"NA":7240},{"trials":7152,"activeCount":85},[],{"trials":7154,"activeCount":85},[7155,7161,7168,7177,7184,7191,7200,7206,7212,7217,7221,7227],{"nctId":7156,"briefTitle":7157,"status":114,"phases":7158,"primaryCompletion":1169,"completion":1169,"start":308,"enrollment":1750,"conditions":7159,"interventions":7160},"NCT01406132","A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects",[74],[18,710],[813],{"nctId":7162,"briefTitle":7163,"status":114,"phases":7164,"primaryCompletion":3929,"completion":3929,"start":3661,"enrollment":118,"conditions":7165,"interventions":7167},"NCT01484964","A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation",[74],[710,7166,18],"Bioavailability of ASP015K",[813],{"nctId":7169,"briefTitle":7170,"status":114,"phases":7171,"primaryCompletion":7172,"completion":7172,"start":7173,"enrollment":118,"conditions":7174,"interventions":7176},"NCT02586194","Pharmacokinetics Study in Patients With Impaired Hepatic Function",[74],"2016-09-27","2015-12-28",[7175],"Patients With Impaired Hepatic Function",[813],{"nctId":7178,"briefTitle":7179,"status":114,"phases":7180,"primaryCompletion":809,"completion":809,"start":4112,"enrollment":1474,"conditions":7181,"interventions":7183},"NCT01364974","A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K",[74],[18,710,7182],"Pharmacodynamics",[813],{"nctId":7185,"briefTitle":7186,"status":114,"phases":7187,"primaryCompletion":2609,"completion":2609,"start":5759,"enrollment":1372,"conditions":7188,"interventions":7190},"NCT01182077","A Study to Assess Drug Interaction of ASP015K and Midazolam",[74],[15,7189],"Pharmacokinetics of ASP015K and Midazolam",[813,4044],{"nctId":7192,"briefTitle":7193,"status":114,"phases":7194,"primaryCompletion":7195,"completion":7195,"start":7196,"enrollment":6172,"conditions":7197,"interventions":7199},"NCT02603497","Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function",[74],"2016-12-19","2015-11-24",[7198],"Patients With Impaired Renal Function",[813],{"nctId":7201,"briefTitle":7202,"status":114,"phases":7203,"primaryCompletion":3231,"completion":3231,"start":3171,"enrollment":3453,"conditions":7204,"interventions":7205},"NCT01430078","A Study to Assess the Bioavailability of ASP015K",[74],[15],[813,813],{"nctId":7207,"briefTitle":7208,"status":114,"phases":7209,"primaryCompletion":3661,"completion":3661,"start":3661,"enrollment":1372,"conditions":7210,"interventions":7211},"NCT01486017","A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K",[74],[7166,710,18],[813],{"nctId":7213,"briefTitle":7179,"status":114,"phases":7214,"primaryCompletion":1298,"completion":1298,"start":1120,"enrollment":708,"conditions":7215,"interventions":7216},"NCT01387087",[74],[18,710],[813],{"nctId":805,"briefTitle":806,"status":114,"phases":7218,"primaryCompletion":808,"completion":808,"start":809,"enrollment":118,"conditions":7219,"interventions":7220},[74],[18,811,710],[813,798],{"nctId":7222,"briefTitle":7223,"status":114,"phases":7224,"primaryCompletion":808,"completion":808,"start":808,"enrollment":118,"conditions":7225,"interventions":7226},"NCT01430065","Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers",[74],[710,811,18],[813,852],{"nctId":7228,"briefTitle":7229,"status":114,"phases":7230,"primaryCompletion":3171,"completion":3171,"start":2609,"enrollment":719,"conditions":7231,"interventions":7233},"NCT01190670","A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus",[74],[15,7232],"Pharmacokinetics of ASP015K and Tacrolimus",[852,813],{"trials":7235,"activeCount":85},[],{"trials":7237,"activeCount":85},[],{"trials":7239,"activeCount":85},[],{"trials":7241,"activeCount":85},[],{"intervention":7243,"totalTrials":1846,"cells":7244},"darexaban",{"EARLY_PHASE1":7245,"PHASE1":7247,"PHASE2":7288,"PHASE3":7290,"PHASE4":7292,"NA":7294},{"trials":7246,"activeCount":85},[],{"trials":7248,"activeCount":85},[7249,7257,7265,7272,7280],{"nctId":7250,"briefTitle":7251,"status":114,"phases":7252,"primaryCompletion":318,"completion":318,"start":1169,"enrollment":11,"conditions":7253,"interventions":7255},"NCT01406002","To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)",[74],[7254,18],"Pharmacokinetics of Darexaban and Metabolites",[7243,7256],"Rifampicin",{"nctId":7258,"briefTitle":7259,"status":114,"phases":7260,"primaryCompletion":3188,"completion":3188,"start":1169,"enrollment":11,"conditions":7261,"interventions":7263},"NCT01409603","To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects",[74],[7262,18],"Pharmacodynamic Interaction",[7243,7264],"Naproxen",{"nctId":7266,"briefTitle":7267,"status":114,"phases":7268,"primaryCompletion":318,"completion":318,"start":1169,"enrollment":11,"conditions":7269,"interventions":7270},"NCT01405989","To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)",[74],[7254,18],[7243,7271],"ketoconazole",{"nctId":7273,"briefTitle":7274,"status":114,"phases":7275,"primaryCompletion":846,"completion":846,"start":378,"enrollment":1541,"conditions":7276,"interventions":7277},"NCT01409616","To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects",[74],[7262,18],[7243,7243,7278,7279],"Acetyl Salicylic Acid","clopidogrel",{"nctId":7281,"briefTitle":7282,"status":114,"phases":7283,"primaryCompletion":860,"completion":860,"start":847,"enrollment":118,"conditions":7284,"interventions":7286},"NCT01424332","To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their Effects",[74],[7285,18],"Pharmacodynamic and Pharmacokinetic Interaction",[7287,7278],"Darexaban",{"trials":7289,"activeCount":85},[],{"trials":7291,"activeCount":85},[],{"trials":7293,"activeCount":85},[],{"trials":7295,"activeCount":85},[],{"intervention":3176,"totalTrials":105,"cells":7297},{"EARLY_PHASE1":7298,"PHASE1":7300,"PHASE2":7318,"PHASE3":7320,"PHASE4":7322,"NA":7324},{"trials":7299,"activeCount":85},[],{"trials":7301,"activeCount":85},[7302,7306,7314],{"nctId":3168,"briefTitle":3169,"status":114,"phases":7303,"primaryCompletion":820,"completion":820,"start":3171,"enrollment":3172,"conditions":7304,"interventions":7305},[74],[18,3174],[3114,3176],{"nctId":7307,"briefTitle":7308,"status":114,"phases":7309,"primaryCompletion":1985,"completion":1985,"start":3188,"enrollment":7310,"conditions":7311,"interventions":7312},"NCT01199523","A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females",[74],352,[18],[1027,7313],"moxifloxacin",{"nctId":4355,"briefTitle":4356,"status":114,"phases":7315,"primaryCompletion":378,"completion":378,"start":4111,"enrollment":4358,"conditions":7316,"interventions":7317},[74],[4360],[4348,3176],{"trials":7319,"activeCount":85},[],{"trials":7321,"activeCount":85},[],{"trials":7323,"activeCount":85},[],{"trials":7325,"activeCount":85},[],{"intervention":363,"totalTrials":158,"cells":7327},{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7342,"PHASE3":7344,"PHASE4":7346,"NA":7348},{"trials":7329,"activeCount":85},[],{"trials":7331,"activeCount":85},[7332,7336],{"nctId":351,"briefTitle":352,"status":353,"phases":7333,"primaryCompletion":355,"completion":355,"start":356,"enrollment":275,"conditions":7334,"interventions":7335},[74],[358,359,360,361],[363,364,365,366],{"nctId":7337,"briefTitle":7338,"status":114,"phases":7339,"primaryCompletion":5759,"completion":5759,"start":971,"enrollment":4103,"conditions":7340,"interventions":7341},"NCT00816764","A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer",[74],[358,359,360,361],[363],{"trials":7343,"activeCount":85},[],{"trials":7345,"activeCount":85},[],{"trials":7347,"activeCount":85},[],{"trials":7349,"activeCount":85},[],{"intervention":7351,"totalTrials":158,"cells":7352},"Solifenacin succinate suspension 5 mg",{"EARLY_PHASE1":7353,"PHASE1":7355,"PHASE2":7376,"PHASE3":7378,"PHASE4":7380,"NA":7382},{"trials":7354,"activeCount":85},[],{"trials":7356,"activeCount":85},[7357,7367],{"nctId":7358,"briefTitle":7359,"status":114,"phases":7360,"primaryCompletion":7361,"completion":7361,"start":7362,"enrollment":1211,"conditions":7363,"interventions":7364},"NCT01262391","Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents",[74],"2011-08-14","2010-10-20",[33],[7365,7351,7366],"Solifenacin succinate suspension 2.5 mg","Solifenacin succinate suspension 10 mg",{"nctId":7368,"briefTitle":7369,"status":114,"phases":7370,"primaryCompletion":7371,"completion":7371,"start":7372,"enrollment":4634,"conditions":7373,"interventions":7375},"NCT01539707","Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder",[74],"2012-08-13","2012-03-13",[24,7374],"Neurogenic Detrusor Overactivity",[7351],{"trials":7377,"activeCount":85},[],{"trials":7379,"activeCount":85},[],{"trials":7381,"activeCount":85},[],{"trials":7383,"activeCount":85},[],{"intervention":7385,"totalTrials":158,"cells":7386},"mirabegron OCAS",{"EARLY_PHASE1":7387,"PHASE1":7389,"PHASE2":7405,"PHASE3":7407,"PHASE4":7409,"NA":7411},{"trials":7388,"activeCount":85},[],{"trials":7390,"activeCount":85},[7391,7398],{"nctId":7392,"briefTitle":7393,"status":114,"phases":7394,"primaryCompletion":2009,"completion":2009,"start":1485,"enrollment":3453,"conditions":7395,"interventions":7397},"NCT01478529","A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation",[74],[1025,7396,18],"Bioavailability",[7385,1027],{"nctId":7399,"briefTitle":7400,"status":114,"phases":7401,"primaryCompletion":1075,"completion":1075,"start":961,"enrollment":7402,"conditions":7403,"interventions":7404},"NCT01478503","To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females",[74],96,[2047,18],[7385],{"trials":7406,"activeCount":85},[],{"trials":7408,"activeCount":85},[],{"trials":7410,"activeCount":85},[],{"trials":7412,"activeCount":85},[],{"intervention":7271,"totalTrials":158,"cells":7414},{"EARLY_PHASE1":7415,"PHASE1":7417,"PHASE2":7431,"PHASE3":7433,"PHASE4":7435,"NA":7437},{"trials":7416,"activeCount":85},[],{"trials":7418,"activeCount":85},[7419,7423],{"nctId":7266,"briefTitle":7267,"status":114,"phases":7420,"primaryCompletion":318,"completion":318,"start":1169,"enrollment":11,"conditions":7421,"interventions":7422},[74],[7254,18],[7243,7271],{"nctId":7424,"briefTitle":7425,"status":114,"phases":7426,"primaryCompletion":2020,"completion":2020,"start":1317,"enrollment":118,"conditions":7427,"interventions":7428},"NCT01476800","A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers",[74],[18,3590],[7429,7430],"YM178 OCAS","Ketoconazole",{"trials":7432,"activeCount":85},[],{"trials":7434,"activeCount":85},[],{"trials":7436,"activeCount":85},[],{"trials":7438,"activeCount":85},[],{"intervention":7440,"totalTrials":158,"cells":7441},"TRK-100STP",{"EARLY_PHASE1":7442,"PHASE1":7444,"PHASE2":7461,"PHASE3":7463,"PHASE4":7465,"NA":7467},{"trials":7443,"activeCount":85},[],{"trials":7445,"activeCount":85},[7446,7454],{"nctId":7447,"briefTitle":7448,"status":114,"phases":7449,"primaryCompletion":3661,"completion":3661,"start":3204,"enrollment":3224,"conditions":7450,"interventions":7453},"NCT01423435","Study to Compare Pharmacokinetic Profiles of TRK-100STP in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males",[74],[7451,7452],"Healthy Adult Male","Pharmacokinetics of TRK-100-STP",[7440],{"nctId":7455,"briefTitle":7456,"status":114,"phases":7457,"primaryCompletion":1240,"completion":1240,"start":1498,"enrollment":118,"conditions":7458,"interventions":7459},"NCT00719758","Drug-Drug Interaction Study of TRK-100STP",[74],[15],[7440,7460],"AST-120",{"trials":7462,"activeCount":85},[],{"trials":7464,"activeCount":85},[],{"trials":7466,"activeCount":85},[],{"trials":7468,"activeCount":85},[],{"intervention":4044,"totalTrials":158,"cells":7470},{"EARLY_PHASE1":7471,"PHASE1":7473,"PHASE2":7483,"PHASE3":7485,"PHASE4":7487,"NA":7489},{"trials":7472,"activeCount":85},[],{"trials":7474,"activeCount":85},[7475,7479],{"nctId":4037,"briefTitle":4038,"status":114,"phases":7476,"primaryCompletion":3205,"completion":3205,"start":1011,"enrollment":118,"conditions":7477,"interventions":7478},[74],[4041,4042,30],[2103,4044],{"nctId":7185,"briefTitle":7186,"status":114,"phases":7480,"primaryCompletion":2609,"completion":2609,"start":5759,"enrollment":1372,"conditions":7481,"interventions":7482},[74],[15,7189],[813,4044],{"trials":7484,"activeCount":85},[],{"trials":7486,"activeCount":85},[],{"trials":7488,"activeCount":85},[],{"trials":7490,"activeCount":85},[],{"intervention":7278,"totalTrials":158,"cells":7492},{"EARLY_PHASE1":7493,"PHASE1":7495,"PHASE2":7505,"PHASE3":7507,"PHASE4":7509,"NA":7511},{"trials":7494,"activeCount":85},[],{"trials":7496,"activeCount":85},[7497,7501],{"nctId":7273,"briefTitle":7274,"status":114,"phases":7498,"primaryCompletion":846,"completion":846,"start":378,"enrollment":1541,"conditions":7499,"interventions":7500},[74],[7262,18],[7243,7243,7278,7279],{"nctId":7281,"briefTitle":7282,"status":114,"phases":7502,"primaryCompletion":860,"completion":860,"start":847,"enrollment":118,"conditions":7503,"interventions":7504},[74],[7285,18],[7287,7278],{"trials":7506,"activeCount":85},[],{"trials":7508,"activeCount":85},[],{"trials":7510,"activeCount":85},[],{"trials":7512,"activeCount":85},[],{"intervention":7514,"totalTrials":158,"cells":7515},"ASP3026",{"EARLY_PHASE1":7516,"PHASE1":7518,"PHASE2":7537,"PHASE3":7539,"PHASE4":7541,"NA":7543},{"trials":7517,"activeCount":85},[],{"trials":7519,"activeCount":85},[7520,7526],{"nctId":7521,"briefTitle":7522,"status":114,"phases":7523,"primaryCompletion":3133,"completion":3133,"start":1011,"enrollment":19,"conditions":7524,"interventions":7525},"NCT01401504","Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors",[74],[286],[7514],{"nctId":7527,"briefTitle":7528,"status":114,"phases":7529,"primaryCompletion":2240,"completion":7530,"start":1530,"enrollment":3310,"conditions":7531,"interventions":7536},"NCT01284192","Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)",[74],"2016-03",[7532,7533,7534,286,7535],"Advanced Malignancies","Positive for Anaplastic Lymphoma Kinase","Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS","B-Cell Lymphoma",[7514],{"trials":7538,"activeCount":85},[],{"trials":7540,"activeCount":85},[],{"trials":7542,"activeCount":85},[],{"trials":7544,"activeCount":85},[],{"intervention":7546,"totalTrials":158,"cells":7547},"ASP3325",{"EARLY_PHASE1":7548,"PHASE1":7550,"PHASE2":7569,"PHASE3":7571,"PHASE4":7573,"NA":7575},{"trials":7549,"activeCount":85},[],{"trials":7551,"activeCount":85},[7552,7561],{"nctId":7553,"briefTitle":7554,"status":114,"phases":7555,"primaryCompletion":7556,"completion":7556,"start":7557,"enrollment":118,"conditions":7558,"interventions":7560},"NCT02510274","Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan",[74],"2014-11-04","2014-05-12",[3508,7559],"Hyperphosphatemia Undergoing Hemodialysis",[7546],{"nctId":7562,"briefTitle":7563,"status":114,"phases":7564,"primaryCompletion":7565,"completion":7565,"start":5146,"enrollment":749,"conditions":7566,"interventions":7568},"NCT02500953","A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects",[74],"2013-12",[7567],"Pharmacokinetics of ASP3325 in Non-elderly, Healthy Adult Japanese Male and Female, and Caucasian Male Subjects",[7546],{"trials":7570,"activeCount":85},[],{"trials":7572,"activeCount":85},[],{"trials":7574,"activeCount":85},[],{"trials":7576,"activeCount":85},[],{"intervention":7578,"totalTrials":81,"cells":7579},"Bisoprolol",{"EARLY_PHASE1":7580,"PHASE1":7582,"PHASE2":7592,"PHASE3":7594,"PHASE4":7596,"NA":7598},{"trials":7581,"activeCount":85},[],{"trials":7583,"activeCount":85},[7584],{"nctId":7585,"briefTitle":7586,"status":114,"phases":7587,"primaryCompletion":333,"completion":333,"start":1022,"enrollment":3453,"conditions":7588,"interventions":7590},"NCT01284868","A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.",[74],[30,7589],"Pharmacodynamics of Mirabegron",[1027,7578,7591],"propranolol",{"trials":7593,"activeCount":85},[],{"trials":7595,"activeCount":85},[],{"trials":7597,"activeCount":85},[],{"trials":7599,"activeCount":85},[],{"intervention":7591,"totalTrials":81,"cells":7601},{"EARLY_PHASE1":7602,"PHASE1":7604,"PHASE2":7610,"PHASE3":7612,"PHASE4":7614,"NA":7616},{"trials":7603,"activeCount":85},[],{"trials":7605,"activeCount":85},[7606],{"nctId":7585,"briefTitle":7586,"status":114,"phases":7607,"primaryCompletion":333,"completion":333,"start":1022,"enrollment":3453,"conditions":7608,"interventions":7609},[74],[30,7589],[1027,7578,7591],{"trials":7611,"activeCount":85},[],{"trials":7613,"activeCount":85},[],{"trials":7615,"activeCount":85},[],{"trials":7617,"activeCount":85},[],{"intervention":364,"totalTrials":81,"cells":7619},{"EARLY_PHASE1":7620,"PHASE1":7622,"PHASE2":7628,"PHASE3":7630,"PHASE4":7632,"NA":7634},{"trials":7621,"activeCount":85},[],{"trials":7623,"activeCount":85},[7624],{"nctId":351,"briefTitle":352,"status":353,"phases":7625,"primaryCompletion":355,"completion":355,"start":356,"enrollment":275,"conditions":7626,"interventions":7627},[74],[358,359,360,361],[363,364,365,366],{"trials":7629,"activeCount":85},[],{"trials":7631,"activeCount":85},[],{"trials":7633,"activeCount":85},[],{"trials":7635,"activeCount":85},[],{"intervention":7637,"totalTrials":81,"cells":7638},"Minidril",{"EARLY_PHASE1":7639,"PHASE1":7641,"PHASE2":7649,"PHASE3":7651,"PHASE4":7653,"NA":7655},{"trials":7640,"activeCount":85},[],{"trials":7642,"activeCount":85},[7643],{"nctId":7644,"briefTitle":7645,"status":114,"phases":7646,"primaryCompletion":896,"completion":896,"start":971,"enrollment":1372,"conditions":7647,"interventions":7648},"NCT01297179","A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill",[74],[30,1025],[1704,7637],{"trials":7650,"activeCount":85},[],{"trials":7652,"activeCount":85},[],{"trials":7654,"activeCount":85},[],{"trials":7656,"activeCount":85},[],{"intervention":7658,"totalTrials":81,"cells":7659},"ASG-5ME",{"EARLY_PHASE1":7660,"PHASE1":7662,"PHASE2":7670,"PHASE3":7672,"PHASE4":7674,"NA":7676},{"trials":7661,"activeCount":85},[],{"trials":7663,"activeCount":85},[7664],{"nctId":7665,"briefTitle":7666,"status":114,"phases":7667,"primaryCompletion":3947,"completion":3947,"start":3231,"enrollment":3310,"conditions":7668,"interventions":7669},"NCT01228760","A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer",[74],[6744],[7658],{"trials":7671,"activeCount":85},[],{"trials":7673,"activeCount":85},[],{"trials":7675,"activeCount":85},[],{"trials":7677,"activeCount":85},[],{"intervention":7679,"totalTrials":81,"cells":7680},"AGS-22M6E",{"EARLY_PHASE1":7681,"PHASE1":7683,"PHASE2":7696,"PHASE3":7698,"PHASE4":7700,"NA":7702},{"trials":7682,"activeCount":85},[],{"trials":7684,"activeCount":85},[7685],{"nctId":7686,"briefTitle":7687,"status":114,"phases":7688,"primaryCompletion":7689,"completion":7689,"start":7690,"enrollment":16,"conditions":7691,"interventions":7694},"NCT01409135","A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4",[74],"2015-04-27","2011-07-11",[323,7692,7693],"Medical Oncology","Neoplasms",[7679,7695],"ASG-22CE",{"trials":7697,"activeCount":85},[],{"trials":7699,"activeCount":85},[],{"trials":7701,"activeCount":85},[],{"trials":7703,"activeCount":85},[],{"intervention":7695,"totalTrials":81,"cells":7705},{"EARLY_PHASE1":7706,"PHASE1":7708,"PHASE2":7714,"PHASE3":7716,"PHASE4":7718,"NA":7720},{"trials":7707,"activeCount":85},[],{"trials":7709,"activeCount":85},[7710],{"nctId":7686,"briefTitle":7687,"status":114,"phases":7711,"primaryCompletion":7689,"completion":7689,"start":7690,"enrollment":16,"conditions":7712,"interventions":7713},[74],[323,7692,7693],[7679,7695],{"trials":7715,"activeCount":85},[],{"trials":7717,"activeCount":85},[],{"trials":7719,"activeCount":85},[],{"trials":7721,"activeCount":85},[],{"intervention":7723,"totalTrials":81,"cells":7724},"desipramine",{"EARLY_PHASE1":7725,"PHASE1":7727,"PHASE2":7735,"PHASE3":7737,"PHASE4":7739,"NA":7741},{"trials":7726,"activeCount":85},[],{"trials":7728,"activeCount":85},[7729],{"nctId":7730,"briefTitle":7731,"status":114,"phases":7732,"primaryCompletion":4112,"completion":4112,"start":971,"enrollment":22,"conditions":7733,"interventions":7734},"NCT01478568","To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together",[74],[1025,18],[1027,7723],{"trials":7736,"activeCount":85},[],{"trials":7738,"activeCount":85},[],{"trials":7740,"activeCount":85},[],{"trials":7742,"activeCount":85},[],{"intervention":3339,"totalTrials":81,"cells":7744},{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7753,"PHASE3":7755,"PHASE4":7757,"NA":7759},{"trials":7746,"activeCount":85},[],{"trials":7748,"activeCount":85},[7749],{"nctId":3333,"briefTitle":3334,"status":114,"phases":7750,"primaryCompletion":1279,"completion":1279,"start":1485,"enrollment":118,"conditions":7751,"interventions":7752},[74],[15,3337],[3319,3339],{"trials":7754,"activeCount":85},[],{"trials":7756,"activeCount":85},[],{"trials":7758,"activeCount":85},[],{"trials":7760,"activeCount":85},[],{"intervention":7256,"totalTrials":81,"cells":7762},{"EARLY_PHASE1":7763,"PHASE1":7765,"PHASE2":7771,"PHASE3":7773,"PHASE4":7775,"NA":7777},{"trials":7764,"activeCount":85},[],{"trials":7766,"activeCount":85},[7767],{"nctId":7250,"briefTitle":7251,"status":114,"phases":7768,"primaryCompletion":318,"completion":318,"start":1169,"enrollment":11,"conditions":7769,"interventions":7770},[74],[7254,18],[7243,7256],{"trials":7772,"activeCount":85},[],{"trials":7774,"activeCount":85},[],{"trials":7776,"activeCount":85},[],{"trials":7778,"activeCount":85},[],{"intervention":7264,"totalTrials":81,"cells":7780},{"EARLY_PHASE1":7781,"PHASE1":7783,"PHASE2":7789,"PHASE3":7791,"PHASE4":7793,"NA":7795},{"trials":7782,"activeCount":85},[],{"trials":7784,"activeCount":85},[7785],{"nctId":7258,"briefTitle":7259,"status":114,"phases":7786,"primaryCompletion":3188,"completion":3188,"start":1169,"enrollment":11,"conditions":7787,"interventions":7788},[74],[7262,18],[7243,7264],{"trials":7790,"activeCount":85},[],{"trials":7792,"activeCount":85},[],{"trials":7794,"activeCount":85},[],{"trials":7796,"activeCount":85},[],{"intervention":7365,"totalTrials":81,"cells":7798},{"EARLY_PHASE1":7799,"PHASE1":7801,"PHASE2":7807,"PHASE3":7809,"PHASE4":7811,"NA":7813},{"trials":7800,"activeCount":85},[],{"trials":7802,"activeCount":85},[7803],{"nctId":7358,"briefTitle":7359,"status":114,"phases":7804,"primaryCompletion":7361,"completion":7361,"start":7362,"enrollment":1211,"conditions":7805,"interventions":7806},[74],[33],[7365,7351,7366],{"trials":7808,"activeCount":85},[],{"trials":7810,"activeCount":85},[],{"trials":7812,"activeCount":85},[],{"trials":7814,"activeCount":85},[],{"intervention":7366,"totalTrials":81,"cells":7816},{"EARLY_PHASE1":7817,"PHASE1":7819,"PHASE2":7825,"PHASE3":7827,"PHASE4":7829,"NA":7831},{"trials":7818,"activeCount":85},[],{"trials":7820,"activeCount":85},[7821],{"nctId":7358,"briefTitle":7359,"status":114,"phases":7822,"primaryCompletion":7361,"completion":7361,"start":7362,"enrollment":1211,"conditions":7823,"interventions":7824},[74],[33],[7365,7351,7366],{"trials":7826,"activeCount":85},[],{"trials":7828,"activeCount":85},[],{"trials":7830,"activeCount":85},[],{"trials":7832,"activeCount":85},[],{"intervention":7834,"totalTrials":81,"cells":7835},"rifampin",{"EARLY_PHASE1":7836,"PHASE1":7838,"PHASE2":7846,"PHASE3":7848,"PHASE4":7850,"NA":7852},{"trials":7837,"activeCount":85},[],{"trials":7839,"activeCount":85},[7840],{"nctId":7841,"briefTitle":7842,"status":114,"phases":7843,"primaryCompletion":3574,"completion":3574,"start":971,"enrollment":118,"conditions":7844,"interventions":7845},"NCT00776516","Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers",[74],[3590],[1027,7834],{"trials":7847,"activeCount":85},[],{"trials":7849,"activeCount":85},[],{"trials":7851,"activeCount":85},[],{"trials":7853,"activeCount":85},[],{"intervention":7855,"totalTrials":81,"cells":7856},"extended release tacrolimus",{"EARLY_PHASE1":7857,"PHASE1":7859,"PHASE2":7868,"PHASE3":7870,"PHASE4":7872,"NA":7874},{"trials":7858,"activeCount":85},[],{"trials":7860,"activeCount":85},[7861],{"nctId":7862,"briefTitle":7863,"status":114,"phases":7864,"primaryCompletion":1240,"completion":1240,"start":6912,"enrollment":4103,"conditions":7865,"interventions":7866},"NCT00818194","Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers",[74],[15],[7855,7867],"cyclosporine A microemulsion",{"trials":7869,"activeCount":85},[],{"trials":7871,"activeCount":85},[],{"trials":7873,"activeCount":85},[],{"trials":7875,"activeCount":85},[],{"intervention":7867,"totalTrials":81,"cells":7877},{"EARLY_PHASE1":7878,"PHASE1":7880,"PHASE2":7886,"PHASE3":7888,"PHASE4":7890,"NA":7892},{"trials":7879,"activeCount":85},[],{"trials":7881,"activeCount":85},[7882],{"nctId":7862,"briefTitle":7863,"status":114,"phases":7883,"primaryCompletion":1240,"completion":1240,"start":6912,"enrollment":4103,"conditions":7884,"interventions":7885},[74],[15],[7855,7867],{"trials":7887,"activeCount":85},[],{"trials":7889,"activeCount":85},[],{"trials":7891,"activeCount":85},[],{"trials":7893,"activeCount":85},[],{"intervention":7895,"totalTrials":81,"cells":7896},"OSI-930",{"EARLY_PHASE1":7897,"PHASE1":7899,"PHASE2":7907,"PHASE3":7909,"PHASE4":7911,"NA":7913},{"trials":7898,"activeCount":85},[],{"trials":7900,"activeCount":85},[7901],{"nctId":7902,"briefTitle":7903,"status":114,"phases":7904,"primaryCompletion":1022,"completion":846,"start":1279,"enrollment":3206,"conditions":7905,"interventions":7906},"NCT00513851","Phase 1 Study of OSI-930 in Cancer Patients",[74],[3821],[7895,7895],{"trials":7908,"activeCount":85},[],{"trials":7910,"activeCount":85},[],{"trials":7912,"activeCount":85},[],{"trials":7914,"activeCount":85},[],{"intervention":1015,"totalTrials":81,"cells":7916},{"EARLY_PHASE1":7917,"PHASE1":7919,"PHASE2":7925,"PHASE3":7927,"PHASE4":7929,"NA":7931},{"trials":7918,"activeCount":85},[],{"trials":7920,"activeCount":85},[7921],{"nctId":1007,"briefTitle":1008,"status":114,"phases":7922,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":118,"conditions":7923,"interventions":7924},[74],[1013,30],[1015,1016,1017],{"trials":7926,"activeCount":85},[],{"trials":7928,"activeCount":85},[],{"trials":7930,"activeCount":85},[],{"trials":7932,"activeCount":85},[],{"intervention":1016,"totalTrials":81,"cells":7934},{"EARLY_PHASE1":7935,"PHASE1":7937,"PHASE2":7943,"PHASE3":7945,"PHASE4":7947,"NA":7949},{"trials":7936,"activeCount":85},[],{"trials":7938,"activeCount":85},[7939],{"nctId":1007,"briefTitle":1008,"status":114,"phases":7940,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":118,"conditions":7941,"interventions":7942},[74],[1013,30],[1015,1016,1017],{"trials":7944,"activeCount":85},[],{"trials":7946,"activeCount":85},[],{"trials":7948,"activeCount":85},[],{"trials":7950,"activeCount":85},[],{"intervention":7952,"totalTrials":81,"cells":7953},"ASP1948",{"EARLY_PHASE1":7954,"PHASE1":7956,"PHASE2":7967,"PHASE3":7969,"PHASE4":7971,"NA":7973},{"trials":7955,"activeCount":85},[],{"trials":7957,"activeCount":85},[7958],{"nctId":7959,"briefTitle":7960,"status":114,"phases":7961,"primaryCompletion":7962,"completion":7962,"start":7963,"enrollment":1191,"conditions":7964,"interventions":7966},"NCT04094506","Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors",[74],"2022-02-02","2019-10-30",[7965],"Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies",[7952],{"trials":7968,"activeCount":85},[],{"trials":7970,"activeCount":85},[],{"trials":7972,"activeCount":85},[],{"trials":7974,"activeCount":85},[],{"intervention":5754,"totalTrials":81,"cells":7976},{"EARLY_PHASE1":7977,"PHASE1":7979,"PHASE2":7985,"PHASE3":7987,"PHASE4":7989,"NA":7991},{"trials":7978,"activeCount":85},[],{"trials":7980,"activeCount":85},[7981],{"nctId":5747,"briefTitle":5748,"status":114,"phases":7982,"primaryCompletion":5750,"completion":5750,"start":5751,"enrollment":4103,"conditions":7983,"interventions":7984},[74],[18],[5740,5754],{"trials":7986,"activeCount":85},[],{"trials":7988,"activeCount":85},[],{"trials":7990,"activeCount":85},[],{"trials":7992,"activeCount":85},[],{"intervention":3475,"totalTrials":81,"cells":7994},{"EARLY_PHASE1":7995,"PHASE1":7997,"PHASE2":8003,"PHASE3":8005,"PHASE4":8007,"NA":8009},{"trials":7996,"activeCount":85},[],{"trials":7998,"activeCount":85},[7999],{"nctId":3469,"briefTitle":3470,"status":114,"phases":8000,"primaryCompletion":355,"completion":355,"start":318,"enrollment":118,"conditions":8001,"interventions":8002},[74],[15,3473],[3452,3475],{"trials":8004,"activeCount":85},[],{"trials":8006,"activeCount":85},[],{"trials":8008,"activeCount":85},[],{"trials":8010,"activeCount":85},[],{"intervention":8012,"totalTrials":81,"cells":8013},"Z-338",{"EARLY_PHASE1":8014,"PHASE1":8016,"PHASE2":8024,"PHASE3":8026,"PHASE4":8028,"NA":8030},{"trials":8015,"activeCount":85},[],{"trials":8017,"activeCount":85},[8018],{"nctId":8019,"briefTitle":8020,"status":114,"phases":8021,"primaryCompletion":808,"completion":808,"start":896,"enrollment":1372,"conditions":8022,"interventions":8023},"NCT00920998","Effect of Food Intake on Pharmacokinetic Profiles of Z-338",[74],[15],[8012],{"trials":8025,"activeCount":85},[],{"trials":8027,"activeCount":85},[],{"trials":8029,"activeCount":85},[],{"trials":8031,"activeCount":85},[],{"intervention":8033,"totalTrials":81,"cells":8034},"ASP8374",{"EARLY_PHASE1":8035,"PHASE1":8037,"PHASE2":8047,"PHASE3":8049,"PHASE4":8051,"NA":8053},{"trials":8036,"activeCount":85},[],{"trials":8038,"activeCount":85},[8039],{"nctId":8040,"briefTitle":8041,"status":114,"phases":8042,"primaryCompletion":8043,"completion":8043,"start":8044,"enrollment":1750,"conditions":8045,"interventions":8046},"NCT03945253","Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors",[74],"2020-06-12","2019-08-05",[3821],[8033],{"trials":8048,"activeCount":85},[],{"trials":8050,"activeCount":85},[],{"trials":8052,"activeCount":85},[],{"trials":8054,"activeCount":85},[],{"intervention":3483,"totalTrials":81,"cells":8056},{"EARLY_PHASE1":8057,"PHASE1":8059,"PHASE2":8065,"PHASE3":8067,"PHASE4":8069,"NA":8071},{"trials":8058,"activeCount":85},[],{"trials":8060,"activeCount":85},[8061],{"nctId":3477,"briefTitle":3478,"status":114,"phases":8062,"primaryCompletion":3188,"completion":3188,"start":355,"enrollment":3453,"conditions":8063,"interventions":8064},[74],[15,3481],[3452,3483],{"trials":8066,"activeCount":85},[],{"trials":8068,"activeCount":85},[],{"trials":8070,"activeCount":85},[],{"trials":8072,"activeCount":85},[],{"intervention":3678,"totalTrials":81,"cells":8074},{"EARLY_PHASE1":8075,"PHASE1":8077,"PHASE2":8083,"PHASE3":8085,"PHASE4":8087,"NA":8089},{"trials":8076,"activeCount":85},[],{"trials":8078,"activeCount":85},[8079],{"nctId":3672,"briefTitle":3673,"status":114,"phases":8080,"primaryCompletion":3204,"completion":3204,"start":1010,"enrollment":118,"conditions":8081,"interventions":8082},[74],[15,3676],[3651,3678],{"trials":8084,"activeCount":85},[],{"trials":8086,"activeCount":85},[],{"trials":8088,"activeCount":85},[],{"trials":8090,"activeCount":85},[],{"intervention":8092,"totalTrials":81,"cells":8093},"ASP5878",{"EARLY_PHASE1":8094,"PHASE1":8096,"PHASE2":8105,"PHASE3":8107,"PHASE4":8109,"NA":8111},{"trials":8095,"activeCount":85},[],{"trials":8097,"activeCount":85},[8098],{"nctId":8099,"briefTitle":8100,"status":114,"phases":8101,"primaryCompletion":8102,"completion":8102,"start":2431,"enrollment":5123,"conditions":8103,"interventions":8104},"NCT02038673","An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors",[74],"2017-07-19",[3861],[8092],{"trials":8106,"activeCount":85},[],{"trials":8108,"activeCount":85},[],{"trials":8110,"activeCount":85},[],{"trials":8112,"activeCount":85},[],{"intervention":7279,"totalTrials":81,"cells":8114},{"EARLY_PHASE1":8115,"PHASE1":8117,"PHASE2":8123,"PHASE3":8125,"PHASE4":8127,"NA":8129},{"trials":8116,"activeCount":85},[],{"trials":8118,"activeCount":85},[8119],{"nctId":7273,"briefTitle":7274,"status":114,"phases":8120,"primaryCompletion":846,"completion":846,"start":378,"enrollment":1541,"conditions":8121,"interventions":8122},[74],[7262,18],[7243,7243,7278,7279],{"trials":8124,"activeCount":85},[],{"trials":8126,"activeCount":85},[],{"trials":8128,"activeCount":85},[],{"trials":8130,"activeCount":85},[],{"intervention":8132,"totalTrials":81,"cells":8133},"ASP2408",{"EARLY_PHASE1":8134,"PHASE1":8136,"PHASE2":8146,"PHASE3":8148,"PHASE4":8150,"NA":8152},{"trials":8135,"activeCount":85},[],{"trials":8137,"activeCount":85},[8138],{"nctId":8139,"briefTitle":8140,"status":114,"phases":8141,"primaryCompletion":8142,"completion":8142,"start":332,"enrollment":118,"conditions":8143,"interventions":8145},"NCT02140125","A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects",[74],"2013-10",[15,8144],"Pharmacokinetics of ASP2408",[8132],{"trials":8147,"activeCount":85},[],{"trials":8149,"activeCount":85},[],{"trials":8151,"activeCount":85},[],{"trials":8153,"activeCount":85},[],{"intervention":8155,"totalTrials":81,"cells":8156},"ESN364",{"EARLY_PHASE1":8157,"PHASE1":8159,"PHASE2":8169,"PHASE3":8171,"PHASE4":8173,"NA":8175},{"trials":8158,"activeCount":85},[],{"trials":8160,"activeCount":85},[8161],{"nctId":8162,"briefTitle":8163,"status":114,"phases":8164,"primaryCompletion":8165,"completion":8165,"start":8166,"enrollment":1531,"conditions":8167,"interventions":8168},"NCT03436849","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects",[74],"2018-05-23","2018-02-22",[18],[8155],{"trials":8170,"activeCount":85},[],{"trials":8172,"activeCount":85},[],{"trials":8174,"activeCount":85},[],{"trials":8176,"activeCount":85},[],{"intervention":7429,"totalTrials":81,"cells":8178},{"EARLY_PHASE1":8179,"PHASE1":8181,"PHASE2":8187,"PHASE3":8189,"PHASE4":8191,"NA":8193},{"trials":8180,"activeCount":85},[],{"trials":8182,"activeCount":85},[8183],{"nctId":7424,"briefTitle":7425,"status":114,"phases":8184,"primaryCompletion":2020,"completion":2020,"start":1317,"enrollment":118,"conditions":8185,"interventions":8186},[74],[18,3590],[7429,7430],{"trials":8188,"activeCount":85},[],{"trials":8190,"activeCount":85},[],{"trials":8192,"activeCount":85},[],{"trials":8194,"activeCount":85},[],{"intervention":3491,"totalTrials":81,"cells":8196},{"EARLY_PHASE1":8197,"PHASE1":8199,"PHASE2":8205,"PHASE3":8207,"PHASE4":8209,"NA":8211},{"trials":8198,"activeCount":85},[],{"trials":8200,"activeCount":85},[8201],{"nctId":3485,"briefTitle":3486,"status":114,"phases":8202,"primaryCompletion":355,"completion":355,"start":318,"enrollment":118,"conditions":8203,"interventions":8204},[74],[15,3489],[3452,3491],{"trials":8206,"activeCount":85},[],{"trials":8208,"activeCount":85},[],{"trials":8210,"activeCount":85},[],{"trials":8212,"activeCount":85},[],{"intervention":8214,"totalTrials":81,"cells":8215},"AGS-16M8F",{"EARLY_PHASE1":8216,"PHASE1":8218,"PHASE2":8227,"PHASE3":8229,"PHASE4":8231,"NA":8233},{"trials":8217,"activeCount":85},[],{"trials":8219,"activeCount":85},[8220],{"nctId":8221,"briefTitle":8222,"status":114,"phases":8223,"primaryCompletion":4057,"completion":4057,"start":2044,"enrollment":11,"conditions":8224,"interventions":8226},"NCT01114230","A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer",[74],[5731,8225],"Pharmacokinetics of AGS-16M8F",[8214],{"trials":8228,"activeCount":85},[],{"trials":8230,"activeCount":85},[],{"trials":8232,"activeCount":85},[],{"trials":8234,"activeCount":85},[],{"intervention":3199,"totalTrials":81,"cells":8236},{"EARLY_PHASE1":8237,"PHASE1":8239,"PHASE2":8245,"PHASE3":8247,"PHASE4":8249,"NA":8251},{"trials":8238,"activeCount":85},[],{"trials":8240,"activeCount":85},[8241],{"nctId":3193,"briefTitle":3194,"status":114,"phases":8242,"primaryCompletion":355,"completion":355,"start":3196,"enrollment":1372,"conditions":8243,"interventions":8244},[74],[30,3127],[3114,3199],{"trials":8246,"activeCount":85},[],{"trials":8248,"activeCount":85},[],{"trials":8250,"activeCount":85},[],{"trials":8252,"activeCount":85},[],{"intervention":3210,"totalTrials":81,"cells":8254},{"EARLY_PHASE1":8255,"PHASE1":8257,"PHASE2":8263,"PHASE3":8265,"PHASE4":8267,"NA":8269},{"trials":8256,"activeCount":85},[],{"trials":8258,"activeCount":85},[8259],{"nctId":3201,"briefTitle":3202,"status":114,"phases":8260,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":3206,"conditions":8261,"interventions":8262},[74],[15,3127,3208],[3114,3210],{"trials":8264,"activeCount":85},[],{"trials":8266,"activeCount":85},[],{"trials":8268,"activeCount":85},[],{"trials":8270,"activeCount":85},[],{"intervention":8272,"totalTrials":81,"cells":8273},"AGS-16M18",{"EARLY_PHASE1":8274,"PHASE1":8276,"PHASE2":8286,"PHASE3":8288,"PHASE4":8290,"NA":8292},{"trials":8275,"activeCount":85},[],{"trials":8277,"activeCount":85},[8278],{"nctId":8279,"briefTitle":8280,"status":353,"phases":8281,"primaryCompletion":355,"completion":355,"start":971,"enrollment":8,"conditions":8282,"interventions":8285},"NCT00816686","A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer",[74],[8283,8284,1934],"Carcinoma, Renal Cell","Kidney Neoplasms",[8272],{"trials":8287,"activeCount":85},[],{"trials":8289,"activeCount":85},[],{"trials":8291,"activeCount":85},[],{"trials":8293,"activeCount":85},[],{"intervention":8295,"totalTrials":81,"cells":8296},"OSI-930 and erlotinib",{"EARLY_PHASE1":8297,"PHASE1":8299,"PHASE2":8307,"PHASE3":8309,"PHASE4":8311,"NA":8313},{"trials":8298,"activeCount":85},[],{"trials":8300,"activeCount":85},[8301],{"nctId":8302,"briefTitle":8303,"status":114,"phases":8304,"primaryCompletion":355,"completion":2609,"start":1210,"enrollment":3206,"conditions":8305,"interventions":8306},"NCT00603356","Phase I Study of OSI-930 and Erlotinib in Cancer Tumors",[74],[3821],[8295],{"trials":8308,"activeCount":85},[],{"trials":8310,"activeCount":85},[],{"trials":8312,"activeCount":85},[],{"trials":8314,"activeCount":85},[],{"intervention":8316,"totalTrials":81,"cells":8317},"ASP8302",{"EARLY_PHASE1":8318,"PHASE1":8320,"PHASE2":8330,"PHASE3":8332,"PHASE4":8334,"NA":8336},{"trials":8319,"activeCount":85},[],{"trials":8321,"activeCount":85},[8322],{"nctId":8323,"briefTitle":8324,"status":114,"phases":8325,"primaryCompletion":8326,"completion":8326,"start":8327,"enrollment":3125,"conditions":8328,"interventions":8329},"NCT03361540","ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects",[74],"2018-04-30","2017-11-14",[18],[8316],{"trials":8331,"activeCount":85},[],{"trials":8333,"activeCount":85},[],{"trials":8335,"activeCount":85},[],{"trials":8337,"activeCount":85},[],{"intervention":3217,"totalTrials":81,"cells":8339},{"EARLY_PHASE1":8340,"PHASE1":8342,"PHASE2":8348,"PHASE3":8350,"PHASE4":8352,"NA":8354},{"trials":8341,"activeCount":85},[],{"trials":8343,"activeCount":85},[8344],{"nctId":3212,"briefTitle":3213,"status":114,"phases":8345,"primaryCompletion":308,"completion":308,"start":333,"enrollment":334,"conditions":8346,"interventions":8347},[74],[15,3127],[3114,3217],{"trials":8349,"activeCount":85},[],{"trials":8351,"activeCount":85},[],{"trials":8353,"activeCount":85},[],{"trials":8355,"activeCount":85},[],{"intervention":7460,"totalTrials":81,"cells":8357},{"EARLY_PHASE1":8358,"PHASE1":8360,"PHASE2":8366,"PHASE3":8368,"PHASE4":8370,"NA":8372},{"trials":8359,"activeCount":85},[],{"trials":8361,"activeCount":85},[8362],{"nctId":7455,"briefTitle":7456,"status":114,"phases":8363,"primaryCompletion":1240,"completion":1240,"start":1498,"enrollment":118,"conditions":8364,"interventions":8365},[74],[15],[7440,7460],{"trials":8367,"activeCount":85},[],{"trials":8369,"activeCount":85},[],{"trials":8371,"activeCount":85},[],{"trials":8373,"activeCount":85},[],{"intervention":1035,"totalTrials":81,"cells":8375},{"EARLY_PHASE1":8376,"PHASE1":8378,"PHASE2":8384,"PHASE3":8386,"PHASE4":8388,"NA":8390},{"trials":8377,"activeCount":85},[],{"trials":8379,"activeCount":85},[8380],{"nctId":1029,"briefTitle":1030,"status":114,"phases":8381,"primaryCompletion":333,"completion":333,"start":846,"enrollment":118,"conditions":8382,"interventions":8383},[74],[1033,1013,30],[1035,1000],{"trials":8385,"activeCount":85},[],{"trials":8387,"activeCount":85},[],{"trials":8389,"activeCount":85},[],{"trials":8391,"activeCount":85},[],{"intervention":8393,"totalTrials":81,"cells":8394},"metoprolol",{"EARLY_PHASE1":8395,"PHASE1":8397,"PHASE2":8405,"PHASE3":8407,"PHASE4":8409,"NA":8411},{"trials":8396,"activeCount":85},[],{"trials":8398,"activeCount":85},[8399],{"nctId":8400,"briefTitle":8401,"status":114,"phases":8402,"primaryCompletion":835,"completion":835,"start":6419,"enrollment":22,"conditions":8403,"interventions":8404},"NCT01478490","To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol",[74],[1025,18],[1027,8393],{"trials":8406,"activeCount":85},[],{"trials":8408,"activeCount":85},[],{"trials":8410,"activeCount":85},[],{"trials":8412,"activeCount":85},[],{"intervention":3240,"totalTrials":81,"cells":8414},{"EARLY_PHASE1":8415,"PHASE1":8417,"PHASE2":8423,"PHASE3":8425,"PHASE4":8427,"NA":8429},{"trials":8416,"activeCount":85},[],{"trials":8418,"activeCount":85},[8419],{"nctId":3235,"briefTitle":3236,"status":114,"phases":8420,"primaryCompletion":318,"completion":318,"start":3196,"enrollment":334,"conditions":8421,"interventions":8422},[74],[15,3127],[3114,3240],{"trials":8424,"activeCount":85},[],{"trials":8426,"activeCount":85},[],{"trials":8428,"activeCount":85},[],{"trials":8430,"activeCount":85},[],{"intervention":8432,"totalTrials":81,"cells":8433},"ASP8062",{"EARLY_PHASE1":8434,"PHASE1":8436,"PHASE2":8445,"PHASE3":8447,"PHASE4":8449,"NA":8451},{"trials":8435,"activeCount":85},[],{"trials":8437,"activeCount":85},[8438],{"nctId":8439,"briefTitle":8440,"status":114,"phases":8441,"primaryCompletion":8442,"completion":8442,"start":770,"enrollment":3224,"conditions":8443,"interventions":8444},"NCT03183739","Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects",[74],"2017-10-06",[30],[8432],{"trials":8446,"activeCount":85},[],{"trials":8448,"activeCount":85},[],{"trials":8450,"activeCount":85},[],{"trials":8452,"activeCount":85},[],{"intervention":3499,"totalTrials":81,"cells":8454},{"EARLY_PHASE1":8455,"PHASE1":8457,"PHASE2":8463,"PHASE3":8465,"PHASE4":8467,"NA":8469},{"trials":8456,"activeCount":85},[],{"trials":8458,"activeCount":85},[8459],{"nctId":3493,"briefTitle":3494,"status":114,"phases":8460,"primaryCompletion":355,"completion":355,"start":318,"enrollment":118,"conditions":8461,"interventions":8462},[74],[15,3497],[3452,3499],{"trials":8464,"activeCount":85},[],{"trials":8466,"activeCount":85},[],{"trials":8468,"activeCount":85},[],{"trials":8470,"activeCount":85},[],{"intervention":5778,"totalTrials":81,"cells":8472},{"EARLY_PHASE1":8473,"PHASE1":8475,"PHASE2":8481,"PHASE3":8483,"PHASE4":8485,"NA":8487},{"trials":8474,"activeCount":85},[],{"trials":8476,"activeCount":85},[8477],{"nctId":5771,"briefTitle":5772,"status":114,"phases":8478,"primaryCompletion":5774,"completion":5774,"start":5775,"enrollment":16,"conditions":8479,"interventions":8480},[74],[30],[5740,5778],{"trials":8482,"activeCount":85},[],{"trials":8484,"activeCount":85},[],{"trials":8486,"activeCount":85},[],{"trials":8488,"activeCount":85},[],{"intervention":3260,"totalTrials":81,"cells":8490},{"EARLY_PHASE1":8491,"PHASE1":8493,"PHASE2":8499,"PHASE3":8501,"PHASE4":8503,"NA":8505},{"trials":8492,"activeCount":85},[],{"trials":8494,"activeCount":85},[8495],{"nctId":3255,"briefTitle":3256,"status":114,"phases":8496,"primaryCompletion":355,"completion":355,"start":308,"enrollment":2538,"conditions":8497,"interventions":8498},[74],[18],[3114,3260],{"trials":8500,"activeCount":85},[],{"trials":8502,"activeCount":85},[],{"trials":8504,"activeCount":85},[],{"trials":8506,"activeCount":85},[],{"intervention":8508,"totalTrials":81,"cells":8509},"OSI-027",{"EARLY_PHASE1":8510,"PHASE1":8512,"PHASE2":8522,"PHASE3":8524,"PHASE4":8526,"NA":8528},{"trials":8511,"activeCount":85},[],{"trials":8513,"activeCount":85},[8514],{"nctId":8515,"briefTitle":8516,"status":114,"phases":8517,"primaryCompletion":3947,"completion":3947,"start":1498,"enrollment":8518,"conditions":8519,"interventions":8521},"NCT00698243","Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma",[74],128,[8520],"Any Solid Tumor or Lymphoma",[8508],{"trials":8523,"activeCount":85},[],{"trials":8525,"activeCount":85},[],{"trials":8527,"activeCount":85},[],{"trials":8529,"activeCount":85},[],{"intervention":8531,"totalTrials":81,"cells":8532},"ONO-5920 \u002F YM529",{"EARLY_PHASE1":8533,"PHASE1":8535,"PHASE2":8545,"PHASE3":8547,"PHASE4":8549,"NA":8551},{"trials":8534,"activeCount":85},[],{"trials":8536,"activeCount":85},[8537],{"nctId":8538,"briefTitle":8539,"status":114,"phases":8540,"primaryCompletion":846,"completion":846,"start":1022,"enrollment":1474,"conditions":8541,"interventions":8544},"NCT00965978","A Study to Evaluate Food Effect on ONO-5920\u002FYM529 Intermittent Formulation",[74],[4848,8542,8543],"Osteoporosis, Postmenopausal","Bone Diseases",[8531],{"trials":8546,"activeCount":85},[],{"trials":8548,"activeCount":85},[],{"trials":8550,"activeCount":85},[],{"trials":8552,"activeCount":85},[],{"intervention":8554,"totalTrials":81,"cells":8555},"ASP0777",{"EARLY_PHASE1":8556,"PHASE1":8558,"PHASE2":8567,"PHASE3":8569,"PHASE4":8571,"NA":8573},{"trials":8557,"activeCount":85},[],{"trials":8559,"activeCount":85},[8560],{"nctId":8561,"briefTitle":8562,"status":114,"phases":8563,"primaryCompletion":3847,"completion":3847,"start":8564,"enrollment":3206,"conditions":8565,"interventions":8566},"NCT01406145","A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil",[74],"2011-06-16",[6810],[8554],{"trials":8568,"activeCount":85},[],{"trials":8570,"activeCount":85},[],{"trials":8572,"activeCount":85},[],{"trials":8574,"activeCount":85},[],{"intervention":8576,"totalTrials":81,"cells":8577},"bleselumab",{"EARLY_PHASE1":8578,"PHASE1":8580,"PHASE2":8590,"PHASE3":8592,"PHASE4":8594,"NA":8596},{"trials":8579,"activeCount":85},[],{"trials":8581,"activeCount":85},[8582],{"nctId":8583,"briefTitle":8584,"status":114,"phases":8585,"primaryCompletion":8586,"completion":8586,"start":8587,"enrollment":972,"conditions":8588,"interventions":8589},"NCT01279538","A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation",[74],"2012-01-23","2010-11-17",[21],[8576],{"trials":8591,"activeCount":85},[],{"trials":8593,"activeCount":85},[],{"trials":8595,"activeCount":85},[],{"trials":8597,"activeCount":85},[],{"intervention":852,"totalTrials":6468,"cells":8599},{"EARLY_PHASE1":8600,"PHASE1":8602,"PHASE2":8616,"PHASE3":8685,"PHASE4":8828,"NA":8897},{"trials":8601,"activeCount":85},[],{"trials":8603,"activeCount":85},[8604,8608,8612],{"nctId":4046,"briefTitle":4047,"status":114,"phases":8605,"primaryCompletion":4049,"completion":4049,"start":2282,"enrollment":118,"conditions":8606,"interventions":8607},[74],[4041,4051,30],[2285,826],{"nctId":7222,"briefTitle":7223,"status":114,"phases":8609,"primaryCompletion":808,"completion":808,"start":808,"enrollment":118,"conditions":8610,"interventions":8611},[74],[710,811,18],[813,852],{"nctId":7228,"briefTitle":7229,"status":114,"phases":8613,"primaryCompletion":3171,"completion":3171,"start":2609,"enrollment":719,"conditions":8614,"interventions":8615},[74],[15,7232],[852,813],{"trials":8617,"activeCount":85},[8618,8628,8637,8641,8645,8652,8659,8663,8667,8671,8677,8681],{"nctId":8619,"briefTitle":8620,"status":114,"phases":8621,"conditions":8622,"interventions":8627},"NCT00189761","A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients",[75],[8623,8624,8625,8626],"Bone Marrow Transplantation","Graft Versus Host Disease","Graft-Vs-Host Disease","Graft-Versus-Host Disease",[852],{"nctId":8629,"briefTitle":8630,"status":114,"phases":8631,"primaryCompletion":1066,"completion":1066,"enrollment":8632,"conditions":8633,"interventions":8636},"NCT00189787","Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma",[75],370,[8634,8635],"Asthma, Bronchial","Bronchial Asthma",[826],{"nctId":6641,"briefTitle":6642,"status":114,"phases":8638,"primaryCompletion":1498,"completion":1498,"start":4289,"enrollment":6644,"conditions":8639,"interventions":8640},[75],[5507,35],[852,6632],{"nctId":817,"briefTitle":818,"status":114,"phases":8642,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":8643,"interventions":8644},[75],[21],[825,826,827,828,829],{"nctId":8646,"briefTitle":8647,"status":114,"phases":8648,"primaryCompletion":983,"completion":983,"enrollment":8649,"conditions":8650,"interventions":8651},"NCT00189722","Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma",[75],160,[8634,8635],[852],{"nctId":8653,"briefTitle":8654,"status":114,"phases":8655,"primaryCompletion":3205,"completion":3205,"start":1985,"enrollment":719,"conditions":8656,"interventions":8658},"NCT01224028","A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients",[75],[8657],"IgA Nephropathy",[852],{"nctId":4185,"briefTitle":4186,"status":114,"phases":8660,"primaryCompletion":971,"completion":971,"start":4188,"enrollment":4189,"conditions":8661,"interventions":8662},[75],[21],[901,826],{"nctId":4193,"briefTitle":4194,"status":114,"phases":8664,"primaryCompletion":971,"completion":971,"start":1585,"enrollment":2432,"conditions":8665,"interventions":8666},[75],[35],[4198,826],{"nctId":4200,"briefTitle":4201,"status":114,"phases":8668,"primaryCompletion":971,"completion":971,"start":919,"enrollment":4189,"conditions":8669,"interventions":8670},[75],[35],[4198,826],{"nctId":8672,"briefTitle":8673,"status":114,"phases":8674,"start":918,"conditions":8675,"interventions":8676},"NCT00189748","A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-",[75],[8623,8624,8626,8625],[852],{"nctId":831,"briefTitle":832,"status":114,"phases":8678,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":8679,"interventions":8680},[75],[35],[826,839,840,841],{"nctId":843,"briefTitle":844,"status":114,"phases":8682,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":8683,"interventions":8684},[75],[850],[825,852,798,853],{"trials":8686,"activeCount":85},[8687,8691,8698,8705,8709,8716,8723,8729,8736,8743,8750,8756,8760,8766,8770,8774,8778,8782,8789,8797,8803,8809,8817,8824],{"nctId":3773,"briefTitle":3774,"status":114,"phases":8688,"completion":1585,"start":3776,"enrollment":3777,"conditions":8689,"interventions":8690},[76],[699],[852,776],{"nctId":8692,"briefTitle":8693,"status":114,"phases":8694,"primaryCompletion":1953,"completion":1953,"start":1095,"enrollment":320,"conditions":8695,"interventions":8697},"NCT00643071","Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients",[76],[8696],"Ulcerative Colitis",[852],{"nctId":8699,"briefTitle":8700,"status":114,"phases":8701,"primaryCompletion":1043,"completion":1043,"start":895,"enrollment":8702,"conditions":8703,"interventions":8704},"NCT00295594","Comparing Efficacy & Safety of Tacrolimus With\u002FWithout MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.",[76],627,[35],[826],{"nctId":857,"briefTitle":858,"status":114,"phases":8706,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":8707,"interventions":8708},[76],[864],[826,828,866],{"nctId":8710,"briefTitle":8711,"status":114,"phases":8712,"primaryCompletion":2872,"completion":2872,"start":918,"enrollment":8713,"conditions":8714,"interventions":8715},"NCT00189839","A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation",[76],699,[21],[826],{"nctId":8717,"briefTitle":8718,"status":114,"phases":8719,"primaryCompletion":1210,"completion":1210,"start":5817,"enrollment":6713,"conditions":8720,"interventions":8722},"NCT00384202","A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients",[76],[8721],"Transplantation",[852],{"nctId":8724,"briefTitle":8725,"status":114,"phases":8726,"primaryCompletion":6912,"completion":6912,"start":1095,"enrollment":5918,"conditions":8727,"interventions":8728},"NCT00347048","Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients",[76],[8696],[826],{"nctId":8730,"briefTitle":8731,"status":114,"phases":8732,"primaryCompletion":1498,"completion":1498,"start":1279,"enrollment":4358,"conditions":8733,"interventions":8735},"NCT00309088","FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients",[76],[8734],"Myasthenia Gravis",[826],{"nctId":8737,"briefTitle":8738,"status":114,"phases":8739,"primaryCompletion":3533,"completion":3533,"start":331,"enrollment":8740,"conditions":8741,"interventions":8742},"NCT01325571","A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis",[76],83,[8734],[852],{"nctId":8744,"briefTitle":8745,"status":114,"phases":8746,"primaryCompletion":1317,"completion":1317,"start":1085,"enrollment":8747,"conditions":8748,"interventions":8749},"NCT00296361","To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.",[76],634,[21],[852],{"nctId":8751,"briefTitle":4427,"status":114,"phases":8752,"completion":2020,"enrollment":8753,"conditions":8754,"interventions":8755},"NCT00293930",[76],645,[751],[852],{"nctId":879,"briefTitle":880,"status":114,"phases":8757,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":8758,"interventions":8759},[76],[886,887],[852,889,840,890,326],{"nctId":8761,"briefTitle":8762,"status":114,"phases":8763,"primaryCompletion":4111,"completion":4111,"start":1485,"enrollment":12,"conditions":8764,"interventions":8765},"NCT00309101","An Open Study for Steroid Resistant, Non-Thymectomized MG Patients",[76],[8734],[826],{"nctId":892,"briefTitle":893,"status":114,"phases":8767,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":8768,"interventions":8769},[76],[21],[901,852,902,828],{"nctId":915,"briefTitle":916,"status":114,"phases":8771,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":8772,"interventions":8773},[76],[21],[852,798,923],{"nctId":925,"briefTitle":926,"status":114,"phases":8775,"primaryCompletion":821,"completion":821,"start":928,"enrollment":929,"conditions":8776,"interventions":8777},[76],[21],[826,828,932,866],{"nctId":1769,"briefTitle":1770,"status":114,"phases":8779,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":730,"conditions":8780,"interventions":8781},[76],[21],[826,826,944,1777,829,1778,1779],{"nctId":8783,"briefTitle":8784,"status":114,"phases":8785,"primaryCompletion":1954,"completion":1954,"start":1085,"enrollment":8786,"conditions":8787,"interventions":8788},"NCT00296309","Comparing Efficacy & Safety of Tacrolimus & MMF With\u002FWithout Induction in the Elderly Following Kidney Transplantation.",[76],267,[21],[852],{"nctId":8790,"briefTitle":8791,"status":114,"phases":8792,"primaryCompletion":378,"completion":378,"start":8793,"enrollment":8794,"conditions":8795,"interventions":8796},"NCT00481481","Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects",[76],"2007-04",346,[8721],[826],{"nctId":8798,"briefTitle":8799,"status":114,"phases":8800,"primaryCompletion":907,"completion":907,"start":5817,"enrollment":8518,"conditions":8801,"interventions":8802},"NCT00384137","A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients",[76],[8721],[852],{"nctId":8804,"briefTitle":8805,"status":114,"phases":8806,"start":897,"enrollment":334,"conditions":8807,"interventions":8808},"NCT00429377","Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study",[76],[1828],[826],{"nctId":8810,"briefTitle":8811,"status":114,"phases":8812,"primaryCompletion":1190,"completion":1190,"start":961,"enrollment":309,"conditions":8813,"interventions":8815},"NCT00321074","Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts",[76],[8814],"LIVER TRANSPLANTATION",[8816],"TACROLIMUS",{"nctId":8818,"briefTitle":8819,"status":114,"phases":8820,"primaryCompletion":2872,"completion":2872,"start":918,"enrollment":8821,"conditions":8822,"interventions":8823},"NCT00189826","A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.",[76],475,[35],[826],{"nctId":1823,"briefTitle":1824,"status":353,"phases":8825,"primaryCompletion":1658,"completion":1658,"start":1826,"enrollment":263,"conditions":8826,"interventions":8827},[76],[1828],[826,1830,1831,1832,841],{"trials":8829,"activeCount":85},[8830,8834,8842,8846,8850,8857,8861,8870,8874,8881,8885,8891],{"nctId":958,"briefTitle":959,"status":114,"phases":8831,"primaryCompletion":896,"completion":896,"start":961,"enrollment":962,"conditions":8832,"interventions":8833},[77],[21],[827,965,826,966,828,866],{"nctId":8835,"briefTitle":8836,"status":114,"phases":8837,"primaryCompletion":6912,"completion":1298,"start":1561,"enrollment":8838,"conditions":8839,"interventions":8841},"NCT00106392","A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy",[77],131,[8840,322],"Erectile Dysfunction",[852],{"nctId":1875,"briefTitle":1876,"status":114,"phases":8843,"primaryCompletion":847,"completion":847,"start":1878,"enrollment":1879,"conditions":8844,"interventions":8845},[77],[1881],[826,1883,866],{"nctId":968,"briefTitle":969,"status":114,"phases":8847,"primaryCompletion":971,"completion":971,"start":319,"enrollment":972,"conditions":8848,"interventions":8849},[77],[21,974,975],[852,798,977,326],{"nctId":8851,"briefTitle":8852,"status":114,"phases":8853,"primaryCompletion":1772,"completion":1772,"start":8854,"enrollment":8518,"conditions":8855,"interventions":8856},"NCT01511003","A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)",[77],"2011-12-05",[699],[852],{"nctId":1787,"briefTitle":1788,"status":114,"phases":8858,"primaryCompletion":1436,"completion":1790,"start":1791,"enrollment":908,"conditions":8859,"interventions":8860},[77],[21],[852,1480,829],{"nctId":8862,"briefTitle":8863,"status":114,"phases":8864,"completion":8865,"start":8866,"enrollment":1955,"conditions":8867,"interventions":8869},"NCT00510913","A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure",[77],"2000-09","1999-02",[8868,21],"Graft Rejection",[826],{"nctId":2298,"briefTitle":2299,"status":114,"phases":8871,"primaryCompletion":1485,"completion":1485,"start":2301,"enrollment":2302,"conditions":8872,"interventions":8873},[77],[1881,2304],[852,889],{"nctId":8875,"briefTitle":8876,"status":114,"phases":8877,"primaryCompletion":971,"completion":971,"start":1279,"enrollment":8878,"conditions":8879,"interventions":8880},"NCT00319917","A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients",[77],123,[699],[826],{"nctId":979,"briefTitle":980,"status":353,"phases":8882,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":8883,"interventions":8884},[77],[21],[852,828,326],{"nctId":8886,"briefTitle":8887,"status":114,"phases":8888,"primaryCompletion":3698,"completion":3698,"start":1953,"enrollment":972,"conditions":8889,"interventions":8890},"NCT01224418","A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate",[77],[699],[852],{"nctId":8892,"briefTitle":8893,"status":114,"phases":8894,"primaryCompletion":3205,"completion":3205,"start":3698,"enrollment":1394,"conditions":8895,"interventions":8896},"NCT01224041","Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate",[77],[699],[852],{"trials":8898,"activeCount":85},[8899,8909,8918],{"nctId":8900,"briefTitle":8901,"status":114,"phases":8902,"primaryCompletion":8903,"completion":8903,"start":8904,"enrollment":8905,"conditions":8906,"interventions":8908},"NCT02159651","A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia",[],"2019-12-23","2014-04-01",179,[8907],"Interstitial Pneumonia Associated With Polymyositis\u002FDermatomyositis",[826],{"nctId":8910,"briefTitle":8911,"status":114,"phases":8912,"primaryCompletion":8913,"completion":8913,"start":8914,"enrollment":8915,"conditions":8916,"interventions":8917},"NCT01410747","A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations",[],"2020-01-31","2007-04-10",1484,[1828],[852],{"nctId":8919,"briefTitle":8920,"status":114,"phases":8921,"primaryCompletion":8922,"completion":8922,"start":332,"enrollment":8923,"conditions":8924,"interventions":8925},"NCT01870908","Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients",[],"2015-03",664,[699],[826,8926],"biological agents",{"intervention":1027,"totalTrials":3150,"cells":8928},{"EARLY_PHASE1":8929,"PHASE1":8931,"PHASE2":9006,"PHASE3":9014,"PHASE4":9042,"NA":9065},{"trials":8930,"activeCount":85},[],{"trials":8932,"activeCount":85},[8933,8937,8941,8945,8949,8955,8963,8967,8973,8977,8981,8985,8989,8997],{"nctId":7585,"briefTitle":7586,"status":114,"phases":8934,"primaryCompletion":333,"completion":333,"start":1022,"enrollment":3453,"conditions":8935,"interventions":8936},[74],[30,7589],[1027,7578,7591],{"nctId":7644,"briefTitle":7645,"status":114,"phases":8938,"primaryCompletion":896,"completion":896,"start":971,"enrollment":1372,"conditions":8939,"interventions":8940},[74],[30,1025],[1704,7637],{"nctId":7730,"briefTitle":7731,"status":114,"phases":8942,"primaryCompletion":4112,"completion":4112,"start":971,"enrollment":22,"conditions":8943,"interventions":8944},[74],[1025,18],[1027,7723],{"nctId":7841,"briefTitle":7842,"status":114,"phases":8946,"primaryCompletion":3574,"completion":3574,"start":971,"enrollment":118,"conditions":8947,"interventions":8948},[74],[3590],[1027,7834],{"nctId":8950,"briefTitle":8951,"status":114,"phases":8952,"primaryCompletion":333,"completion":333,"start":896,"enrollment":1357,"conditions":8953,"interventions":8954},"NCT01285596","A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex",[74],[30,1025],[1704],{"nctId":8956,"briefTitle":8957,"status":114,"phases":8958,"primaryCompletion":8959,"completion":8959,"start":8960,"enrollment":16,"conditions":8961,"interventions":8962},"NCT02211846","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder",[74],"2015-09-21","2014-09-21",[7374,24,1025],[1704],{"nctId":7392,"briefTitle":7393,"status":114,"phases":8964,"primaryCompletion":2009,"completion":2009,"start":1485,"enrollment":3453,"conditions":8965,"interventions":8966},[74],[1025,7396,18],[7385,1027],{"nctId":8968,"briefTitle":8969,"status":114,"phases":8970,"primaryCompletion":1022,"completion":1022,"start":809,"enrollment":3181,"conditions":8971,"interventions":8972},"NCT00939757","Study of the Effect of Food on the Pharmacokinetics of Mirabegron",[74],[15,1025],[1027],{"nctId":2041,"briefTitle":2042,"status":114,"phases":8974,"primaryCompletion":820,"completion":820,"start":2044,"enrollment":1474,"conditions":8975,"interventions":8976},[74],[2046,18,2047],[1027,1143],{"nctId":1019,"briefTitle":1020,"status":114,"phases":8978,"primaryCompletion":1022,"completion":1022,"start":896,"enrollment":1023,"conditions":8979,"interventions":8980},[74],[30,1025],[1000,1027],{"nctId":7307,"briefTitle":7308,"status":114,"phases":8982,"primaryCompletion":1985,"completion":1985,"start":3188,"enrollment":7310,"conditions":8983,"interventions":8984},[74],[18],[1027,7313],{"nctId":8400,"briefTitle":8401,"status":114,"phases":8986,"primaryCompletion":835,"completion":835,"start":6419,"enrollment":22,"conditions":8987,"interventions":8988},[74],[1025,18],[1027,8393],{"nctId":8990,"briefTitle":8991,"status":114,"phases":8992,"primaryCompletion":820,"completion":820,"start":1985,"enrollment":8993,"conditions":8994,"interventions":8996},"NCT01284309","A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects",[74],321,[8995],"Intraocular Pressure",[1704],{"nctId":8998,"briefTitle":8999,"status":114,"phases":9000,"primaryCompletion":9001,"completion":9001,"start":9002,"enrollment":9003,"conditions":9004,"interventions":9005},"NCT00940121","Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron",[74],"2009-07-13","2009-04-30",91,[15,1025],[1027,1027],{"trials":9007,"activeCount":85},[9008],{"nctId":9009,"briefTitle":9010,"status":114,"phases":9011,"primaryCompletion":1042,"completion":1042,"start":2872,"enrollment":6785,"conditions":9012,"interventions":9013},"NCT00410514","A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)",[75],[1046,1047],[1704],{"trials":9015,"activeCount":85},[9016,9025,9034,9038],{"nctId":9017,"briefTitle":9018,"status":114,"phases":9019,"primaryCompletion":9020,"completion":9020,"start":9021,"enrollment":9022,"conditions":9023,"interventions":9024},"NCT00662909","A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",[76],"2009-04-22","2008-03-28",2149,[33],[1704],{"nctId":9026,"briefTitle":9027,"status":114,"phases":9028,"primaryCompletion":9029,"completion":9029,"start":9030,"enrollment":9031,"conditions":9032,"interventions":9033},"NCT00912964","A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",[76],"2010-04-27","2009-04-28",2030,[33],[1704],{"nctId":1696,"briefTitle":1697,"status":114,"phases":9035,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1701,"conditions":9036,"interventions":9037},[76],[33],[1704,1090],{"nctId":1716,"briefTitle":1717,"status":114,"phases":9039,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":1721,"conditions":9040,"interventions":9041},[76],[33],[1704,1090],{"trials":9043,"activeCount":85},[9044,9048,9057,9061],{"nctId":1727,"briefTitle":1728,"status":114,"phases":9045,"primaryCompletion":1730,"completion":1730,"start":1731,"enrollment":1732,"conditions":9046,"interventions":9047},[77],[1734],[1704,1736,1737,1738,1090],{"nctId":9049,"briefTitle":9050,"status":114,"phases":9051,"primaryCompletion":9052,"completion":9052,"start":9053,"enrollment":9054,"conditions":9055,"interventions":9056},"NCT01745094","A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients",[77],"2013-07-23","2012-10-01",223,[24],[1027,2875],{"nctId":2072,"briefTitle":2073,"status":114,"phases":9058,"primaryCompletion":2075,"completion":2075,"start":2076,"enrollment":2077,"conditions":9059,"interventions":9060},[77],[24],[1704,2062],{"nctId":1740,"briefTitle":1741,"status":114,"phases":9062,"primaryCompletion":1743,"completion":1743,"start":307,"enrollment":118,"conditions":9063,"interventions":9064},[77],[1745,15],[1099,1027],{"trials":9066,"activeCount":85},[9067,9076],{"nctId":9068,"briefTitle":9069,"status":114,"phases":9070,"primaryCompletion":9071,"completion":9071,"start":9072,"enrollment":9073,"conditions":9074,"interventions":9075},"NCT01898624","Specified Drug Use-results Survey of Betanis Tablets",[],"2018-01-10","2012-12-04",300,[24],[1027],{"nctId":9077,"briefTitle":9078,"status":114,"phases":9079,"primaryCompletion":8922,"completion":8922,"start":5460,"enrollment":9080,"conditions":9081,"interventions":9083},"NCT02570035","Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease",[],316,[24,9082],"Cardiovascular Disease",[1704],{"intervention":3994,"totalTrials":1180,"cells":9085},{"EARLY_PHASE1":9086,"PHASE1":9088,"PHASE2":9090,"PHASE3":9109,"PHASE4":9163,"NA":9187},{"trials":9087,"activeCount":85},[],{"trials":9089,"activeCount":85},[],{"trials":9091,"activeCount":85},[9092,9096,9100],{"nctId":3986,"briefTitle":3987,"status":114,"phases":9093,"primaryCompletion":3989,"completion":3989,"start":3990,"enrollment":3991,"conditions":9094,"interventions":9095},[75],[3280],[3994,690],{"nctId":4004,"briefTitle":4005,"status":114,"phases":9097,"primaryCompletion":4007,"completion":4007,"start":4008,"enrollment":4009,"conditions":9098,"interventions":9099},[75],[27],[3994,690],{"nctId":9101,"briefTitle":9102,"status":114,"phases":9103,"primaryCompletion":9104,"completion":9104,"start":9105,"enrollment":9106,"conditions":9107,"interventions":9108},"NCT00621868","A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus",[75],"2009-03-14","2008-03-26",361,[6787],[3994],{"trials":9110,"activeCount":85},[9111,9115,9123,9131,9139,9143,9147,9155,9159],{"nctId":4956,"briefTitle":4957,"status":114,"phases":9112,"primaryCompletion":4959,"completion":4959,"start":4960,"enrollment":4961,"conditions":9113,"interventions":9114},[76],[27],[3994,4945],{"nctId":9116,"briefTitle":9117,"status":114,"phases":9118,"primaryCompletion":9119,"completion":9119,"start":4959,"enrollment":9120,"conditions":9121,"interventions":9122},"NCT01672762","A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients",[76],"2013-04-13",174,[27],[3994],{"nctId":9124,"briefTitle":9125,"status":114,"phases":9126,"primaryCompletion":9127,"completion":9127,"start":9128,"enrollment":4139,"conditions":9129,"interventions":9130},"NCT01054092","A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients",[76],"2011-07-22","2010-01-14",[27],[3994],{"nctId":9132,"briefTitle":9133,"status":114,"phases":9134,"primaryCompletion":9135,"completion":9135,"start":9136,"enrollment":4508,"conditions":9137,"interventions":9138},"NCT01057628","A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients",[76],"2010-11-06","2010-01-13",[27],[3994],{"nctId":4672,"briefTitle":4673,"status":114,"phases":9140,"primaryCompletion":3308,"completion":3308,"start":4675,"enrollment":2029,"conditions":9141,"interventions":9142},[76],[27],[3994,4654],{"nctId":5480,"briefTitle":5481,"status":114,"phases":9144,"primaryCompletion":5483,"completion":5483,"start":5484,"enrollment":920,"conditions":9145,"interventions":9146},[76],[27],[3994,5469],{"nctId":9148,"briefTitle":9149,"status":114,"phases":9150,"primaryCompletion":9151,"completion":4521,"start":9152,"enrollment":466,"conditions":9153,"interventions":9154},"NCT02897219","A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus",[76],"2017-07-22","2016-08-29",[3270],[3994],{"nctId":4019,"briefTitle":4020,"status":114,"phases":9156,"primaryCompletion":3289,"completion":3289,"start":4022,"enrollment":4023,"conditions":9157,"interventions":9158},[76],[27],[3994,3294],{"nctId":5597,"briefTitle":5598,"status":114,"phases":9160,"primaryCompletion":5600,"completion":5600,"start":4960,"enrollment":5601,"conditions":9161,"interventions":9162},[76],[27],[3994,5586],{"trials":9164,"activeCount":85},[9165,9169,9177],{"nctId":2580,"briefTitle":2581,"status":114,"phases":9166,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":2585,"conditions":9167,"interventions":9168},[77],[27],[2588,2567],{"nctId":9170,"briefTitle":9171,"status":114,"phases":9172,"primaryCompletion":9173,"completion":9173,"start":9174,"enrollment":1541,"conditions":9175,"interventions":9176},"NCT02291874","Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)",[77],"2016-07-07","2014-10-08",[27],[2588],{"nctId":9178,"briefTitle":9179,"status":114,"phases":9180,"primaryCompletion":9181,"completion":9182,"start":9183,"enrollment":9184,"conditions":9185,"interventions":9186},"NCT02175784","A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus",[77],"2015-03-31","2015-12-07","2014-03-31",262,[27],[3994],{"trials":9188,"activeCount":85},[9189],{"nctId":9190,"briefTitle":9191,"status":114,"phases":9192,"primaryCompletion":7035,"completion":7035,"start":9193,"enrollment":9194,"conditions":9195,"interventions":9197},"NCT02479399","Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients",[],"2014-07-17",11412,[9196],"Type 2 Diabetes",[3994],{"intervention":1736,"totalTrials":1191,"cells":9199},{"EARLY_PHASE1":9200,"PHASE1":9202,"PHASE2":9204,"PHASE3":9206,"PHASE4":9208,"NA":9249},{"trials":9201,"activeCount":85},[],{"trials":9203,"activeCount":85},[],{"trials":9205,"activeCount":85},[],{"trials":9207,"activeCount":85},[],{"trials":9209,"activeCount":85},[9210,9220,9227,9231,9235,9239,9245],{"nctId":9211,"briefTitle":9212,"status":114,"phases":9213,"primaryCompletion":9214,"completion":9214,"start":9215,"enrollment":9216,"conditions":9217,"interventions":9219},"NCT01093534","Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.",[77],"2011-06-23","2010-01-19",547,[9218,24],"Detrusor Overactivity",[2875],{"nctId":9221,"briefTitle":9222,"status":114,"phases":9223,"primaryCompletion":3661,"completion":3661,"start":355,"enrollment":1541,"conditions":9224,"interventions":9226},"NCT01318837","A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment",[77],[9225],"Over Active Bladder",[2875],{"nctId":1727,"briefTitle":1728,"status":114,"phases":9228,"primaryCompletion":1730,"completion":1730,"start":1731,"enrollment":1732,"conditions":9229,"interventions":9230},[77],[1734],[1704,1736,1737,1738,1090],{"nctId":9049,"briefTitle":9050,"status":114,"phases":9232,"primaryCompletion":9052,"completion":9052,"start":9053,"enrollment":9054,"conditions":9233,"interventions":9234},[77],[24],[1027,2875],{"nctId":2869,"briefTitle":2870,"status":114,"phases":9236,"primaryCompletion":821,"completion":821,"start":2872,"enrollment":1976,"conditions":9237,"interventions":9238},[77],[24],[2875,2856],{"nctId":9240,"briefTitle":9241,"status":114,"phases":9242,"primaryCompletion":1658,"completion":1658,"start":846,"enrollment":972,"conditions":9243,"interventions":9244},"NCT02667470","Reproducibility Study of OABSS and Its Response to Treatment",[77],[24],[1736],{"nctId":3087,"briefTitle":3088,"status":114,"phases":9246,"primaryCompletion":1530,"completion":1530,"start":355,"enrollment":11,"conditions":9247,"interventions":9248},[77],[3091],[1736,3074],{"trials":9250,"activeCount":85},[9251,9258],{"nctId":9252,"briefTitle":9253,"status":114,"phases":9254,"primaryCompletion":3204,"completion":3204,"start":3698,"enrollment":9255,"conditions":9256,"interventions":9257},"NCT00985387","Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients",[],1215,[33,24],[1736],{"nctId":9259,"briefTitle":9260,"status":114,"phases":9261,"primaryCompletion":5122,"completion":5122,"start":846,"enrollment":2010,"conditions":9262,"interventions":9263},"NCT01122563","A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment",[],[24],[1736],{"intervention":4512,"totalTrials":1191,"cells":9265},{"EARLY_PHASE1":9266,"PHASE1":9268,"PHASE2":9279,"PHASE3":9285,"PHASE4":9331,"NA":9333},{"trials":9267,"activeCount":85},[],{"trials":9269,"activeCount":85},[9270],{"nctId":9271,"briefTitle":9272,"status":114,"phases":9273,"primaryCompletion":9274,"completion":9274,"start":1709,"enrollment":3453,"conditions":9275,"interventions":9278},"NCT01083888","ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis",[74],"2010-06-07",[9276,9277,3583],"Anemia","Hemodialysis",[4512],{"trials":9280,"activeCount":85},[9281],{"nctId":4504,"briefTitle":4505,"status":114,"phases":9282,"primaryCompletion":4507,"completion":4507,"start":2097,"enrollment":4508,"conditions":9283,"interventions":9284},[75],[4510],[4512,4513],{"trials":9286,"activeCount":85},[9287,9291,9295,9304,9314,9322],{"nctId":4517,"briefTitle":4518,"status":114,"phases":9288,"primaryCompletion":4520,"completion":4521,"start":4522,"enrollment":1586,"conditions":9289,"interventions":9290},[76],[4524],[4512,4495],{"nctId":4889,"briefTitle":4890,"status":114,"phases":9292,"primaryCompletion":4892,"completion":4893,"start":4894,"enrollment":4895,"conditions":9293,"interventions":9294},[76],[3508],[4512,4878],{"nctId":9296,"briefTitle":9297,"status":114,"phases":9298,"primaryCompletion":9299,"completion":9299,"start":9300,"enrollment":1357,"conditions":9301,"interventions":9303},"NCT02780141","A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia",[76],"2017-12-12","2016-06-02",[9302],"ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia",[4512],{"nctId":9305,"briefTitle":9306,"status":114,"phases":9307,"primaryCompletion":9308,"completion":771,"start":9309,"enrollment":9310,"conditions":9311,"interventions":9313},"NCT02779764","A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment",[76],"2017-05-16","2016-05-16",164,[9312],"Hemodialysis Patients With Renal Anemia",[4512],{"nctId":9315,"briefTitle":9316,"status":114,"phases":9317,"primaryCompletion":9318,"completion":9318,"start":9319,"enrollment":1541,"conditions":9320,"interventions":9321},"NCT02964936","A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia",[76],"2018-08-15","2017-01-11",[3508],[4512],{"nctId":9323,"briefTitle":9324,"status":114,"phases":9325,"primaryCompletion":9326,"completion":9326,"start":9327,"enrollment":3125,"conditions":9328,"interventions":9330},"NCT02780726","A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia",[76],"2017-08-02","2016-06-22",[9329],"Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia",[4512],{"trials":9332,"activeCount":85},[],{"trials":9334,"activeCount":85},[9335],{"nctId":9336,"briefTitle":9337,"status":114,"phases":9338,"primaryCompletion":9339,"completion":9339,"start":9340,"enrollment":9341,"conditions":9342,"interventions":9344},"NCT04408820","Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia",[],"2025-06-23","2020-06-01",2104,[9343],"Renal Anemia",[9345],"Roxadustat",{"intervention":2542,"totalTrials":8,"cells":9347},{"EARLY_PHASE1":9348,"PHASE1":9350,"PHASE2":9352,"PHASE3":9377,"PHASE4":9390,"NA":9400},{"trials":9349,"activeCount":85},[],{"trials":9351,"activeCount":85},[],{"trials":9353,"activeCount":85},[9354,9358,9367],{"nctId":6505,"briefTitle":6506,"status":114,"phases":9355,"primaryCompletion":6508,"completion":6509,"start":6510,"enrollment":2442,"conditions":9356,"interventions":9357},[75],[4547],[6513,6496],{"nctId":9359,"briefTitle":9360,"status":114,"phases":9361,"primaryCompletion":9362,"completion":9362,"start":9363,"enrollment":2538,"conditions":9364,"interventions":9366},"NCT01534052","A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100",[75],"2017-04-18","2011-10-21",[9365],"Castration-Resistant Prostate Cancer (CRPC)",[2542],{"nctId":9368,"briefTitle":9369,"status":114,"phases":9370,"primaryCompletion":9371,"completion":9372,"start":9373,"enrollment":9374,"conditions":9375,"interventions":9376},"NCT01302041","A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy",[75],"2012-07-29","2017-04-27","2011-05-06",67,[322],[2542],{"trials":9378,"activeCount":85},[9379],{"nctId":9380,"briefTitle":9381,"status":114,"phases":9382,"primaryCompletion":9383,"completion":9384,"start":9385,"enrollment":9386,"conditions":9387,"interventions":9389},"NCT02294461","An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants",[76],"2015-09-20","2024-07-17","2014-04-23",395,[9388],"Progressive Metastatic Prostate Cancer",[2542],{"trials":9391,"activeCount":85},[9392,9396],{"nctId":2533,"briefTitle":2534,"status":114,"phases":9393,"primaryCompletion":2536,"completion":2536,"start":2537,"enrollment":2538,"conditions":9394,"interventions":9395},[77],[2540],[2542,2520],{"nctId":3004,"briefTitle":3005,"status":114,"phases":9397,"primaryCompletion":3007,"completion":3007,"start":3008,"enrollment":3009,"conditions":9398,"interventions":9399},[77],[322],[2542,2991],{"trials":9401,"activeCount":85},[9402],{"nctId":9403,"briefTitle":9404,"status":114,"phases":9405,"primaryCompletion":9406,"completion":9406,"start":9407,"enrollment":9408,"conditions":9409,"interventions":9411},"NCT02669771","Long-Term Specified Drug Use-Results Survey for Xtandi Capsule",[],"2018-11-30","2014-11-30",1018,[9410],"Castration-resistant Prostate Cancer",[6513],{"intervention":5084,"totalTrials":275,"cells":9413},{"EARLY_PHASE1":9414,"PHASE1":9416,"PHASE2":9418,"PHASE3":9420,"PHASE4":9426,"NA":9441},{"trials":9415,"activeCount":85},[],{"trials":9417,"activeCount":85},[],{"trials":9419,"activeCount":85},[],{"trials":9421,"activeCount":85},[9422],{"nctId":5077,"briefTitle":5078,"status":114,"phases":9423,"primaryCompletion":847,"completion":860,"start":1790,"enrollment":5080,"conditions":9424,"interventions":9425},[76],[5082,4373],[5084,5066],{"trials":9427,"activeCount":85},[9428,9434],{"nctId":9429,"briefTitle":9430,"status":114,"phases":9431,"primaryCompletion":308,"completion":308,"start":808,"enrollment":1420,"conditions":9432,"interventions":9433},"NCT00918411","A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome",[77],[3932],[5084],{"nctId":9435,"briefTitle":9436,"status":114,"phases":9437,"primaryCompletion":3204,"completion":3204,"start":3231,"enrollment":9438,"conditions":9439,"interventions":9440},"NCT01225237","A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients",[77],296,[3932],[5084],{"trials":9442,"activeCount":85},[9443],{"nctId":9444,"briefTitle":9445,"status":114,"phases":9446,"primaryCompletion":9447,"completion":9447,"start":9448,"enrollment":9449,"conditions":9450,"interventions":9451},"NCT02612649","Special Drug Use Surveillance of Irribow in Female Patients",[],"2018-03-31","2015-10-01",793,[3949],[5084],{"intervention":9453,"totalTrials":275,"cells":9454},"linaclotide",{"EARLY_PHASE1":9455,"PHASE1":9457,"PHASE2":9459,"PHASE3":9471,"PHASE4":9494,"NA":9496},{"trials":9456,"activeCount":85},[],{"trials":9458,"activeCount":85},[],{"trials":9460,"activeCount":85},[9461],{"nctId":9462,"briefTitle":9463,"status":114,"phases":9464,"primaryCompletion":9465,"completion":9465,"start":9466,"enrollment":9467,"conditions":9468,"interventions":9470},"NCT01714843","A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome",[75],"2013-12-07","2012-08-10",559,[9469],"Constipation-predominant Irritable Bowel Syndrome (IBS-C)",[9453],{"trials":9472,"activeCount":85},[9473,9483],{"nctId":9474,"briefTitle":9475,"status":114,"phases":9476,"primaryCompletion":9477,"completion":9478,"start":9479,"enrollment":9480,"conditions":9481,"interventions":9482},"NCT02809105","A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation",[76],"2016-11-14","2017-11-10","2016-06-24",186,[6117],[9453],{"nctId":9484,"briefTitle":9485,"status":114,"phases":9486,"primaryCompletion":9487,"completion":9488,"start":9489,"enrollment":9490,"conditions":9491,"interventions":9493},"NCT02316899","Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome",[76],"2015-09-19","2016-03-29","2014-10-21",500,[9492],"Irritable Bowel Syndrome With Constipation (IBS-C)",[9453],{"trials":9495,"activeCount":85},[],{"trials":9497,"activeCount":85},[9498],{"nctId":9499,"briefTitle":9500,"status":114,"phases":9501,"primaryCompletion":9502,"completion":9502,"start":9503,"enrollment":9504,"conditions":9505,"interventions":9507},"NCT03471728","Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)",[],"2021-12-31","2017-10-02",2475,[9506,9492],"Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases)",[9453],{"intervention":9509,"totalTrials":158,"cells":9510},"Amevive exposure",{"EARLY_PHASE1":9511,"PHASE1":9513,"PHASE2":9515,"PHASE3":9517,"PHASE4":9519,"NA":9521},{"trials":9512,"activeCount":85},[],{"trials":9514,"activeCount":85},[],{"trials":9516,"activeCount":85},[],{"trials":9518,"activeCount":85},[],{"trials":9520,"activeCount":85},[],{"trials":9522,"activeCount":85},[9523,9529],{"nctId":9524,"briefTitle":9525,"status":353,"phases":9526,"primaryCompletion":5122,"completion":5122,"start":1120,"enrollment":334,"conditions":9527,"interventions":9528},"NCT00795353","Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[],[1396],[9509],{"nctId":9530,"briefTitle":9531,"status":353,"phases":9532,"primaryCompletion":2282,"completion":2282,"start":6831,"enrollment":105,"conditions":9533,"interventions":9535},"NCT00342862","AMEVIVE® Pregnancy Registry",[],[9534],"Pregnancy",[9509],{"intervention":9537,"totalTrials":158,"cells":9538},"bixalomer",{"EARLY_PHASE1":9539,"PHASE1":9541,"PHASE2":9543,"PHASE3":9545,"PHASE4":9547,"NA":9549},{"trials":9540,"activeCount":85},[],{"trials":9542,"activeCount":85},[],{"trials":9544,"activeCount":85},[],{"trials":9546,"activeCount":85},[],{"trials":9548,"activeCount":85},[],{"trials":9550,"activeCount":85},[9551,9560],{"nctId":9552,"briefTitle":9553,"status":114,"phases":9554,"primaryCompletion":9555,"completion":9555,"start":9556,"enrollment":8878,"conditions":9557,"interventions":9559},"NCT01903213","Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis",[],"2019-12-31","2013-03-19",[9558],"Chronic Renal Failure",[9537],{"nctId":9561,"briefTitle":9562,"status":114,"phases":9563,"primaryCompletion":9564,"completion":9564,"start":9565,"enrollment":9566,"conditions":9567,"interventions":9568},"NCT02805348","Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease",[],"2018-12-31","2016-06-01",144,[3508],[9569],"Bixalomer",{"intervention":9571,"totalTrials":158,"cells":9572},"Betanis",{"EARLY_PHASE1":9573,"PHASE1":9575,"PHASE2":9577,"PHASE3":9579,"PHASE4":9581,"NA":9583},{"trials":9574,"activeCount":85},[],{"trials":9576,"activeCount":85},[],{"trials":9578,"activeCount":85},[],{"trials":9580,"activeCount":85},[],{"trials":9582,"activeCount":85},[],{"trials":9584,"activeCount":85},[9585,9593],{"nctId":9586,"briefTitle":9587,"status":114,"phases":9588,"primaryCompletion":9589,"completion":9589,"start":377,"enrollment":9590,"conditions":9591,"interventions":9592},"NCT01919047","Drug Use-Results Survey of Betanis Tablets in Japan",[],"2014-07",10711,[24],[9571],{"nctId":9594,"briefTitle":9595,"status":114,"phases":9596,"primaryCompletion":9597,"completion":9597,"start":3534,"enrollment":9598,"conditions":9599,"interventions":9600},"NCT01901120","Long-Term Specified Drug Use-results Survey of Betanis Tablets",[],"2016-09",1263,[24],[9571],{"intervention":9602,"totalTrials":81,"cells":9603},"Regnite",{"EARLY_PHASE1":9604,"PHASE1":9606,"PHASE2":9608,"PHASE3":9610,"PHASE4":9612,"NA":9614},{"trials":9605,"activeCount":85},[],{"trials":9607,"activeCount":85},[],{"trials":9609,"activeCount":85},[],{"trials":9611,"activeCount":85},[],{"trials":9613,"activeCount":85},[],{"trials":9615,"activeCount":85},[9616],{"nctId":9617,"briefTitle":9618,"status":114,"phases":9619,"primaryCompletion":9620,"completion":9620,"start":9053,"enrollment":9621,"conditions":9622,"interventions":9623},"NCT01887613","Specified Drug Use-Results Survey of Regnite",[],"2019-02-28",1597,[4131],[9602],{"intervention":9625,"totalTrials":81,"cells":9626},"Graceptor®",{"EARLY_PHASE1":9627,"PHASE1":9629,"PHASE2":9631,"PHASE3":9633,"PHASE4":9635,"NA":9637},{"trials":9628,"activeCount":85},[],{"trials":9630,"activeCount":85},[],{"trials":9632,"activeCount":85},[],{"trials":9634,"activeCount":85},[],{"trials":9636,"activeCount":85},[],{"trials":9638,"activeCount":85},[9639],{"nctId":9640,"briefTitle":9641,"status":114,"phases":9642,"primaryCompletion":9643,"completion":9643,"start":9644,"enrollment":9645,"conditions":9646,"interventions":9648},"NCT02160054","Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)",[],"2016-03-31","2013-11-15",289,[9647],"the Maintenance Phase After Kidney Transplantation",[9625],{"intervention":9650,"totalTrials":81,"cells":9651},"Quetiapine",{"EARLY_PHASE1":9652,"PHASE1":9654,"PHASE2":9656,"PHASE3":9658,"PHASE4":9660,"NA":9662},{"trials":9653,"activeCount":85},[],{"trials":9655,"activeCount":85},[],{"trials":9657,"activeCount":85},[],{"trials":9659,"activeCount":85},[],{"trials":9661,"activeCount":85},[],{"trials":9663,"activeCount":85},[9664],{"nctId":9665,"briefTitle":9666,"status":114,"phases":9667,"primaryCompletion":9668,"completion":9668,"start":9669,"enrollment":3444,"conditions":9670,"interventions":9672},"NCT03403790","A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder",[],"2020-03-19","2018-01-15",[9671,3713],"Depression",[9650],{"intervention":9674,"totalTrials":81,"cells":9675},"atrovastatin",{"EARLY_PHASE1":9676,"PHASE1":9678,"PHASE2":9680,"PHASE3":9682,"PHASE4":9684,"NA":9686},{"trials":9677,"activeCount":85},[],{"trials":9679,"activeCount":85},[],{"trials":9681,"activeCount":85},[],{"trials":9683,"activeCount":85},[],{"trials":9685,"activeCount":85},[],{"trials":9687,"activeCount":85},[9688],{"nctId":9689,"briefTitle":9690,"status":114,"phases":9691,"primaryCompletion":1659,"completion":1659,"start":3171,"enrollment":9692,"conditions":9693,"interventions":9695},"NCT01446679","Special Drug Use-Results Survey of Lipitor Tablets",[],24050,[9694],"Hypercholesterolemia",[9674],{"intervention":9697,"totalTrials":81,"cells":9698},"Zolbetuximab",{"EARLY_PHASE1":9699,"PHASE1":9701,"PHASE2":9703,"PHASE3":9705,"PHASE4":9707,"NA":9709},{"trials":9700,"activeCount":85},[],{"trials":9702,"activeCount":85},[],{"trials":9704,"activeCount":85},[],{"trials":9706,"activeCount":85},[],{"trials":9708,"activeCount":85},[],{"trials":9710,"activeCount":85},[9711],{"nctId":9712,"briefTitle":9713,"status":114,"phases":9714,"primaryCompletion":9715,"completion":9715,"start":9716,"enrollment":4103,"conditions":9717,"interventions":9720},"NCT03528629","A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma",[78],"2020-06-09","2018-06-08",[9718,9719],"Gastric Cancer","Gastro-esophageal Junction (GEJ) Cancer",[9697],{"intervention":9722,"totalTrials":81,"cells":9723},"Celecoxib",{"EARLY_PHASE1":9724,"PHASE1":9726,"PHASE2":9728,"PHASE3":9730,"PHASE4":9732,"NA":9734},{"trials":9725,"activeCount":85},[],{"trials":9727,"activeCount":85},[],{"trials":9729,"activeCount":85},[],{"trials":9731,"activeCount":85},[],{"trials":9733,"activeCount":85},[],{"trials":9735,"activeCount":85},[9736],{"nctId":9737,"briefTitle":9738,"status":114,"phases":9739,"primaryCompletion":9740,"completion":9740,"start":9741,"enrollment":9742,"conditions":9743,"interventions":9745},"NCT01876121","Celecoxib Japan Observational Study for the Patients With Acute Pain",[],"2013-04","2012-07",784,[9744],"Patients With Traumatic Pain, Post-surgical Pain and Tooth Extract Pain",[9722],{"intervention":8926,"totalTrials":81,"cells":9747},{"EARLY_PHASE1":9748,"PHASE1":9750,"PHASE2":9752,"PHASE3":9754,"PHASE4":9756,"NA":9758},{"trials":9749,"activeCount":85},[],{"trials":9751,"activeCount":85},[],{"trials":9753,"activeCount":85},[],{"trials":9755,"activeCount":85},[],{"trials":9757,"activeCount":85},[],{"trials":9759,"activeCount":85},[9760],{"nctId":8919,"briefTitle":8920,"status":114,"phases":9761,"primaryCompletion":8922,"completion":8922,"start":332,"enrollment":8923,"conditions":9762,"interventions":9763},[],[699],[826,8926],{"intervention":9765,"totalTrials":81,"cells":9766},"Suglat®",{"EARLY_PHASE1":9767,"PHASE1":9769,"PHASE2":9771,"PHASE3":9773,"PHASE4":9775,"NA":9777},{"trials":9768,"activeCount":85},[],{"trials":9770,"activeCount":85},[],{"trials":9772,"activeCount":85},[],{"trials":9774,"activeCount":85},[],{"trials":9776,"activeCount":85},[],{"trials":9778,"activeCount":85},[9779],{"nctId":9780,"briefTitle":9781,"status":114,"phases":9782,"primaryCompletion":9783,"completion":9783,"start":9784,"enrollment":9785,"conditions":9786,"interventions":9787},"NCT02297620","The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients",[],"2015-07","2014-04",8687,[9196],[9765],{"intervention":9789,"totalTrials":81,"cells":9790},"Vesicare",{"EARLY_PHASE1":9791,"PHASE1":9793,"PHASE2":9795,"PHASE3":9797,"PHASE4":9799,"NA":9801},{"trials":9792,"activeCount":85},[],{"trials":9794,"activeCount":85},[],{"trials":9796,"activeCount":85},[],{"trials":9798,"activeCount":85},[],{"trials":9800,"activeCount":85},[],{"trials":9802,"activeCount":85},[9803],{"nctId":9804,"briefTitle":9805,"status":114,"phases":9806,"primaryCompletion":1826,"completion":1826,"start":5759,"enrollment":9807,"conditions":9808,"interventions":9809},"NCT01489709","Post Marketing Survey of Vesicare in Japan",[],1160,[24],[9789],{"intervention":9811,"totalTrials":81,"cells":9812},"abatacept",{"EARLY_PHASE1":9813,"PHASE1":9815,"PHASE2":9817,"PHASE3":9819,"PHASE4":9821,"NA":9823},{"trials":9814,"activeCount":85},[],{"trials":9816,"activeCount":85},[],{"trials":9818,"activeCount":85},[],{"trials":9820,"activeCount":85},[],{"trials":9822,"activeCount":85},[],{"trials":9824,"activeCount":85},[9825],{"nctId":9826,"briefTitle":9827,"status":114,"phases":9828,"primaryCompletion":3929,"completion":3929,"start":820,"enrollment":11,"conditions":9829,"interventions":9830},"NCT01339481","A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept",[],[699],[9811],{"intervention":9832,"totalTrials":81,"cells":9833},"Kiklin",{"EARLY_PHASE1":9834,"PHASE1":9836,"PHASE2":9838,"PHASE3":9840,"PHASE4":9842,"NA":9844},{"trials":9835,"activeCount":85},[],{"trials":9837,"activeCount":85},[],{"trials":9839,"activeCount":85},[],{"trials":9841,"activeCount":85},[],{"trials":9843,"activeCount":85},[],{"trials":9845,"activeCount":85},[9846],{"nctId":9847,"briefTitle":9848,"status":114,"phases":9849,"primaryCompletion":5750,"completion":5750,"start":2608,"enrollment":9850,"conditions":9851,"interventions":9853},"NCT01901107","Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients",[],1078,[9852],"Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis",[9832],{"intervention":9855,"totalTrials":81,"cells":9856},"Alefacept exposure",{"EARLY_PHASE1":9857,"PHASE1":9859,"PHASE2":9861,"PHASE3":9863,"PHASE4":9865,"NA":9867},{"trials":9858,"activeCount":85},[],{"trials":9860,"activeCount":85},[],{"trials":9862,"activeCount":85},[],{"trials":9864,"activeCount":85},[],{"trials":9866,"activeCount":85},[],{"trials":9868,"activeCount":85},[9869],{"nctId":9870,"briefTitle":9871,"status":353,"phases":9872,"primaryCompletion":1371,"completion":1371,"start":897,"enrollment":9873,"conditions":9874,"interventions":9875},"NCT00454701","Assessment and Tracking of Long-term Alefacept Safety",[],1897,[751],[9855]]